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iAbstract
Maternal obesity and diabetes increase the risk of delivering large for
gestational age infants (LGA), who have higher risk of long term obesity or
metabolic syndrome [1]. As the underpinning mechanisms of how fetal growth
is regulated by the placenta remain unclear [2], this thesis has investigated
placental responses to high maternal BMI and gestational diabetes.
Spanish pregnant women recruited at 20 gestational weeks were classified
according to pre-pregnancy BMI as control (BMI<25kg/m2; n=59), overweight
(BMI=25-30kg/m2; n=29) or obese (BMI>30kg/m2; n=22), and gestational
diabetes status (GDM) classified at 28 weeks. Maternal anthropometry and
gestational weight gain (GWG) were measured during pregnancy. Placenta,
cord blood, newborn antrophometry and infant weight were sampled or
measured. Expression of genes involved in placental energy sensing
pathways, folate transporters and DNA methylation was determined using
real-time PCR, and placental triglyceride concentrations, lipid peroxidation and
genomic DNA methylation patterns measured. Data were analysed according
to their parametric distribution by Kruskal-Wallis or 1-way ANOVA.
Despite lower GWG, a greater proportion of obese women exceeded
recommended weight gain [3], had higher placental weight and increased
numbers of LGA infants. Maternal hyperinsulinaemia and hyperglycaemia with
obesity were accompanied by unchanged placental IGFR1 and ISR1
expression, similar cord blood glucose and triglyceride concentrations.
Placental mTOR was halved with obesity, whilst SIRT1 and UCP2 gene
expression were 1.8 and 1.6 fold upregulated respectively with no differences
in TBARS concentrations. Hyperleptinaemia in obese women resulted in
unchanged placental leptin and leptin receptor expression, but higher cord
blood leptin and monocyte concentrations with placental hypermethylation of
genes involved in the immune response. Lower folate concentrations in obese
PRWKHUV OHG WR VLPLODU FRUG EORRG IRODWH DQG GHFUHDVHG SODFHQWDO )5Į EXW
raised DNMT1, mRNA expression. No major differences were observed with
GDM, probably due to small sample size.
In conclusion, it appears that the placenta can protect the fetus of obese
women by increasing antioxidant capacity, compensating for maternal
hyperglycaemia and lower folate. However, maternal obesity was associated
with enhanced cord blood leptin and monocyte concentrations, increased
placental weight and more LGA delivery, leaving infants at ongoing risk of
increased adiposity and inflammation. Therefore, ongoing studies are
currently exploring these interacting aspects.
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1Chapter 1 - Introduction
21.1. General study overview
This thesis investigates the influence of differences in maternal body mass
index (BMI) and glucose tolerance during pregnancy on specific aspects of
placental function relating to energy metabolism. In the first study, the
metabolic status of pregnant women with a high BMI, gestational diabetes or
with both conditions was assessed through analysis of maternal dietary
intake, weight gain and physiological characteristics during pregnancy. The
relative influences of these maternal conditions on placental, fetal and
newborn growth were further examined by analysing anthropometry of the
placenta, fetus and infant during the first year of postnatal age, and fetal
physiological characteristics at the time of delivery as reflected in cord blood.
In the second study, the crucial role of the placenta for maternal-fetal
exchange of nutrients and hormones was assessed by analysing placental
gene expression of some of the genes involved in key molecular pathways,
including placental insulin signalling, oxidative stress and inflammation.
Finally, the third study investigated folate status in the mother, placenta and
fetus through analysis of maternal and cord blood concentrations of folate,
and placental gene expression of key folate transporters. Placental DNA
methylation was also assessed in order to further elucidate the contribution of
maternal high BMI and/or gestational diabetes on epigenetic modifications
within the placenta and potential critical pathways.
In this Chapter, current knowledge on the relative and combined contributions
of obesity and diabetes in pregnancy to maternal, placental and fetal
physiopathological adaptations will be summarised and potential metabolic
pathways and molecular mechanisms within the placenta will be highlighted.
31.2. Early life programming
In recent decades, the rapid increase in metabolic disorders worldwide has
centered attention towards potential critical factors in early stages of
GHYHORSPHQW > @ 6LQFH WKH ³7KULIW\ 3KHQRW\SHʦ K\SRWKHVLV E\ +DOHV DQG
Barker was published in 1991 [6], new insights on metabolic adaptations in a
poor nutritional fetal environment started to be investigated. Such
adaptations include both an enhanced capacity to store fat through alteration
in insulin sensitivity and an adaptive response to optimize the growth of key
organs at a detriment to growth of less vital organs. The hypothesis
suggested that these adaptations are strategies for survival in similarly poor
nutritional post-natal environments; however, when exposed to over-
nutrition, maternal nutritional restricted offspring become more at risk to
develop metabolic disorders like obesity and type 2 diabetes mellitus (T2DM).
Epidemiological and animal studies following Barkers theory have confirmed a
link between birth weight and increased risk of metabolic diseases later in life
[7, 8], highlighting the crucial role of the in utero environment. The
phenotype of an individual is determined both in utero (maternal genetics and
nutritional state) and from early postnatal environmental factors (lifestyle
choices and habits) [9] (Figure 1.1). Poor nutrition in utero followed by
normal postnatal growth is a risk factor for the increased incidence of cardio-
vascular disease (CVD) [10], glucose intolerance and T2DM [6].
In the last twenty years, the dramatic surge in obesity and maternal obesity
have opened intriguing new insights focused on the potential detrimental
effect of these conditions on maternal and fetal health. Current evidence links
obesity and diabetes in pregnancy to the onset of the metabolic syndrome,
including obesity and diabetes, in the offspring [11-13]. However, the number
of studies investigating pregnancy outcomes among obese women is still
limited and needs further investigation.
4Figure 1.1: Programming of offspring obesity.
Fetal body composition, metabolism and gene expression can be directly or indirectly
influenced by the mother to develop patterns resulting in future obesity or other
metabolic disorders. The placenta can respond to the in utero metabolic environment
by altering transport processes, gene expression and metabolism. Adapted from [14].
51.3. The obesity pandemic
The past twenty years have seen a steep increase in being overweight and
obesity worldwide along with associated health risks. In 2005 the World
Health Organization (WHO) declared obesity as a worldwide pandemic and
estimated more than 1.4 billion adults as overweight with a body mass index
(BMI) range between 25 - 29.9 kg/m2 [15, 16]. Amongst these, over 200
PLOOLRQ PHQ DQG QHDUO\  PLOOLRQ ZRPHQ ZHUH FOLQLFDOO\ REHVH %0, 
30kg/m2). The BMI represents an efficient and widely used measure to
estimate adiposity and increased health risks related to excess body fat [17]
and it is defined as:
BMI = Body weight (kg) / Height2 (m2)
As recently discussed in the Lancet, changes in the global food system,
including reduction in time spent preparing food, excess food intake, dietary
imbalance, low physical activity, are the major drivers of this staggering rise
in obesity. Also, substantial differences in socio-cultural and economic
environment contribute to a wide variation in the incidence of obesity across
populations [15]. Global interventions have been undertaken although our
genetics is emerging to be critical in the present obesity epidemic [18]. The
continuous growth of obesity within the next two decades estimate 65 million
more obese adults in the USA and 11 million more obese adults in the UK by
2030 [19].
This will probably get worse as there is a parallel rise in childhood obesity as
reported by the European Environment and Health Information system
(ENHIS) in 2009 [20]. Greater body weight in infancy and childhood
significantly enhances the risk of becoming obese as an adult [21] with up to
70% of obese adolescents remaining obese as adults [22]. The consequent
increase of being overweight and obesity among pregnant women is also of
particular concern due to its additional risks for both the mother and newborn
[23, 24].
6The potential transgenerational transmission of obesity highlights the urgency
to further understand the impact of high BMI in pregnancy in order to improve
public health interventions.
1.4. Obesity in pregnancy
The National Health and Nutrition Examination Survey (NHANES) reported
that in the USA, the incidence of obesity in women between 20 and 39 years
of age tripled between 1960 and 2000 [25]. More recently in the UK, the
mean BMI of pregnant women at their first prenatal booking increased by
1.37 kg/m2 in 2004 compared to 1990 [26]. Obesity among American
pregnant women ranges from 18.5% to 38.3%, depending on the study-
cohort and cut-off point used [27]. A review from Guelinckx et al. summarised
the prevalence of prepregnancy overweight and obesity among pregnant
women from different countries [28, 29], showing that the incidence of
obesity ranges from 1.8% (China) to 25.3% (USA, New York), using WHO
criteria (Figure 1.2).
Maternal obesity may be related to the onset of metabolic syndrome in the
offspring through the association between maternal BMI with offspring
adiposity [12, 23, 30]. Obese gravidae experienced higher incidence of
obstetric complications, miscarriage [24], stillbirth as well as neonatal death
[31]. Furthermore, common complications seen in obese mothers include
gestational diabetes mellitus (GDM) and preeclampsia [32], conditions
associated with different birth outcomes. A large proportion of studies link
high pre-pregnancy BMI with GDM and fetal macrosomia, which results in
large for gestational age (LGA) offspring [33, 34]. Those neonates are at
increased risk of obesity and insulin resistance when they become adults [35].
On the other hand, a greater proportion of obese women develop
preeclampsia and give birth to small for gestational age (SGA) offspring [36,
37]. Whether these neonatal outcomes are caused by increased [38] or
reduced energy intake during pregnancy [39], is still under investigation [40].
7Figure 1.2: Prevalence (%) of overweight and obesity in pregnant women.
Overweight and obesity in pregnant women using data from the World Health
Organization (WHO) and the *Institute of Medicine (IOM). Adapted from [27].
Overall, it is clear that the underlying cause of maternal obesity is
multifactorial, taking into account caloric intake, physical activity and potential
genetic components. However, the exact contribution of each factor to
offspring health is still unclear and will be examined in more detail in the
following sections.
81.4.1. Maternal diet and nutrient intake
Maternal diet during pregnancy may influence outcomes of pregnancy and
childhood. Whilst diet in the first trimester may be more important for organs
development and differentiation, diet later in pregnancy may be important for
overall fetal growth and brain development [41]. Beneficial changes in diet, if
continued after pregnancy, may have long term benefits for womens health.
In 2010 the NICE published public health guidelines on dietary and physical
activity interventions for weight management before, during and after
pregnancy [42]. However, data on determinants of dietary quality during
pregnancy are scarce. Recent studies emphasize the importance of specific
aspects of a healthy maternal dietary pattern, such as the association of folic
acid intake in a Mediterranean diet compared with that in a Western diet and
spina bifida [43], and the association of high calcium intake with greater bone
mass in the offspring at the age of 9 years [41]. In obese pregnancies,
inadequate intake of vitamin D, calcium, folate and iron can partly explain the
occurrence of complications such as neural tube defects [41, 44].
Overweight and obesity have been related to diet of poor quality, unbalanced
[45], rich in fat and low in dietary fibre and essential micronutrients [41, 46].
This is, in turn, associated with increased maternal weight gain with important
implications for long term maternal [47] and offspring obesity [48, 49]. Both
animal [46] and epidemiological studies [50] have shown that prolonged
reduction in maternal food intake or consuming an imbalanced diet at critical
stages of development compromise offsprings health. Given the adverse
consequences of obesity, these women might be encouraged to diet during
pregnancy with the aim to reduce or minimise the negative outcomes [39].
One of the major factors that influence nutrient intake, dietary restriction and
its health awareness is socioeconomic status [22]. Women consuming poorly
balanced diets, with high sugar and fat content and inadequate micronutrient
status, are usually younger, have lower educational attainment and have
higher pre-pregnancy BMI [41].
9Women who diet in pregnancy are characterised as having a low annual
income, pre-existing T2DM and/or mental stress and current smoking [51].
Successful intervention strategies are hence directed to those mothers of
lower socioeconomic status at risk of poor diet, obesity or hyperglycaemia
[52, 53]. Nutritional interventions have indicated that a health conscious diet
leads to less total energy intake, reflected by less dietary fat and more fruit
[54]. Conversely, a Western diet, based on red and processed meat with
high fat products, increases the risk of having a SGA infant [54].
In addition, the type and amount of dietary carbohydrate also have highly
significant effects on fetal growth and size at birth. Women consuming a low
glycaemic index diet were found to have reduced levels of triglycerides (TG),
total cholesterol and C-reactive protein (CRP) and a lower cardiovascular risk
[55]. As reviewed by Clapp these women deliver normal sized infants within
the 25th and 75th body weight centiles whereas a high glycaemic diet during
pregnancy is associated with overgrown infants [56]. A large epidemiological
study confirmed these findings by directly linking glycaemic index of the diet,
plasma glucose, fetal growth and birth weight [57].
As such, the need to optimise dietary intake as well as lifestyle habits before,
during and after pregnancy is becoming essential, especially in pregnant
women with high BMI.
1.4.2. Maternal weight gain
The consumption of an unhealthy diet in pregnancy is often associated with
increased gestational weight gain (GWG) with adverse consecuences for
mother, fetus and the newborn [47, 58]. Longitudinal studies link maternal
weight gain in pregnancy with offspring birth weight and their BMI later in life
[59], although some others have not observed differences [60].
In 1990 the Institute of Medicine (IOM) recommended target weight gain
ranges for pregnant women and, recently, acknowledged the need to consider
additional factors for each individual, including the severity of obesity [61].
10
Therefore, in 2009, new IOM guidelines were published based on the WHO
cut-off point for the BMI categories [61], in which a specific narrow range of
recommended weight gain for obese women was also included (Table 1.1).
However, the NICE has recently reported that there are no evidence-based UK
guidelines on recommended GWG [42] as the amount of weight a woman may
gain in pregnancy can vary a great deal with only some of being due to
increased body fat.
Table 1.1: Recommended gestational weight gain.
World Health Organization (WHO) and Institute of Medicine
(IOM) classifications
Total weight gain Rates of weight gain 2
nd
and 3
rd
trimester
Pre-pregnancy BMI
categories
BMI
(kg/m
2
)
Range in
kg
Range in
lbs
Range in
kg/week
Range in
lbs/week
Underweight < 18.5 12.5 - 18 28 - 40 0.44 - 0.58 1 - 1.3
Normal weight 18.5 - 24.9 11.5 - 16 25 - 35 0.35 - 0.50 0.8 - 1
Overweight 25.0 - 29.9 7 - 11.5 15 - 25 0.23 - 0.33 0.5 - 0.7
2EHVLW\     
Weight gain during pregnancy according to pre-pregnancy BMI categories as
recommended by the World Health Organization (WHO) and Institute of Medicine
(IOM) in 2009. Calculations assume a 0.52 kg (1.14.4 lbs) weight gain in the first
trimester (based on [61]).
Exceeding the recommended GWG [61] has been associated with greater
adiposity and metabolic traits in children as well as greater postpartum weight
retention in the mother [59]. In fact, there is strong evidence linking high
GWG with subsequent maternal overweight and long term obesity [47, 58].
In addition, increases in BMI before and between pregnancies have been
highly associated with enhanced risk of adverse pregnancy outcomes [62, 63]
and childhood obesity [64]. Despite greater GWG being associated with high
maternal BMI [48] and the development of GDM [65], it is also frequent
among mothers with a lean BMI [66].
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Prevention of excessive weight gain before, and between pregnancies in
women with a healthy BMI is therefore recommended [3].
Finally, current evidence pointed out that the prevalence of excessive
gestational weight gain declined, and weight loss increased, as obesity
became more severe [32]. The resulting offspring have enhanced risk of being
SGA with long term adverse outcome [67, 68]. As such, to avoid such
consequences, overweight and obese women are recommended to diet before
planning a pregnancy rather than during the gestational period [42].
1.5. Gestational diabetes mellitus
The increasing prevalence of obesity among women of reproductive age is
contributing to the development of GDM [69]. There are different types of
diabetes mellitus, depending either on beta-cell failure to produce insulin
(Type 1 diabetes mellitus (T1DM)) or on a chronic defect in their function,
ultimately resulting in beta-cell resistance to insulins activity (T2DM) [70].
GDM, by definition, occurs only in pregnancy, usually in the second half [71],
and shares pathophysiologic similarity with T2DM [72]. This condition is
characterised by greater reduction in insulin sensitivity and insufficient insulin
production to meet pregnancy demands [33]. The increased insulin resistance
of GDM women, together with decreased pancreatic beta-cell reserve, triggers
impaired glucose tolerance, ultimately resulting in a state of hyperglycaemia
and hyperinsulinaemia in the maternal circulation [73].
The diagnosis of GDM worldwide is made by using 75 g glucose load.
However, different countries have recommended various glucose loads (50,
75 or 100 g) in non pregnant individuals [74]. It is controversial whether
maternal hyperglycemia less severe than that required for a diagnosis of
diabetes is associated with increased risks of adverse pregnancy outcomes.
As such, based on the results of the Hyperglycaemia and Adverse Pregnancy
Outcome (HAPO) study [75], an international group of experts has developed
recommendations for diagnostic criteria for GDM.
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Essentially, pregnant women at high risk of GDM are screened by taking a
glucose challenge test (GCT) between 16 and 20 weeks of gestation and a
timely oral glucose tolerance test (OGTT) (usually within a week) if the
plasma glucose concentration is above 7.5 mmol/l. An early negative or
positive GCT followed by a negative OGTT results in a second screening test,
which is undertaken in the later period of pregnancy (26-30 gestational
weeks) [76].
Clinical factors reported to predict the development of T2DM in women with a
history of GDM include high pre-pregnancy BMI as well as elevated fasting
glucose and hyperglycaemia in pregnancy [74]. It is currently estimated that
about half of women of childbearing age are either overweight or obese [42],
and, in England, 15.6% of women at the start of pregnancy are obese [23].
On the other hand, 10-25% of pregnant women develop GDM [77, 78],
among which 65-75% are overweight or obese [75, 79], making it difficult to
tease apart the relative contribution of maternal BMI and glycaemia on
pregnancy outcomes. Similar to obese pregnant women, those with GDM are
at increased risk for perinatal morbidity as well as impaired glucose tolerance
and T2DM in the years post-pregnancy [72, 80]. In addition, their children
have an increased risk of developing obesity, insulin resistance and
hypertension in childhood and early adulthood [70, 81]. Therefore,
considerable attention has been focused on the pathological effects of obesity
and how they may be related to insulin resistance, beta-cell dysfunction, and
the clinical development of GDM and T2DM. The emerging risk factors linking
maternal obesity with GDM will be discussed in the following section.
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1.6. Metabolic alterations with obesity and
diabetes
Glucose and macronutrient intake have been associated with oxidative stress
and inflammatory changes through an increase in fat mass [82]. Chronic
overnutrition, high adiposity and hyperlipidaemia are common features of
obesity and represent a pro-inflammatory state associated with oxidative
stress [83]. Pregnancies complicated by obesity are characterised by a
greater degree of insulin resistance, hyperlipidaemia, exaggerated
inflammatory response and poor microvascular function [22].
A potential role of visceral fat [84] in contributing to increased lipid response
in obese individuals with greater degree of oxidative stress has been
highlighted [31, 83]. The resulting lipotoxicity seems to be responsible for the
observed endothelial abnormality of obese women and can influence gene
expression by acting as ligands for nuclear receptors. Oxidised lipids have
been shown to induce plasminogen activator inhibitor-1 (PAI1) expression and
reduce insulin-mediated vasodilatation [85]. Increased levels of plasma
cytokines induced by oxysterols reflect the tight correlation between obesity,
oxidative stress and inflammation [86]. This has been confirmed by laser
Doppler imaging showing impaired endothelial function, dyslipidaemia and
inflammatory up-regulation in obese pregnant women [83].
Furthermore, enhanced circulating levels of CRP, tumour necrosis factor-alpha
71)ĮLQWHUOHXNLQ,/DQGOHSWLQDUHUHSRUWHGLQREHVHZRPHQDVDUHVXOW
of higher visceral adiposity [87, 88].
These generate an acute inflammatory response among obese subjects
leading to the recruitment of macrophages. Increased monocyte chemotactic
protein-1 (MCP1) in adipose tissue [89, 90] as well as in the placenta [91-93]
contribute to the chronic inflammatory status of obesity. Similarly, as a result
of GDM, an increase in a wide range of cytokines, growth factors and
hormones is observed in the maternal circulation of GDM women.
14
Paradisi et al. provided evidence that the endothelial dysfunction found in
diabetic pregnant women is strongly correlated with elevated plasma glucose
independent of the degree of adiposity [94]. Women who develop diabetes
show higher incidence of obesity, abnormal insulin secretory function and
insulin resistance [34]. The chronic inflammation and adipokine dysregulation
caused by obesity is related to insulin resistance and beta-cell dysfunction
contributing to the development of T2DM [95] (Figure 1.3).
Figure 1.3: Overnutrition and obesity activate the immune system.
(A) Overnutrition and obesity cause activation of the immune system, which in turn
promotes insulin resistance, ultimately, leading to type 2 diabetes mellitus (T2DM).
(B) Inflammatory markers resulting from obesity can be indirectly associated with the
GHYHORSPHQWRI7'071)ĮWXPRUQHFURVLVIDFWRUDOSKD,/LQWHUOHXNLQ
Obesity, T2DM and insulin resistance are similarly associated with raised
concentrations of non-specific markers of the immune system including total
gamma-globulin concentration, white blood cell count, and CRP. Excess of free
fatty acids (FFA), reactive oxygen species (ROS) and pro-inflammatory
cytokines activate c-Jun N-terminal kinase (JNK) and nuclear factor kappa-
light-chain-enhancer of activated B cells (NFkB) signalling [96, 97].
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Accordingly, it seems that inflammation critically links obesity, insulin
resistance and obesity-related diseases through modulation of insulin
signalling. However, the mechanisms underlying the inflammatory state of
obesity and T2DM are still under investigation.
As will be discussed in section 1.7, post-receptor defects in the insulin
signalling cascade seem to be responsible for this condition [98].
1.7. Insulin signalling in obese and GDM
pregnancies
Obesity is a common antecedent of GDM and many of the biochemical
mediators of insulin resistance associated with obesity have been identified in
small studies of women with GDM or a history of diabetes [99, 100]. These
mediators include increased circulating leptin [101] and the inflammatory
PDUNHUV 71)Į >@ DQG &53 >@ ,Q DGGLWLRQ GHFUHDVHG OHYHOV RI
adiponectin [104] and increased fat in liver and muscle [105] are other
markers of insulin resistance. In vitro studies of adipose tissue and skeletal
muscle from women with GDM reveal abnormalities in the insulin signalling
pathway as a result of altered levels of cytokines and hormones [73, 106].
These aberrations in insulin signalling are similar to the ones reported with
maternal obesity and cause changes in the expression levels of its
FRPSRQHQWVUHVXOWLQJLQUHGXFHGLQVXOLQDFWLRQ71)ĮLPSDLUVLQVXOLQUHFHSWRU
(IR) signalling by inhibition of IR substrate-1 (IRS1) activity whereas
hyperleptinaemia leads to insulin resistance by activation of suppressor of
cytokine signalling (SOCS) proteins. These ultimately reduce leptin and IR
signalling [107]. Abnormal subcellular localization of glucose transporter 4
(GLUT4) [108] and decreased expression of peroxisome-proliferator activated
UHFHSWRUJDPPD 33$5Ǆ >@ DUH DOVR GHWHFWHG LQ *'0 SUHJQDQFLHV DQG
could contribute to the observed reductions in insulin-mediated glucose
transport.
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Insulin activates two main signalling pathways: the phosphatidylinositol 3-
kinase/protein kinase B (PI3K/PKB) and the mitogen-activated protein kinase
(MAPK) pathway [110] (Figure 1.4). The PI3K/PKB pathway induces the
metabolic effect of insulin resulting in translocation of GLUT4 together with
glycogen and protein synthesis. On the other hand, the MAPK pathway
stimulates proliferation, migration and angiogenesis.
Experiments using knockout mice and isolated cells in vitro suggest that MAPK
signalling is mainly activated via IRS1 whereas IR substrate 2 (IRS2) plays a
key role in the regulation of carbohydrate metabolism [111]. Therefore,
expression changes of any insulin signalling component may affect IR signal
transduction and ultimately, insulins effects.
Figure 1.4: Insulin signalling pathways.
Insulin binds to its receptor (IR), triggering the tyrosine kinase activity which causes
activation of the enzyme mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-kinase/protein kinase B (PI3K/PKB).
A) Activation of MAPK leads to completion of mitogenic functions like cell growth and
gene expression. B) Activation of PI-3K leads to crucial metabolic functions (synthesis
of lipids, proteins and glycogen) and cell survival and proliferation. Most importantly,
the PI3K pathway is responsible for passive diffusion of glucose in cell through
translocation of GLUT4.
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1.8. Regulation of human fetal growth
The intrauterine environment in which the fetus develops represents a major
physiological, hormonal and environmental challenge for its survival and long
term health. Embryonic nourishment prior to implantation is initially
histiotrophic, with the trophectoderm phagocytosing first oviductal and then
uterine secretions. Following implantation and establishment of the
chorioallantoic placenta, the nourishment of the fetus is provided by exchange
between the maternal and fetal circulation (haemotrophic nutrition) [112].
The assumption that in humans the transition to haemotrohic nutrition occurs
soon after implantation has been recently questioned. In fact, there is now
evidence that the maternal placental circulation is not fully established until
the end of the first trimester, with the uterine glands releasing secretions into
the intervillous space until at least 8 weeks of pregnancy, which are then
taken up by the syncytiotrophoblast [113, 114]. Histiotrophic nutrition
provides nutrients under a low oxygen concentration, so reducing the risk of
damage from free radical during the sensitive period of organogenesis. Once
this is complete, and fetal oxygen requirements rise, transition to
haemotrophic nutrition at the start of the second trimester follows, with the
complete establishment of the maternal placental circulation.
Thus, multidirectional interactions between mother, placenta and fetus during
development are critical to regulate and ensure normal fetal growth. Key
gestational adjustments involving circulatory and metabolic changes are
necessary to provide adequate nutrition and oxygen to the fetus, which, on
the other hand, influences maternal nutrient supply and oxygen via the
placenta. This crucial organ represents the maternal fetal exchange barrier
and regulates fetal growth through the production and metabolism of growth-
regulating hormones such as insulin-like growth factors (IGFs), leptin and
glucocorticoids (GC) [115-117]. In addition, the placenta will respond to fetal
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endocrine signals via changes in its morphology, activation of transport
systems and production of its own hormones.
As such, the placenta not only promotes fetal growth, but also influences
maternal physiology and even behaviour. Similarly, maternal hormones such
as insulin, leptin, and insulin-like growth factor-1 (IGF1) regulate placental
nutrient transport and the maternal side of the placenta expresses numerous
hormone receptors, including receptors for insulin [118], IGF1 [119], and
leptin [120]. This is consistent with regulation of trophoblast function by
maternal hormones.
1.8.1. Maternal metabolic changes in pregnancy
During pregnancy, the mother modifies her metabolism in order to meet the
nutritional needs of the developing fetus. The first trimester is an anabolic
state characterised by increased maternal body weight through hyperphagia
and storage of nutrients in adipose tissue (Figure 1.5). This is facilitated by
increasing insulin sensitivity of adipose tissue which promotes de novo
lipogenesis [121]. Lean women increase their fat stores more than obese
women per kilogram body weight, which is likely be mediated by their higher
insulin sensitivity in early pregnancy [122].
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Figure 1.5: Anabolic maternal metabolism in the 1st trimester of pregnancy.
The mother stores lipids, carbohydrates and proteins as a result of the enhanced
insulin sensitivity and hyperphagia.
From mid- to late gestation, maternal lipid metabolism switches to a catabolic
state as a result of elevated fetal nutrient demand (Figure 1.6). In this stage,
maternal insulin sensitivity significantly decreases allowing the mother to
provide large amounts of nutrients to the fetal placental unit via diffusion or
active transport across the placenta. Adipose tissue lipolytic activity increases
under the hormonal control of progesterone, cortisol, prolactin and leptin
[123]. Also, high circulating oestrogens cause a decrease in extra-hepatic
lipoprotein lipase (LPL) activity [124] while the intestinal absorption of dietary
fats increases [125].
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Figure 1.6: Catabolic maternal metabolism in the 3rd trimester of pregnancy.
Catabolic maternal metabolism in the 3rd trimester of pregnancy provides availability
of nutrients to sustain fetal growth. GH: Growth hormone; hPL: Human placental
lactogen; pLPL: placental lipoprotein lipase; NEFA: Non-esterified fatty acids; TG:
Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.
All these events result in elevations of FFA and glycerol plasma concentrations
taken up by the liver. Hyperlipidaemia occurs during this phase, representing
the increased levels of lipolytic products in the circulation combined with
enhanced TG production by the liver. TG do not cross the placenta but are
used to release FFA, which are transported through the placenta to provide a
source of energy for the fetus. During the last week of gestation, mainly
under fasting conditions, FFA and glycerol released from the adipose tissue
are also taken up by the liver and undergo beta-oxidation to form ketones
[126]. These substrates cross the placenta and provide fuel for the fetus, and
can, otherwise, be used by maternal tissues. During the first trimester,
protein synthesis remains similar to that of non-pregnant women, whereas in
the second and third trimesters this increases by 15% and 25%, respectively
[127].
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Overall, throughout gestation, protein synthesis in maternal tissues increases
whereas a slightly reduction (about 10%) in amino acids oxidation occurs.
Pregnancy is a state of insulin resistance, characterised by a 40-80%
decrease in insulin sensitivity throughout gestation [128]. Whilst a majority of
women maintain normal glucose tolerance, approximately 10-25% develop
GDM [42]. As previously summarised, insulin resistance in GDM cannot be
sufficiently compensated by maternal insulin production resulting in
hyperglycaemia and hyperinsulinaemia [129]. This significant reduction of
insulin sensitivity is also observed in obese women with normal glucose
tolerance and GDM during late gestation [130].
All three major insulin target tissues (liver, skeletal muscle and adipose
tissue) develop insulin resistance during normal pregnancy and to an even
greater extent when associated with obesity and GDM. Insulin stimulated
glucose transport in skeletal muscle decreases considerably during pregnancy,
becoming worse in GDM subjects [131]. Similar results occur in isolated
adipocytes where a more severe decrease in glucose transport occurs in
obese women with GDM [132]. Additionally, obese subjects with or without
GDM show decreased suppression of hepatic glucose production during insulin
infusion with advancing gestation [130, 133].
As discussed in Section 1.8.6, various placental hormones can reprogramme
maternal physiology to meet fetal needs. However the cellular mechanisms
for this complex transition are still unclear [134].
1.8.2. The placenta: the programming agent
The placenta constitutes the active interface between the maternal and fetal
circulation, regulating maternal physiological changes and fetal homeostasis.
In fact, this vital organ provides a wide range of functions, including immune-
protection and supply of nutrients and oxygen to the growing fetus [135], and
receives and transmits endocrine signals between the mother and the fetus
[136].
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The slowing in placental growth at 35-36 gestational weeks reflects the major
structural changes in this organ allowing a considerable increase in its
function. The rise in maternal-placental blood flow throughout pregnancy is
reflected by a 40 fold increase in the fetal/placental weight ratio from 6 weeks
to term [137]. This higher efficiency results from vascular adaptations during
development, which ensure the transport of nutrients across the placenta.
Any perturbations in the maternal compartment influence placental function
and trigger adaptive responses in the growing fetus.
Placental insufficiency, which reflects a reduced ability of the placenta to
exchange nutrients and waste products between mother and fetus, is the
main cause of IUGR in the absence of maternal undernutrition or fetal genetic
anomaly [138]. For many years placental insufficiency has been associated
exclusively with reduced blood flow through the uterine and/or fetoplacental
circulations [139, 140] as a result of abnormal vascular development [141] or
dysregulation of uterine and/or fetoplacental vessels [114]. However, recent
evidence pointed out that placental insufficiency can additionally involve
physical abnormalities, including decreased surface area and increased
thickness of the exchange barrier, and molecular abnormalities [138]. Among
these, reduced activity of key plasma membrane nutrient transporters in the
syncytiotrophoblast, such as glucose and System A amino acid transporter
have been associated to IUGR [142, 143].
In diabetes, the placenta undergoes a variety of structural and functional
changes, which depend on a range of variables. Significant factors are the
quality of glycaemic control during placental development, the modality of
treatment, and the period of severe hyperglycaemia. Diabetes at the
beginning of pregnancy may have long term effects on placental development
resulting in adaptive responses to the diabetic environment [144]. Placental
action to compensate excess of maternal glucose may limit fetal growth.
However, if the duration or extent of the diabetic insult exceeds the placental
ability to adequately respond, excessive fetal growth may follow [145].
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Conversely, diabetes experienced at the later stages in gestation, such as in
GDM, will mainly lead to short term changes in a variety of molecules for key
functions including gene expression [133].
The effect of maternal obesity on placental structure at the microscopic level
has not been examined in detail. Given the abnormalities observed in
placental morphology from women with gestational diabetic (i.e. higher
presence of villous immaturity, chorangiosis and ischemia) [146], it is
plausible that obesity may also affect placental structure in a similar way. A
study by Challier et al. supports this hypothesis by demonstrating a 2 to 3
fold increase in placental macrophages in obese women compared with non-
obese women [92]. These observations, together with previous findings, have
demonstrated the critical role of the placenta in fetal programming [147].
Accordingly, the placental phenotype is proposed as a better representation of
the intrauterine environment than birth weight [116].
The following sections will therefore examine aspects of placental function
critical for fetal growth and development with particular emphasis on placental
vascular development and blood flow, nutrient transfer capacity and
regulation of hormone production.
1.8.3. Placental blood flow and vascular
development
As pregnancy progresses, a rise in blood flow from the maternal circulation is
required to compensate the increased metabolic demand from the growing
uterus. Throughout gestation, total maternal blood volume and cardiac output
increase by approximately 40%, and the total utero placental blood flow
represents 25% of cardiac output [148]. The uterine artery volume flow rate
is enhanced by more than 3 fold during pregnancy, partly reflecting an
increased artery diameter and reduced flow resistance [149], which results
from the establishment of the utero-placental circulation.
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Other maternal adaptations during normal pregnancy include the development
of new blood vessels in the uterus, possibly promoted by the placental
hormones human chorionic gonadotropin (hCG) [150] and insulin-like growth
factor-2 (IGF2) [151]. Decreased rates of placental blood flow, reflecting
reduced fetal oxygen and nutrient uptake, are associated with lower fetal and
placental growth [139, 152]. Obese gravidae with impaired endothelial
vasodilatation often show increased incidence of preeclampsia and placental
dysfunction [86], and a high fat diet (HFD) in pregnancy alters placental
haemodynamics and structure [153]. Furthermore, when hyperinsulinaemia is
associated with obesity in pregnancy, these alterations appear to be even
more severe with reduced blood flow to the fetus increasing susceptibility to
stillbirth [39].
The term human placenta consists of a tree-like, villous structure covered by
terminally differentiated syncytiotrophoblast. This syncitium is formed by the
fusion of subjacent cytotrophoblast cells, which are mitotically active during
feto-placental development, contributing to the establishment of the utero-
placental circulation [154]. Throughout the first trimester, the intervillous
space of the developing placenta is separated from the uterine circulation by
plugs of trophoblast cells that occlude the tips of the uteroplacental arteries
[141]. In order for maternal placental blood flow to increase normally, it is
critical that invasive trophoblast cells migrate into the maternal decidua,
resulting in the remodelling and opening of the maternal spiral arteries. This
implicates the degeneration of elastic and smooth muscle tissue in spiral
artery walls and the replacement of endothelial cells by trophoblasts [155]. At
the end of the first trimester, these plugs are dislocated, allowing maternal
blood to flow freely and continuously in the intervillous space. As a result,
maternal blood enters the placenta via the spiral arteries, which delivers blood
directly to the intervillous space (Figure 1.7).
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Figure 1.7: Schematic representation of the human placenta, with a cross-
section representation of terminal villi (inset).
1) The villi are composed of fetal connective tissue and are covered by trophoblasts,
which are the parenchyma of the placenta involved in nutrients exchange and
production of placental hormones. 2) The cytotrophoblast is made up of distinctly
separate cells that form a continuous layer in early pregnancy, which is reduced to a
few scattered large pale cells later in pregnancy. 3) Most villi are free in the intervillous
space (IVS) and are bathed in blood from the maternal vessels. 4) In the area of the
trophoblastic membrane, placental tissue is evaluated for fibrin-type fibrinoid and
matrix-type fibrinoid. Perivillous fibrinoid is a matrix-type fibrinoid that replaces the
trophoblastic cover of the villi. 5) The outer covering of the villi is the
syncytiotrophoblast, a syncytium with many dark-staining nuclei, which, during the
latter half of pregnancy, form groups of aggregated nuclei forming syncytial knots
(from [156]).
The whole process is normally completed by 1618 gestational weeks and
leads to spiral arteries transformation into dilated vessels, which are
unresponsive to vasoconstrictors [141]. Inside the villous core, tissue-resident
macrophages, fibroblasts, and placental blood vessels are surrounded by
extracellular matrix. On the fetal side, blood with low oxygen saturation and
low nutrient concentration is transported by two umbilical arteries, which
enter the placenta.
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These ramify into smaller vessels resulting in a capillary network at the tips of
the villi for then merging again to form the vein of the umbilical cord. Thus,
the maternal and the fetal compartment are in contact with different surfaces
of the placenta. Severe reduction in trophoblast invasion results in decreased
intervillous blood flow and IUGR fetuses [139].
A large body of evidence indicate that increased placental angiogenesis and
feto-placental vessels are features of maternal diabetes. Higher fetal levels of
fibroblast growth factor-2, which stimulate placental angiogenesis, are
associated with T1D diabetes leading to the hypercapillarisation [157].
Increased capillary length, branching and surface area have been reported for
both T1D [158, 159] and GDM [160] although reports on the latter are still
conflicting [161, 162]. Higher levels of circulating glucose and insulin have
profound effects on the fetal vascular system and can be responsible of these
observed changes [163].
Avagliano found that maternal BMI was the major maternal risk factor of
abnormal spiral artery remodelling during pregnancy [164]. This endothelial
dysfunction may result from chronic hypertriglyceridemia and hyperlipidemia
observed in obese subjects. In addition, hyperglycaemia has been shown to
have a direct effect on vascular development [165]. The inflammatory
response generated by obesity is accompanied by impaired vascular and
endothelial function with increase production of angiogenic and factors.
However, comparative studies of placental morphological changes in obese
pregnant women are currently scarcely available in the literature indicating
the need of further research [166].
1.8.4. Placental size and morphology
Placental weight and ratio to birthweight are predictors of the long term
outcome for the offspring as reported in epidemiological data [167]. Increased
placental to fetal weight ratio seems to represent an adaptive process by the
feto-placental unit to an unfavourable maternal environment. Changes in
placental growth have been shown to influence fetal development.
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Whilst intrauterine growth restricted (IUGR) newborns are associated with
smaller placental volume, GDM, even with optimal glycaemic control [168],
leads to greater placental weights and birth weight ratios [169].
One mechanism by which placental size influences nutrient transfer is via
changes in its morphology. In fact, alterations in the placental surface area,
vascularity and cell composition affect placental function. A growing body of
evidence confirms a link between maternal diabetes and changes in placental
morphometry [170], changes in the villous surface area [171] and deposition
of perivillous fibrinoid at sites of epithelial damage [172]. These alterations
reflected a perturbed placental haemodynamic and transport [172].
Interestingly, placental morphology has been shown to be preserved in
diabetic subjects with good glycaemic control [173]. Further studies have
confirmed the presence of morphological abnormalities associated with GDM,
including villous immaturity and chorangiosis [174], degenerative lesions and
abnormal distribution of fibronectin [175].
Obese women show an increased systemic pro-inflammatory status similar to
that of preeclampsia and diabetes, suggesting obesity could be linked to
similar changes in placental morphology. Roberts et al. were the first to
describe structural changes in the placenta of obese women [176].
Unexpectedly, his findings showed only a generalised increased in vessel
muscularisation without any major placental alterations. Additional data is
needed however to explain the link between placental inefficiency and altered
structure in pregnancies complicated by obesity.
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1.8.5. Placental nutrient transport
In physiological conditions, the placenta is able to use 40-60% of the total
glucose and oxygen supplied by the uterine circulation [177]. The remaining
nutrients and metabolites are transferred by different mechanisms through
the two polarized plasma membranes of the syncytiotrophoblast, which are in
contact with both the maternal and the fetal compartment (Figure 1.8). The
microvillous plasma membrane (MVM) of the syncytiotrophoblast faces the
maternal blood whereas the endothelium of the basal plasma membrane (BM)
is adjacent to the fetal capillary [178]. As in other epithelial cells, differences
in type, number and activity of transporters in these two plasma membranes
provide the basis for transplacental transport of primary nutrients [145, 179-
181].
Figure 1.8: Placental nutrient transport is regulated by maternal, placental
and fetal factors.
MVM: microvillous plasma membrane; BM: basal plasma membrane; FATPs: fatty acid
transporter proteins; FABPs: fatty acid binding proteins; GLUTs: glucose transporters.
Adapted from [180].
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Changes in the expression or activity of placental transporters have been
associated to altered fetal growth [182, 183]. Evidences from human data
report that IUGR placentas show alterations in placental vasculogenesis [184],
trophoblast transporters expression [183], trophoblast enzyme activity and
hormone production [185]. Specific upregulation of placental transporters
seems to explain the occurrence of fetal overgrowth in GDM and T1DM [186].
As suggested by Cetin et al., changes in placental nutrient transport resulting
from increased exchange surface area or increased transporter densities,
could further enhance substrate levels and fetal growth in diabetic
pregnancies [187]. On the other hand, no data with respect to placental
transport function are currently available in high BMI pregnancies, making it a
novel and intriguing field of investigation.
1.8.5.1. Glucose
Glucose represents the primary source of energy for the human fetus and the
placenta during development. Fetal glucose production is minimal and,
therefore, it is entirely dependent on placental supply from the maternal
circulation [188]. Net transport of glucose from mother to fetus across the
placenta requires a net maternal-fetal plasma glucose concentration gradient,
which is maintained via facilitated diffusion involving transporters on both
maternal and fetal side of the trophoblast [189].
Glucose transporters (GLUTs) are highly expressed in the MVM allowing rapid
glucose uptake into the placenta for its own use while maintaining a gradient
between the syncytiotrophoblast cell and fetal capillary [188]. The lower
GLUTs expression in the BM, which is in contact with the fetal surface, has
pointed out that this placental membrane represents the rate limiting step in
placental glucose transport [180, 190, 191].
Glucose transporter-1 (GLUT1) is the primary placental glucose transporter in
humans at term and is constantly expressed throughout pregnancy [192].
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Its expression in both MVM and BM increases in the first half of pregnancy and
remains constant thereafter [193], suggesting that this placental glucose
transporter is regulated early in pregnancy, but not at term.
Furthermore, the increase in placental surface area in the latter part of
pregnancy as well as the maintenance of a high GLUT1 density can explain
the increase in placental glucose transport at term [189, 193]. Glucose
transporter 4 (GLUT4), on the other hand, is primarily expressed during the
first trimester [194] and is affected by defective insulin signalling [195] (see
Section 1.7).
It has been hypothesised that excess maternal glucose in pregnancies
complicated by diabetes increases placental glucose transfer to the fetus
[196]. This, in turn, results in fetal hyperglycaemia and hyperinsulinaemia
[197] leading to the delivery of LGA infants [186]. However, macrosomia
occurs even under strict glycaemic control [198], suggesting that
hyperglycaemia alone is not driving fetal overgrowth but other molecules are
involved in the metabolic alterations of diabetes.
In patients with T1DM, hyperglycaemia is detected prior to gestation, whereas
GDM is diagnosed during the second half of pregnancy. Human studies have
demonstrated that patients with GDM controlled by diet had reduced placental
glucose transport compared with insulin treated GDM [199]. Powell et al.
found higher glucose transport activity and enhanced GLUT1 expression in the
BM of placentas from T1DM pregnancies with LGA infants [198]. This was not
observed in pregnant women with GDM delivering LGA offspring [200].
Therefore, the authors suggested that hyperglycaemia upregulates this
transporter in the first trimester leading to accelerated fetal growth in late
gestation. As the activity of GLUT1 is influenced by glucose concentration, and
not by insulin, high glucose levels leads to its saturation [201], pointing out
that this transporter may not be the main cause of macrosomia in diabetic
pregnancies. Although the role of insulin in regulating placental glucose at
term is controversial [117, 202], its effect on placental glucose transport has
been demonstrated in the first trimester [203].
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This has highlighted a potential role of GLUT4 in T1DM pregnancies [195].
Conversely, the incidence of macrosomia in pregnancies complicated by GDM,
even under optimal glycaemic control, suggests that different nutrients other
than glucose can contribute to fetal overgrowth in these complicated
pregnancies (see section 1.8.5.2).
The short- and long term outcomes of maternal obesity for both mother and
fetus have been recently reviewed by Catalano and Ehrenberg [204]. Jones et
al. has demonstrated that mice fed with a HFD (32% energy from fat) are
associated with upregulation of GLUT1 and sodium-dependent neutral amino
acid transporter 2 (SNAT2) in the MVM [205]. This suggests that maternal
HFD and obesity are linked to fetal overgrowth via increasing specific
placental transporters. Ericsson et al. reported that hormones, such as leptin,
growth hormone (GH), IGF1, insulin and cortisol, did not affect glucose
transporter activity at term [117]. In contrast, insulin stimulated glucose
uptake was enhanced in primary villous fragments obtained at 68 weeks of
gestation [203]. This may be related to the presence of the insulin-sensitive
GLUT4 in the cytosol and syncytiotrophoblast MVM in the first trimester.
1.8.5.2. Amino acid transport
The active transport of amino acids across the human placenta is suggested
by a higher concentration of these metabolites in the fetus compared to that
in the mother [206]. Their transport across the polarized syncytiotrophoblast
membranes occurs via proteins located in both the BM and MVM [178, 207].
Accumulative amino acids transporters mediate net uptake of specific amino
acids into the syncytiotrophoblast, which are exchanged for those in the
maternal or fetal circulation by exchange transporters [181]. The function of
the exchangers is dependent on the activity of accumulative transporters on
the MVM and facilitated transporters on the BM, which directs the critical
passage of amino acids from the placenta to the fetus [178]. Thus,
impairment in rate limiting activity of efflux transporters on the BM [190] or
MVM [191] compromises fetal growth.
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As such, in vitro studies of isolated MVM and BM represent a valuable
experimental system to elucidate the cellular mechanisms of this selective
transport through the placenta. Five different transport systems for neutral
amino acids have been identified in the human syncytiotrophoblast using
villous tissue fragments, in vitro perfused placenta, cultured trophoblast cells
and cell lines [207]. Sodium-dependent transporter for alanine, proline,
glycine, and serine (System A) is found mostly active in on the MVM whereas
system ASC, seems to be localized mostly on the BM. The placenta can also
metabolize and process amino acids itself, such as leucine, which are then
transferred to the fetus [207].
Hypoxia, NO, and ROS have been shown to reduce the activity of several
placental amino acid transporters, and a decrease in essential amino acid
transport has been associated with IUGR [208, 209]. Jansson et al. described
higher activity of system A transporter in both T1DM and GDM diabetes [183],
and increased activity of L and ASC transporters in diabetes associated with
fetal macrosomia [179]. In contrast, Kuruvilla et al. described reduced system
A activity in macrosomic babies of diabetic mothers without changes in the
activity of system L in MVM isolated vescicles [210]. In addition, inverse
relationship between placental system A activity and size at birth was
reported by Godfrey et al. [208]. This increased activity with smaller size may
be a compensatory mechanism in smaller neonates.
The findings by Jansson et al. on glucose and amino acid transport have
indicated that GDM is associated with different adaptations than those of
T1DM [198, 200]. They also suggest that fetal macrosomia observed in GDM
pregnancies may depend on higher uptake of neutral amino acids rather than
glucose [183]. On the other hand, the effect of obesity on amino acid
transport has not been studied during obese pregnancy. However, Jones
found that mice fed with a HFD had increased expression of specific placental
amino acid transporters associated with significantly higher fetal growth
[205].
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1.8.5.3. Triglyceride transport
In the third trimester, the increased FA demand is accompanied by a rise in
placental FFA transporters. FFA transfer across the placenta occurs via passive
diffusion as well as by fatty acid binding protein (FABP) and fatty acid
transport protein (FATP) in the MVM and BM [211]. It has been proposed that
high local levels of IL6 stimulate trophoblast FFA accumulation and may
contribute to excessive FFA transfer in pregnancies complicated by high BMI
[212].
GDM is consistently associated with elevated triglyceride levels and this has
been found to be independent of maternal obesity [213]. Recent evidence
links the higher risk for macrosomia in GDM pregnancies to altered maternal
lipid metabolism rather than maternal hyperglycaemia [214]. Radaelli et al.
reported studies in which the placental gene expression profile of women with
normal glucose tolerance and GDM was investigated using oligonucleotide
microarray analysis [214, 215]. A pronounced modification of feto-placental
lipid pathways and selective activation of transplacental lipid fluxes were
observed in pregnancies complicated by GDM.
These findings were confirmed recently by Catalano who reported enhanced
genes for fetoplacental lipid metabolism in fetuses of obese mothers [216]. As
a result, increases in lipid transporters, angiogenic factors and inflammatory
markers may explain the onset of complications in these pregnancies [217,
218].
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1.8.6. Placental hormonal regulation
Placental endocrine activity during pregnancy also plays a crucial role in the
regulation of fetal growth. Hormones secreted by the placental
syncytiotrophoblast include human placental lactogen (hPL), oestrogen,
progesterone, hCG, and human growth factor (hGF) variants.
Placental hormones interfere with insulin-stimulated glucose uptake into
skeletal muscle and adipocytes [219] and with insulins ability to suppress
lipolysis through the enzyme hormone-sensitive lipase (HSL) [220]. In late
pregnancy, failure to fully inhibit lipolysis results in increased release of FFA,
which are significantly higher in obese individuals with GDM [220]. Therefore,
insulin resistance in adipose tissue leads to a rise in circulating FFA, which can
accumulate in non-adipose depots.
In the following sub-sections, the main hormones and metabolic factors
known to influence fetal growth and development will be reviewed along with
the contribution of maternal obesity and diabetes in altering these
mechanisms.
1.8.6.1. Insulin
Maternal insulin cannot cross the placenta [221]. Therefore, the fetus has to
meet its own needs and begins to secrete its own insulin after the tenth week
of gestation [222]. This hormone acts as a signal of nutrient availability
through its action on the IR, thus promoting fetal growth [136]. Insulin
deficiency causes a reduction in fetal growth as fetal tissues decrease their
uptake and utilisation of nutrients [223].
Venous cord blood concentrations of insulin are significantly lower in SGA
neonates and positively correlate with birth weight, birth length, and placental
weight. Conversely, insulin levels in maternal serum or amniotic fluid do not
correlate with birth weight [224]. Furthermore, increased insulin production is
associated with increased fetal growth [169, 186].
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As discussed in Section 1.5, maternal hyperglycaemia in diabetic pregnancies
results in fetal hyperinsulinaemia, which is thought to be the cause of
macrosomia [225] and increased adiposity in infants of diabetic mothers
[226]. However, severe uncontrolled diabetes can also led to SGA newborns
[224] due to compromised uterine blood flow resulting in endothelial
dysfunction and atherosclerosis [94, 225].
Catalano et al. have demonstrated that the chronic depression in insulin
sensitivity found in obese pregnant women results in basal hyperinsulinaemia
and impaired glucose uptake exposing the fetus to hyperglycaemia [216,
227]. In addition, fetal hyperinsulinaemia will follow, resulting in elevated
levels of fetal TG and ultimately to fetal overgrowth [228, 229]. Obese women
in whom GDM develops have a significant increase in insulin response but
decreased insulin sensitivity. Studies in adipose tissue and skeletal muscle
indicate that impaired insulin action is due to defects in the insulin signalling
pathways [106, 230, 231] (see Section 1.7).
1.8.6.2. Insulin-like growth factors
Like insulin, IGF1 and IGF2 are other important growth factors in fetal
development and they are both synthesised in the placenta and fetus. Whilst
IGF1 is present in trophoblast cells at all gestational stages, placental IGF2
expression in cytotrophoblasts becomes undetectable at term [232, 233].
Therefore, IGF2 is thought to be a primary growth factor required for early
development, whereas IGF1 expression is essential for achieving maximal
growth.
Evidence of a link between intrauterine growth and IGFs come from studies in
knockout mice of IGF2 gene. Using a mouse model in which placental-specific
IGF2 had been deleted (P0), Sibley et al. measured nutrient transfer in vivo.
diffusional exchange characteristics of the placenta [234]. The outcome of this
study showed that the diffusing capacity in P0 knockout placentas was
dramatically reduced to 40% of that of wild-type placentas.
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Therefore, placental IGF2 seems to regulate the development of the
diffusional exchange characteristics of the mouse placenta, controlling
placental nutrient supply and fetal growth. In humans, reduced levels of IGF2
are seen in IUGR fetuses [235], whereas LGA fetuses show higher IGF2 levels
[236]. It has been suggested that maternal and placental, rather than fetal
IGFs, regulate syncytiotrophoblast transport function. Reduction in maternal
levels of IGF1 is associated with decreased glucose and amino acid transport
across the placenta, resulting in IUGR offspring [237]. In contrast, increased
maternal levels of IGFs associated with diabetes may influence feto-placental
growth by increasing nutrients transfer across the placenta [238].
At physiological concentrations, both IGF1 and IGF2 bind the IGF1 receptor
(IGF1R), which activates intracellular signalling pathways [237]. In addition,
in embryonic and cancer cells IGF2 binds to an IR isoform with slightly lower
affinity than that of insulin [239]. Mutations of IGF1R gene are associated
with profoundly lower fetal weight, while overexpression of this gene leads to
heavier and longer neonates [237]. Alterations in insulin and IGFs levels
found in diabetic pregnancies can result from the spatial-temporal change in
the expression of their receptors within the placenta. Whilst in the first
trimester, both IR and IGF1R are predominantly expressed on the MVM, which
are directed to the maternal circulation, at term their expression is mainly
found on placental endothelial cells, which are facing fetal blood [118, 240].
This is accompanied by a change in gene expression via activation of insulin
downstream signalling [240]. As such, the shift in IR expression from
trophoblast to endothelium reflects the different regulation of insulin effects
from the mother to the fetus. The morphological and functional placental
changes in T1DM may have their origin early in pregnancy due to the insulin
regulatory effect on trophoblast invasion and migration. Conversely, insulin
involvement in vascular growth can explain the enhanced angiogenesis
characteristic of placentas from GDM pregnancies.
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1.8.6.3. Leptin
The adipokine leptin also influences fetal growth as its concentrations in both
maternal [241] and fetal cord blood are positively correlated with birth weight
[242]. The role of leptin, a plasma protein secreted by adipocytes, is to
regulate food intake and energy expenditure via the hypothalamus [243]. In
addition, its production by placental and fetal tissues has suggested a key role
of leptin in regulating fetal and placental growth [242]. Its regulation differs
from that of adipose tissue, therefore, this hormone may have a different role
during pregnancy [244].
Leptin synthesis and secretion by the trophoblast is likely to be induced by
hCG via activation of MAPK and cAMP signalling pathways [245], and leptin
action through its receptor, promotes protein synthesis and trophoblast
proliferation [246], whilst inhibiting apoptosis [247]. Mucci et al. found an
association between maternal progesterone and cortisol with placental leptin
expression [248] and Smith et al. observed that transplacental leptin transfer
is reduced in association with excess maternal GC leading to IUGR fetuses
[249]. Insulin has been proposed as an important modulator of leptin
expression in the placenta [250, 251], with an increase in leptin
concentrations been reported in obese and insulin-treated diabetic
pregnancies associated with macrosomia [252, 253]. It has been proposed
that high concentrations of insulin in cord blood are correlated with
hyperleptinaemia in the placenta which, in turn, stimulates fetal growth [254].
Newborns of diabetic [255] and obese [256] mothers show impairment of
hypothalamic metabolic regulation associated with leptin resistance during
adulthood. Conversely, leptin inhibits glucose-stimulated insulin secretion
suggesting the existence of a negative feedback system between leptin and
insulin. In contrast, adiponectin and ghrelin have opposite functions to leptin
as they activate the cAMP signalling ensuring trophoblast differentiation
[257].
38
As leptin is co-localised to both syncytiotrophoblast and villous endothelial
cells, it is likely to be release into both the maternal and fetal blood circulation
[244, 252] (Figure 1.9). The transmembrane isoforms of leptin receptor
(ObRa, ObRb) are expressed only on the MVM indicating a possible autocrine
role of leptin at the maternal side [244, 252]. In addition, the peak in
maternal circulating leptin seen in late pregnancy can reflect its binding to the
soluble receptor (ObRe) released by the placenta [258]. This may contribute
to leptin resistance in the mother at the end of pregnancy suggesting an
endocrine activity of this hormone in maternal appetite, energy metabolism
and fat deposition. Placental lactogen and prolactin have been shown to
increase maternal food intake by induction of central leptin resistance, as well
as promote maternal insulin production by beta cells [155].
Figure 1.9: Proposed roles of placental leptin at the maternal-fetal interface.
ObR: leptin receptor. From [244].
Leptin also promotes angiogenesis in human endothelial cells and it may
exhibit an indirect angiogenic role in the placenta through stimulation of
angiogenic factors [244]. Its potential autocrine activity at the maternal-fetal
interface reflects local immunomodulation of pro-inflammatory cytokines such
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Hence increased concentrations of leptin in preeclamptic and diabetic
pregnancies may indicate a protective response of this hormone against
higher levels of pro-inflammatory cytokines [259, 260]. Recent evidence links
this adipokine to the expression of key enzymes for lipid synthesis confirming
their interplay between inflammatory stress and intracellular lipid content
within the placenta [261, 262]. In obese individuals, circulating leptin levels
are usually very high and this chronic hyperleptinaemia seems to desensitise
leptin signal [263]. Maternal hyperleptinaemia and placental leptin resistance
were observed in a group of obese pregnant women [253]. However, it is
unclear the extent to which maternal hyperleptinaemia can influence the
fetus.
1.8.6.4. *OXFRFRUWLFRLGVDQGWKHSODFHQWDOǃ+6'EDUULHU
Maternal cortisol increases about 2.5 fold during pregnancy and represents
another potentially important hormone [264]. Under conditions of GC excess,
there is a decrease in peripheral insulin sensitivity, leading to hyperglycaemia
[265]. These hormones are well known to interfere with insulin signalling in
skeletal muscle by post-receptor mechanisms [266]. Chronic GC treatment
decreases insulin-stimulated glucose uptake and GLUT4 translocation in
skeletal muscle, without reducing the total content of GLUT4 [267, 268].
Furthermore, GC exposure reduces insulin stimulated protein kinase B/v-
akt murine thymoma viral oncogene homolog (PKB/Akt) phosphorylation
[269], although this is not a consistent finding [270]. Similarly, IRS1 protein
content and tyrosine phosphorylation appear to be reduced in skeletal muscle
following GC treatment [271], as is IRS1-associated PI3K [272, 273].
GC are primarily synthesised and secreted by the adrenal cortex, but are also
produced by other tissues, including the placenta [274]. They are essential for
the development and maturation of fetal organs before birth playing a crucial
role in fetal development [275, 276]. Furthermore, GC regulate the
production of hormones associated with the onset of labour such as
prostaglandins [277].
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In fact, in human pregnancies, these hormones are used in the treatment of
preterm deliveries and their administration, especially during late gestation,
promotes maturation of lungs and other organs [177], saving the lives of
infants when born preterm. Nonetheless, administration of excess GC to
pregnant animals and humans is associated with IUGR fetuses [278]. The
resulting offspring have altered activity of the the hypothalamicpituitary-
adrenal (HPA) axis and are susceptible to develop hypertension and
hyperglycaemia in adult life [279, 280]. This has been confirmed also in obese
sheep where moderate energy restriction results in changes of the
development of HPA axis as well as enhanced cortisol response to stress
[281].
Fetal exposure to GC is finely regulated by the family of 11-beta
K\GUR[\VWHURLG GHK\GURJHQDVH ǃ+6' HQ]\PHV ZKLFK KDYH GLIIHUHQW
biological characteristics and tissue distribution within the placenta [185]. The
LVRIRUP ǃ+6' W\SH ǃ+6' LV H[SUHVVHG LQ WKH GHFLGXD SODFHQWDO
extravillous trophoblast, chorion trophoblast, amnion epithelial cells and
JHQHUDWHV DFWLYH FRUWLVRO IURP FRUWLVRQH &RQYHUVHO\ ǃ+6' W\SH
ǃ+6'ZKLFKUHSUHVHQWVWKHSODFHQWDOEDUULHUWRPDWHUQDO*&LVORFDOLVHG
in the placental syncytiotrophoblast and limits the passage of cortisol to the
fetal circulation by converting this active metabolite to inactive cortisone
)LJXUH3K\VLRORJLFDOYDULDWLRQVLQSODFHQWDOǃ+6'DFWLYLW\FDQFDXVH
impaired placental inactivation of cortisol leading to IUGR [282], with
enhanced plasma cortisol levels in adulthood and activated HPA axis [283].
The latter has been shown to ultimately result in altered metabolic profile and
behavioural phenotype.
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Figure 1.10: Glucocorticoids regulation of fetal growth and tissue maturation
WKURXJK SODFHQWDO ǃK\GUR[\VWHURLG GHK\GURJHQDVH W\SH ǃ+6'.
From [284].
At present, there is a lack of knowledge regarding the effect of maternal BMI
DQGJOXFRVHWROHUDQFHRQ*& OHYHOVDQGǃ+6'HQ]\PHV>@ ,QSDWLHQWV
with Cushings syndrome, central obesity is a prominent characteristic [286].
This disease can be caused by disorders of the adrenal glands resulting in
excess level of endogenous GC in the body, mainly cortisol [285]. Evidence
from human and rodent studies shows the existence of higher intracellular
tissue concentrations of cortisol in obese subjects due to increased activity of
ǃ+6' > @ &KDQJHV LQ WKLV HQ]\PH H[SUHVVLRQ UHVXOW LQ WKH
development of insulin resistance, hypertension and associated metabolic
syndrome [285]. Experimental studies reported that offspring of mothers
WUHDWHG ZLWK FDUEHQR[RORQH DQ LQKLELWRU RI SODFHQWDO ǃ+6' KDYH ORZHU
birth weights as well as hypertension and glucose intolerance in later life
[288, 289].
The action of GC is mediated by the GC receptor (GR), a nuclear receptor
located in the cellular cytoplasm of almost all tissues [290, 291].
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The human placenta expresses a variety of GR mRNA transcripts, among
ZKLFK WKH PDMRULW\ LV UHSUHVHQWHG E\ *& UHFHSWRU DOSKD *5Į >@ 7KH
binding of GC to their receptor primarily initiates transcription of target genes
and factors involved in metabolic homeostasis. Also, it can contribute to an
anti-inflammatory status through immunosuppressive action on monocyte and
macrophage differentiation [293]. In response to obesity, a downregulation of
GR has been suggested in subcutaneous adipose tissue but not in visceral
adipose depots, which are still responsive to local GC synthesis [294].
1.9. Placental metabolic regulation
1.9.1. Placental insulin signalling
Insulin signalling is crucial for the regulation of intracellular and blood glucose
levels and its alteration may play a role in the pathophysiology of insulin
resistance associated with obesity and GDM [106, 195]. As illustrated in
Figure 1.11 activation of insulin signalling involves insulin binding to the IR,
which results in receptor autophosphorylation as well as tyrosine
phosphorylation of the insulin substrate receptor (IRS). The subsequent
association of IRS with downstream activators including PI3K allows
regulation of glucose uptake via GLUT4 translocation [272] (Figure 1.11-A).
Alterations in the number of insulin binding sites reflecting placental IR
expression have been documented in various forms of diabetes mellitus
[108]. However, a scarcity of data is available on insulin signalling protein
expression in placental tissue [295]. Previous studies in skeletal muscle [131]
and adipose tissue [109] of GDM pregnant women indicated alterations in
insulin signalling resulting in decreased protein expression of IRS1 along with
increased IRS2. Increased basal serine phosphorylation of IRS1 in skeletal
muscle from mouse and humans has recently been associated with GDM [231,
296, 297] (Figure 1.11-B).
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Figure 1.11: Insulin signalling for glucose uptake.
A) Insulin binds to its receptor causing a conformational change in the receptor that
activates its intrinsic tyrosine kinase activity. This leads to autophosphorylation of the
insulin receptor (IR) resulting in the translocation of glucose transporter-4 (GLUT4) to
the plasma membrane allowing glucose to enter the cells. (B) Gestational diabetes
mellitus (GDM) results in the suppression of several key steps in insulin signalling
mainly by negative regulatory mechanisms: (1,2) Serine phosphorylation of both IR
and IR substrate (IRS) blocks tyrosine phosphorylation on IRS1/2 leading to decreased
recruitment of Phosphatidylinositol 3-kinase (PI3K). Upregulation of cytokines, like
WXPRXUQHFURVLVIDFWRUDOSKD71)ĮRULQFUHDVHGQXWULHQWIOX[LQWRWKHFHOOFDQFDXVH
activation of serine kinases; (2) increased serine phosphorylation on IRS1/2 promotes
its degradation; (3) upregulated placental growth hormone (pGH) increases the
expression of p85 subunit resulting in inhibition of PI3K activity and decreased glucose
uptake.
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These findings have been confirmed by Colomiere et al. in diabetic and obese
placentas suggesting a maternal regulation of these two proteins in GDM
[195]. There is support for a diminished glucose uptake in placental tissue
from GDM individuals [201] reflecting reduced GLUT4 and increased GLUT1
expression [195, 198]. Although the specific serine kinase responsible for
increased IR/IRS1 serine phosphorylation during pregnancy is not known,
several possible candidates have been identified, including increased
activation of JNK1/NFkB and ribosomal protein S6 Kinase (p70S6K) [106].
1.9.2. Placental nutrient sensing
The syncytiotrophoblast plays a unique role in determining fetal growth and
development by functioning as a placental nutrient sensor. Recently, the
mammalian target of rapamycin (mTOR) pathway has been discovered to be
central in trophoblast development and placental nutrient-sensing [298]. In
vitro studies using immortalised human trophoblasts and human
choriocarcinoma cell lines highlighted its role in inducing trophoblasts
proliferation and differentiation through activation of the PI-3 kinase signaling
pathway [299, 300]. Furthermore, Busch et al. demonstrated that this
cytoplasmic molecule contributes to the invasiveness of human trophoblast
cells by secretion of extra cellular matrix remodelling enzymes and its
dysregulation may lead to pregnancy-related pathologies [301]. Placental
insulin/IGF1 signalling as well as fetal glucose and amino acids, act as
upstream regulators of mTOR and are altered in pregnancies complicated by
maternal obesity and GDM [302]. This central molecule also regulates the
transcription of key transporters and enzymes involved in energy intake and
metabolism [303, 304]. It has been suggested that mTOR inactivation can
result by either mTOR autophosphorylation or a mechanism involving the
AMP-activated protein kinase (AMPK) pathway [305, 306]. Constitutive
activation of this Ser/Thr kinase also results in inhibition of IR response to
insulin [307].
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$FHQWUDOUROHRI33$5ǄLQVXSSRUWLQJPDPPDOLDQIHWRSODFHQWDOGHYHORSPHQW
has been suggested from both animal [308] and human studies [309, 310].
The pleiotropic function of this nuclear protein during placentation was
reported in human cultured villous trophoblastic cells isolated from term
placenta [311]. Suwaki et al. showed that hyperglycaemia causes increased
33$5Ǆ H[SUHVVLRQ DFFRPSDQLHG E\ KLJK K&* VHFUHWLRQ DQG GHFUHDVHG FHOO
proliferation, suggesting that this pathway might be involved in the
LPSDLUPHQW RI SODFHQWDO GHYHORSPHQW >@ 33$5Ǆ VLJQDOOLQJ DOVR UHJXODWHV
FFA transport and metabolism, lipid storage, and insulin modulation within the
trophoblast [313].
1.9.3. Placental inflammation
During pregnancy, the placenta [86] and adipose tissue [314] become
important sources of many cytokines and adipokines, the expression of which
is exacerbated by maternal diabetes and obesity. Hauguel-de-Mouzon et al.
found striking homologies between the expression and regulation of cytokines
and inflammatory genes in both term placenta and white adipose tissue,
suggesting that the abnormal metabolic environment generated by obesity
can lead to the propagation of the inflammatory response [315]. In addition,
studies of transcriptional profiling have shown that maternal hyperglycaemia
promotes overexpression of inflammatory genes as well as a range of adipose
tissue related proteins within the placenta [214].
7URSKREODVWFHOOVDUHWKHPDMRUVRXUFHRISODFHQWDO71)ĮOHSWLQDQG,/>@
Integrins and cytokines expressed by the proliferating trophoblast allow it to
switch from a proliferating state to an invasive one [140]. Changes in insulin
VHQVLWLYLW\ IURP HDUO\ WR ODWH JHVWDWLRQ DUH FRUUHODWHG ZLWK SODVPD 71)Į
,QIXVLRQRI71)ĮLQUDW>@DQGKXPDQVNHOHWDOPXVFOHFHOOV>@UHVXOWVLQ
enhanced insulin resistance and its levels are positively correlated with BMI
and hyperinsulinaemia in obesity [319]. Obese women with GDM appear to
KDYHDORFDOIROGLQFUHDVHLQ71)ĮP51$LQVNHOHWDOPXVFOHZKLFKSHUVLVWV
post-partum.
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Adiponectin, which highly correlates with whole body-insulin sensitivity [320],
can increase glucose uptake in skeletal muscle and suppress glucose
production of the liver through AMPK stimulation [321]. This adipokine has
also been associated with FFA oxidation through activation of peroxisome
SUROLIHUDWRUDFWLYDWHGUHFHSWRUDOSKD33$5Į>@$GLSRQHFWLQ UHGXFWLRQ LQ
obesity and GDM could contribute to the decreased insulin sensitivity in those
subjects [323, 324].
As described in Section 1.6, inflammation links obesity with insulin resistance
with potential implications for fetal development and related diseases during
adulthood [93]. In fact, the chronic inflammatory state of obesity is extending
from the mother to the placenta with accumulation of inflammatory markers
such as raised cluster of differentiation 14 and 68 (CD14, CD68), leading to
macrophage infiltration [90, 92]. This may result in increased inflammatory
response in the newborn. In the placenta, leptin can influence the expression
of key enzymes for lipid synthesis confirming the interplay between
inflammatory stress and intracellular lipid content [261, 262]. This hormone
has been shown to regulate lipid metabolism through direct activation of
AMPK and it has been implicated in diabetes associated with obesity [250].
However, results have been inconsistent due to the intricate functions of this
hormone, which acts both centrally and peripherally [325].
Molecular interplays between immune function and metabolism have been
proposed to take place within the placenta with mTOR regulating the
expression of NFkB signalling, thereby promoting pro-inflammatory and pro-
oxidative pathways within the cell [326-328].
,QFRQWUDVW33$5ǄKDVEHHQSURSRVHGDVDQDQWLLQIODPPDWRU\IDFWRULQERWK
KXPDQ DQG DQLPDO VWXGLHV > @ 5HFLSURFDO H[SUHVVLRQ RI 33$5Ǆ DQG
cyclooxygenase-2 (COX2) in human term placenta suggests a role of the
former in the initiation of labour [310]. High levels of circulating FFA and
R[LGLVHG OLSLGV KDYH EHHQ DVVRFLDWHG ZLWK GHFUHDVHG 33$5Ǆ H[SUHVVLRQ DQG
subsequent cytokine activation [309, 329].
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1.9.4. Placental oxidative stress
Along with cytokine production, inflammation is also linked to oxidative stress
in the placenta [113]. This condition is defined as an imbalance between the
production of reactive oxygen species (ROS), such as superoxide, and the
ability of antioxidant enzymes to scavenge ROS. Pregnancy is a state of
oxidative stress due to the high metabolic activity of placental mitochondria
that generate ROS. Intensified ROS production occurs physiologically during
certain stages of placental development as well as under certain pathological
conditions such as in preeclampsia, diabetes and IUGR [37]. Measurements of
partial pressure of oxygen (pO2) within the placenta from women with a
diagnosis of missed miscarriage have associated the establishment of the
maternal-placental circulation with increased oxygen tension [114]. Oxidised
lipids, resulting from the combination of excess fatty acids and oxidative
stress, have been proposed to inhibit trophoblast invasion and influence
placental development by acting as ligands for nuclear receptors [84]. A
surplus of lipid nutrient supply from the mother can therefore, alter placental
gene expression with potential negative impact for the offspring [216, 330].
In addition, growing evidence in overweight and obese adults associates
endothelial oxidative stress with increased expression of nicotinamide adenine
dinucleotide phosphate-oxidase (NADPH oxidase) and selective upregulation
of antioxidative enzymes and NO synthase [331, 332]. Expression of the
antioxidant gene sirtuin-1 (SIRT1) can reduce mTOR pro-inflammatory effect
enhancing cell anti-oxidative capacity [333, 334]. SIRT-1 overexpression in
neurons promotes neurite outgrowth and cell survival through inhibition of the
mTOR signalling [335]. SIRT-1 maintains insulin sensitivity and glucose
homeostasis and its inhibition impairs mTOR signalling resulting in
hyperglycaemia, oxidative damage and insulin resistance [333]. This
pleiotropic protein is involved in the regulation of intracellular metabolism, cell
growth and survival and has been identified as a novel upstream regulator for
AMPK signalling.
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Its stimulation by AMPK via elevation in the cellular NAD(+)/NADH attenuates
ROS-induced apoptosis leading to longevity and improving cellular stress
resistance [336].
Uncoupling protein-2 (UCP2) has been proposed to uncouple beta-oxidation
with energy production and protect the cell from the production of ROS
contributing to the generation of an antioxidant response. There is evidence
that FFA could upregulate UCP2 expression by acting as ligands for PPARs
[308, 337, 338]. Although the complete mechanism is not fully understood,
UCP2 has been found to regulate the production of ROS following
mitochondrial respiration and may influence glucose uptake [339, 340]. In
normal conditions, the expression and activity of this protein is low.
However, alterations in cell homeostasis can induce an increase in UCP2 and
thus decrease the ability of the cell to produce ATP and be protected from
oxidative stress. Maternal obesity and insulin resistance result in enhanced
glucose and FFA availability to the fetus, whose oxidation in the mitochondria
might lead to higher production of ROS [339, 341], activating UCP2
expression as well as NFkB signalling [342].
A proposed mechanism linking oxidative stress and inflammation is presented
in Figure 1.12. Circulating FFA have been also demonstrated to activate
myeloid pro-inflammatory cells through toll-like receptor-4 (TLR4) [343]
whose upregulation has been linked to enhanced adipogenesis and insulin
resistance in several tissues [344, 345]. TLR4 has been proposed as the main
placental receptor which stimulates the inflammatory response against
bacterial infection through NFkB and JNK signalling and may play a major role
in the low grade inflammatory response frequently observed in obese
individuals [346].
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Figure 1.12 : Proposed mechanism of placental metabolism.
)5ĮIRODWHUHFHSWRUDOSKD))$VIUHHIDWW\DFLGV8&3XQFRXSOLQJSURWHLQ526UHDFWLYHR[\JHQVSHFLHV,/LQWHUOHXNLQ71)ĮWXPRXUQHFURVLV
IDFWRUĮ1)N%QXFOHDU IDFWRUNDSSD%7/5 WROO OLNH UHFHSWRU ,*) LQVXOLQOLNHJURZWK IDFWRUV ,5 LQVXOLQ UHFHSWRU ,*)5 ,*) UHFHSWRU ,56
insulin substrate receptor-1/2; Akt:v-akt murine thymoma viral oncogene homolog; TSC1/2: tuberous sclerosis 1/2; mTOR: mammalian target of
rapamycin; p70S6K: ribosomal protein S6 kinase 70kDa polipeptide; 4EBP1/2: initiation factor 4E binding protein 1/2; LEP: leptin; LEPR: leptin receptor;
*& JOXFRFRUWLFRLGV ǃ+6' EHWD K\GUR[\VWHURLG GHK\GURJHQDVH *5Į JOXFRFRUWLFRLG UHFHSWRUDOSKD 0$3.(5. PLWRJHQDFWLYDWHG SURWHLQ
NLQDVHH[WUDFHOOXODU UHJXODWHG NLQDVH -$. MDQXV NLQDVH $03. $03DFWLYDWHG SURWHLQ NLQDVH 33$5Ǆ SHUR[LVRPH SUROLIHUDWRUDFWLYDWHG UHFHSWRU
gamma; FATs: fatty acid transporters; SIRT1: sirtuin-1. Arrows and bars represent activation and inhibition respectively (see text for details).
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1.9.5. Folate metabolism and placental transport
Among the nutrients required during gestation, folate is critically important for
nucleic acid synthesis and cell proliferation, contributing to adequate fetal
growth and development [347]. This water-soluble vitamin is a member of the
B9 family of vitamins (Fig 1.13) involved in several coenzymatic reactions
essential for the one-carbon metabolism of key amino acids including
homocysteine and methionine.
Figure 1.13: The chemical structure of folate.
Folate requirements are estimated to be increased 5- to 10 fold during
pregnancy, driven by its critical importance for growth of the fetus and the
placenta [348, 349]. Maternal folate deficiency has been implicated in a
number of pregnancy complications including increased risk of premature
delivery, neural tube defects (NTDs) and reduced birthweight [44]. The
incidence of such outcomes has been reduced by adequate maternal folate
intake via folic acid supplementation or food fortification [350]. In the USA,
&DQDGDDQG&KLOHPDQGDWRU\IROLFDFLGIRUWL¿FDWLRQRIIRRGKDVDOUHDG\EHHQ
introduced. However, in most other countries where food is unfortified, the
population do not consume the recommended 0.4 mg of food folate per day
[350]. The bioavailability of folate from ingested dietary sources is the only
way of meeting the high demand for folate as mammals are unable to
synthesise this vitamin and body stores are very limited.
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This emphasises the critical importance of placental folate transfer for fetal
development [351]. Overweight and obese pregnant women normally
consume a poor diet lacking in vital micronutrients including iron and folate
[38, 45]. These pregnancy complications have been associated with higher
risk of delivering a child with NTDs [44], although some studies have shown
that this risk is not modified by folic acid food fortification [352] nor is linked
to maternal T2DM [353].
Folate transport within the placenta is dependent on maternal folate
concentrations, as reflected by the positive association between maternal
plasma, umbilical cord plasma and placental folate concentrations. Reduced
placental transport of folate in obese mothers would thus result in fetal folate
deficiency. One of the few studies in the literature investigating placental
folate transport in obese pregnancies, hypothesised an association between
obesity and lower fetal folate concentrations because of impaired placental
folate transport [354]. However, the authors found that obesity did not alter
fetal serum folate and placental folate transport at term.
As proposed by Solanky et al. (Figure 1.14), placental transport of folate from
the mother to the fetus is mediated by the action of polarised folate
transporters [351], which generate a higher folate concentration in the fetus
UHODWLYHWRWKHPRWKHU>@)LUVWIRODWHELQGVWRIRODWHUHFHSWRUDOSKD)5Į
localised to the maternal-facing MVM of the syncytiotrophoblast which
transports the vitamin by receptor-mediated endocytosis. Proton-coupled
high-affinity folate transporter (PCFT) mediates the co-transport of folate and
protons, whereas folate efflux across the fetal-facing BM is ensured via the
reduced folate carrier (RFC) [356]. Expression and localisation of these three
folate transporters within the placenta in early and late pregnancy have been
also demonstrated [351, 357, 358].
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Figure 1.14: Proposed model for folate transport across syncytiotrophoblast
in human placenta. From [351].
)5ĮORFDOLVHGWRWKH090VXUIDFHELQGVIRODWHDQGFRORFDOLVDWLRQRI)5ĮDQG3&)7WR
MVM allows internalisation of both transporters into an endosomal structure.
Acidification of the endosome occurs by vacuolar proton ATPase and a favourable H+
gradient allows the H+-coupled movement of folate by PCFT into the cytoplasm. Whilst
)5ĮDQG3&)7DUHUHF\FOHGEDFNWRWKH090VXUIDFH5)&DWWKH090VXUIDFHSURYLGHV
an alternative folate uptake mechanism. Folate is transported across BM via an
H[FKDQJH PHFKDQLVP E\ 5)& DQG GRHV QRW LQYROYH )5Į RU 3&)7 2WKHU WUDQVSRUW
mechanisms localised to BM may also play a role in folate efflux across this membrane.
)5Į IRODWH UHFHSWRU DOSKD 090 PLFURYLOORXV SODVPD PHPEUDQH 3&)7 SURWRQ
coupled high-affinity folate transporter; RFC: reduced folate carrier; BM: plasma basal
membrane.
Folic acid is not biologically active itself but its biological importance is due to
tetrahydrofolate (THF) and other metabolites obtained after its conversion to
dihydrofolic acid in the liver [359]. This nutrient is crucial to the methionine
cycle (Figure 1.15) by serving as a single carbon donor for 5-methyl
tetrahydrofolate (5-MTHF) to convert homocysteine (Hcy) into methionine by
methionine synthase (MS) [359, 360]. Methionine then acts as the precursor
for the ATP-dependent synthesis of S-adenosylmethionine (SAM), a primary
methyl donor involved in the methylation of DNA, RNA, proteins and
phospholipids [361]. This reaction generates S-adenosylhomocysteine (SAH)
as well as the methylated substrate.
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As efficient cellular metabolism of SAH is crucial to prevent its inhibition of
most SAM-dependent methyltransferases [362], rapid metabolism of Hcy is
required to ensure sustained and optimal function of the methionine cycle in
vivo [361, 362].
Figure 1.15: Homocysteine metabolic pathways.
Folate/folic acid is transported into the cell and converted to tetrahydrofolate (THF) or
may enter the cell as 5-methyltetrahydrofolate (5-MTHF). Homocysteine can be
metabolised by three metabolic pathways as described in text.
MTHFR: 5,10-methylene tetrahydrofolate reductase; MS: methionine synthase; DGM:
GLPHWK\OJO\FLQH%+70EHWDLQH±KRPRF\VWHLQHPHWK\OWUDQVIHUDVH&ǃ6F\VWDWKLRQLQH
beta-synthase; SAM: S-adenosylmethionine. Adapted from [351].
Experimental evidence has revealed that moderately elevated homocysteine
concentrations (1624 µM) may induce cytotoxic and oxidative stress,
resulting in endothelial cell impairment [363]. Furthermore, exposure of
trophoblast cells to Hcy (20 µM) causes increased cell apoptosis leading to
inhibition of trophoblastic function [364].
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Enhanced Hcy and lower folate concentrations in early pregnancy are
associated with lower placental weight and birthweight with higher risk of
adverse pregnancy outcomes [365].
Hcy can be rapidly metabolised in three different ways as illustrated in Figure
1.15 [359, 360, 362]. It can be remethylated to methionine using 5-MTHF as
methyl donor catalysed by the vitamin B12-dependent action of MS. THF is
then re-cycled to form 5-MTHF catalysed by 5,10-methylene tetrahydrofolate
reductase (MTHFR). Otherwise, betaine can be utilised as an alternative
methyl donor for Hcy to generate methionine and dimethylglycine (DMG)
catalysed by betainehomocysteine methyltransferase (BHMT). Hcy can enter
the trans-sulphuration pathway where it is converted to cysteine through the
DFWLRQRIF\VWDWKLRQLQHEHWDV\QWKDVH&ǃ67KHLUUHYHUVLELOLW\RIWKLVUHDFWLRQ
ensures removal of Hcy from the methionine cycle. Consequently, cellular
folate availability and the relative contribution of the Hcy-dependent
metabolic pathways will influence cellular Hcy metabolism. Constitutive
expression of the methionine cycle highlights the pivotal role of folate and one
carbon unit metabolism in maintaining cellular homeostasis, with SAM levels
directing the cellular utilisation of folate metabolites. MTHFR deficiency results
in hypomethylation of DNA [366-368], reflecting a role for folate in DNA
methylation [369] with the potential of programming metabolic dysfunction
and CVD [366].
The importance of maternal folate as a methyl donor during embryogenesis
[347] has been demonstrated in animal studies and will be discussed in more
detail in Section 1.10.
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1.10. Epigenetics and imprinted genes
There are three main processes that are tightly linked to gene expression:
DNA methylation, post-translational histone modifications (e.g. methylation or
acetylation) and nucleosome remodelling. The study of these three
modifications is commonly known as epigenetics, indicating changes in gene
expression or cellular phenotype that do not include alterations in DNA
sequence. Epigenetic modifications within the placenta have been linked to
alterations in feto-placental lipid metabolism [370-372]. DNA methylation
refers to the covalent addition of a methyl group to cytosine residues in
specific genomic regions containing a high frequency of cytosine-phosphate-
guanine (CpG) sites, known as CpG islands [373]. These sites, mostly
associated with promoter regions of genes, are generally not methylated or
have very low levels of CpG methylation throughout the genome [374].
Methylation of CpG islands in the promoter region, termed
hypermethylation, commonly leads to transcriptional repression.
Conversely, no methylation of these CpG sites is known as hypomethylation
and does not silence the gene [375]. Nonetheless, it is not the methylation of
DNA per se that most greatly contributes to the transcriptional repression as
the binding of various elements to methylated stretches of DNA has been
shown to be the main factor [376]. Throughout embryo development
important resetting of methylation patterns of germline and somatic lineage
occurs. Whilst genome methylation of the zygote is almost completely
removed, in between implantation and gastrulation [377], de novo
methylation re-establishes the developing organisms methylation patterns
[378]. Under normal conditions, these patterns are maintained throughout the
rest of the organisms life (Figure 1.16). These finely regulated processes are
ensured by a complex interplay of DNA methyltransferases (DNMTs), which
use SAM as the methyl donor [371, 379]. De novo DNA methyltransferases-3-
DOSKDDQGEHWD'107Į'107ǃH[SUHVVHGPDLQO\GXULQJHDUO\HPEU\R
development, contribute to set up the pattern of methylation [376].
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DNA methyltransferase-1 (DNMT1) adds patterns of methylation to a newly
synthesised DNA strand which is already methylated [380]. Altered levels of
DNMTs can cause hyper- and hypo-methylation leading to down- and up-
regulation of gene expression, respectively [381, 382].
Figure 1.16: DNA methylation changes throughout embryo development.
From [383]. Epigenetic DNA methylation patterns markedly increased during early
embryonic development. De novo DNA methylation patterns are made soon after early
embryogenesis, whereas tissue-specific epigenetic patterns are placed at later
developmental stages. After fertilization, there is active demethylation of the paternal
genome (grey line) and passive demethylation of the maternal genome (black line),
whilst de novo methylation occurs at the blastocyst stage (dotted line).
The process of DNA methylation is dependent on dietary methyl group donors
and cofactors, which are involved in methionine and folate metabolism [347,
366, 367]. Maternal nutritional status before or at the time of conception can
alter the methylation status of genes involved in trophoblast development as
well as in placental transport of folate and other methyl donors [347, 351].
This will result in permanent changes in placental structure and function
providing a direct link between placental function, gene methylation and fetal
programming [347].
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It has been shown that higher maternal insulin resistance is associated with
lower methylation levels in the promoter region of placental adiponectin
[384], suggesting that this epigenetic adaptation might induce persistent
glucose metabolism changes in the mother and offspring later in life.
One class of genes regulated by epigenetic mechanisms are imprinted genes,
the expression of which is dependent on their parent of origin.
Imprinted genes are thought to be essential in the control of embryonic and
placental development [385] as well as in functions later in life such as
behaviours and metabolism [379]. Modifications to normal imprinting pattern
have been associated with human syndromes of fetal overgrowth [386, 387],
IUGR [388] and altered neonatal glucose homeostasis [389]. Consistent with
the growth phenotypes observed, many of the imprinted genes currently
known are expressed in the human placenta [379, 390], highlighting their
role in controlling both fetal demand and placental supply. Thus, disease
pathologies resulting from inappropriate imprinted gene expression may be
due to an abnormal placental function [390]. DNA methylation controls the
expression of the specific allele at differentially methylated regions (DMRs)
[368, 391] by altering the binding of specific transcription factor and enhancer
elements [385, 392]. It has been proposed that paternally expressed genes,
such as IGF2, promote fetal growth while maternally expressed genes, like
insulin-like growth factor receptor-2 (IGF2R), function to better ensure equal
access to maternal resources for each offspring [387, 393].
The evidence linking human DNA methylation and periconceptional nutrition is
limited and does not control for postnatal effects on the epigenome. It has
been reported that two placental imprinted genes (H19 and IGF2), crucial for
placental development and fetal growth, are not altered by diabetic
pregnancies associated with fetal macrosomia [394, 395]. Another recent
report showed that offspring DNA methylation profiling at imprinted loci is
altered by maternal nutrient supplementation [368]. However, no large body
of data is currently available, raising common interest in this epigenetic
phenomenon during critical developmental process.
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Advances in technology have allowed researchers to measure changes in DNA
methylation patterns. The early use of restriction enzymes and Southern
blotting with site-specific probes only consented the evaluation of methylation
at specific restriction sites and required large quantities of DNA each time
[379]. Pretreatment of the DNA with sodium bisulphite is one of the most
widely used techniques to detect cytosine methylation of a specific DNA
sequence in a genomic region [396]. This chemical introduces differences
between methylated and unmethylated sites allowing single-base
discrimination [397]. Methylation-specific PCR uses oligonucleotide primers,
which bind and amplify sequences of template DNA modified by sodium
bisulphite in a methylation- specific manner [398]. These procedures enable
researchers to determine changes in single site DNA methylation.
Novel techniques such as quantitative real-time PCR and pyrosequencing now
allow the relative quantification of the methylation status at multiple CpG
sites within a region reflecting the prevalence of methylated alleles within the
template DNA [379, 399]. Infinium array from Ilumina allows quantitative
measurements of DNA methylation levels at specific single-base resolution
[400-402]. The correlation coefficient between DNA sequence and microarrays
is generally consistent. However, very low or very highly expressed genes can
show variable values causing inaccuracy [403, 404]. This discordance in
microarray data suggests that some array probes do not capture the levels of
the target and therefore, caution should be used when interpreting their
output.
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1.11. Hypothesis and Aims:
The primary hypothesis behind this thesis is that entering pregnancy with a
BMI>25 kg/m2, diabetes or a combination of the two, promotes the
development of metabolic alterations in the placenta leading to decreased
placental nutrient transport efficiency and physiological adaptations in the
mother and fetus. These potentially compromise newborn outcomes by
increasing oxidative stress and amplifying the inflammatory milieu within the
placenta, which can result in structural placental impairment, dysfunction and
damage. Also, maternal obesity and gestational diabetes can influence folate
status in the newborn by changing placental folate transport and DNA
methylation leading to altered DNA methylation profile within the placenta.
In order to answer these questions, the following work will be undertaken:
1. Measurements of anthropometry, circulating hormones and metabolic
factors, as well as placental and newborn outcomes, in a cohort of
women delivering between 2008 and 2011 at the San Cecilio Clinical
Hospital, Granada. Specifically, data was gathered on:
 Maternal body weight, height and parity
 Maternal 7 day food intake of glucose, TG, cholesterol, folate
 Maternal plasma hormones (insulin, leptin), metabolites
(glucose, TG, cholesterol, folate) and immune cells (monocytes,
neutrophils, lymphocytes)
 Placental weight and efficiency
 Cord blood hormones and metabolites (glucose, TG, cholesterol,
folate, monocytes, neutrophils, lymphocytes)
 Newborn weight and growth (up to 12 months of age)
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2. Determination of placental energy homeostasis, oxidative stress and
inflammation on the placental metabolic phenotype through the
analysis of:
 Energy metabolism (leptin and insulin signalling)
 mTOR signalling (mTOR, Akt, AMPK, p70S6K)
 Oxidative stress (UCP2, SIRT1)
 *OXFRFRUWLFRLGPHWDEROLVP*5ǃ+6'
 ,QIODPPDWRU\ VLJQDOOLQJ 33$5Ǆ 7/5 SODFHQWDO 7*
concentrations)
3. Determination of gene regulation of placental folate metabolism and
analysis of DNA methylation in the placenta by identification of
differentially methylated genes:
 )RODWHWUDQVSRUW)5Į3&)75)&DQGPHWDEROLVP07+)
 Placental DNA methylation (DNMT1, -3)
 Profile of differentially methylated genes
 mRNA expression of key target genes identified as differentially
methylated by methylation analysis (Illumina Infinium array)
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Chapter 2 - General materials
and methods
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2.1. Ethical Approval
The proposed research was conducted according to the Declaration of
Helsinkis guidelines and all experimental procedures were approved by the
Medical Ethic Review Committee of Granada University, San Cecilio University
Hospital Ethics Committee and the University of Nottingham Medical School
Ethics Committee. Written informed consent was obtained from all subjects
before their inclusion in the study and participants were assured of anonymity
and confidentiality. After obtaining consent, each participant was allocated a
study number, which was used thereafter for all sample labelling. The signed
consent forms, with study allocation numbers, were held separately from all
other study data. Patient clinical data was retrieved from the clinical medical
records as soon as possible. Anthropometric assessments of mother, fetus
and newborn were undertaken following the standards established by the
Spanish Society of Gynaecology and Obstetrics, the Fetal Foundation and the
Spanish Association of Paediatrics.
2.2. Participants
The subjects were participants in a longitudinal study on fetal adiposity
programming by maternal genetics and nutrition (Preobe study P06-CTS-
02341) undertaken between 2007 and 2010 and funded by Consejería de
Innovación, Ciencia y Empresa de la Junta de Andalucía, Spain.
A total of 350 pregnant women aged between 18 and 45, with singleton
pregnancies, were recruited between 12 and 20 weeks of gestation at three
different primary health care settings (Clinical University Hospital San
Cecilio, Ambulatorio Zaidín-Vergeles, and Hospital Materno-Infantil) in
Granada, Spain. Among these, underweight women (self-reported pre-
pregnancy BMI<18.5 kg/m2, n=4) were excluded as they did not fulfil
inclusion criteria. In addition, 61 women did not complete the study,
attending only 1 or 2 visits, and were not included.
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Consequently, only 285 of 350 women recruited were included in this study
despite some of them (control n=6; obese, n=2) failed to attend the visit at
34th gestational week (Figure 2.1).
Figure 2.1: Participants in Preobe study and classification following BMI and
gestational diabetes criteria.
n=number; gw: gestational weeks; OGTT: oral glucose tolerance test; GDM:
gestational diabetes mellitus; IGT: impaired glucose tolerance.
Several mothers (n=76) dropped out of the study due to incapacity at
attending one of the visits (work and/or family contingencies) and a
substantial number of samples (n=24) were lost during delivery due to
circumstances beyond our control (e.g. clinical complications during labour,
fetal death, among others).
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Of the 285 eligible participants, 16 were diagnosed with GDM, hence, they
were added to the GDM group. Additional participants (n=41) diagnosed with
GDM were recruited between 24th-28th weeks of pregnancy and classified as
GDM. Since 5 women initially diagnosed with GDM were subsequently
classified as having impaired glucose intolerance, they were excluded from
the study. Finally, the total number of women who accomplished the study
following the Preobe criteria was 245 out of 350. Among this, a subpopulation
of 149 subjects was selected according to their BMI, and analysed in the
Nottingham Early Life Nutrition Unit. Here, a further classification of women
with GDM was performed according to their BMI (Figure 2.2).
Figure 2.2: Preobe study.
Final classification of the Preobe participants into 6 groups according to BMI and
gestational diabetes criteria as analysed in the Nottingham Early Life Nutrition Unit.
Other criteria for participant exclusion were receiving any drug treatments,
having type 1 diabetes mellitus (T1DM) or any other diseases different from
those included in the study. Maternal and fetal anthropometry was evaluated
at 24 and 34 weeks of pregnancy and at birth. Gestational age was calculated
as from the last menstrual period and through ultrasound scan considering a
gestational age below 37 weeks as preterm delivery.
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Large (LGA), average (AGA) and small for gestational age (SGA), defined as
>90th, 10-90th, <10th birthweight population centile respectively [25], were
calculated using the Lubchenco growth curves [405] adjusted for newborn
weight and gestational age. Ponderal index (PI) was obtained from the
formula:
PI = Birth weight (g) x 100/ length (cm3)
2.2.1. Pre-pregnancy BMI classification
Maternal pre-pregnancy BMI was calculated as weight in kilograms divided by
height in meters squared. Maternal height was measured at the first antenatal
clinic visit. As maternal weight was not possible to measure before pregnancy,
self-reported weight was used in the calculation of BMI, despite there is
concern about its reliability [42] due to incorrect classification, especially in
women with high BMI [406-408]. At 20 weeks of gestation, the subjects were
divided into three different groups based on their self-reported pre-gestational
BMI. Mothers were either classified as control or comparison group (pre-
SUHJQDQF\%0,NJP2 but <25 kg/m2; normal glucose tolerance; n =
 RYHUZHLJKW SUHSUHJQDQF\ %0,  EXW  NJP2; normal glucose
WROHUDQFHQ DQGREHVHSUHSUHJQDQF\%0,NJP2; normal glucose
tolerance; n = 22). Since maternal weight at delivery was not recorded,
weight gain during pregnancy was calculated using clinical data only recorded
at gestational week 24 and 34. To minimise estimation errors and increase
accuracy, total gestational weight gain was calculated from the last recorded
weight during pregnancy (34 gestational weeks) and self-reported pre-
gestational weight. Each BMI category was then categorized as having gained
inadequate, adequate, or excess weight based on 2009 IOM guidelines [61]
until 34 gestational weeks. According to this, total maternal weight gain at
delivery was divided by 40 (gestational weeks), and then multiplied by 34
(gestational weeks) as shown in Table 2.1.
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Specifically, adequate GWG recommended by IOM was defined for each BMI
category as 9.8-13.6 kg for women of normal BMI, 5.9-9.8 kg for overweight
women and 4.2-7.6 kg for obese women. Inadequate and excessive GWG
were defined as less and more than adequate GWG, respectively.
Table 2.1: Recommendation for weight gain during 40 and 34 gestational
weeks in each pre-pregnancy BMI category according to 2009 Institute of
Medicine (IOM) guidelines.
Total gestational weight gain (GWG) corresponds to IOM weight gain until 40
gestational weeks (gw) [61], whereas GWG within the 2nd-3rd trimester was calculated
by dividing IOM total gestational weight gain by 40gw and multiplying it by 34 gw.
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2.2.2. Gestational diabetes mellitus
+LJK ULVN ZRPHQ LQFOXGLQJ PDWHUQDO DJH   \HDUV %0,   NJP2,
relevant past obstetric and family history and impaired glucose metabolism,
had been previously screened and diagnosed for GDM. This was obtained by
measuring fasting plasma glucose concentration or performing an oral glucose
tolerance test (OGTT) at 16 to 18 weeks of gestation.
An OGTT involves a blood test before breakfast, then again 2 hours after a 75
g oral glucose drink. The results were interpreted according to the National
Diabetes Data Group (NDDG) criteria [409] and the Third International
Workshop-Conference on Gestational Diabetes Mellitus (GDM) [410]. If the
first OGTT test was normal an additional 100 g OGTT was given at 24 to 28
weeks (Table 2.2).
Table 2.2: Criteria for diagnosis of gestational diabetes mellitus (GDM).
GDM was defined when two or more of the following glucose concentrations (fasting
value and values at times after 100g oral glucose) were met or exceed; OGTT: Oral
glucose tolerance test.
Persons whose fasting plasma glucose concentration was less than that
required for a diagnosis of diabetes (<140 mg/dl), and whose plasma glucose
value at 2 hours after a OGTT was intermediate between normal and diabetic
(140-199 mg/dl), were classified as impaired glucose tolerance (IGT). In
Nottingham, IGT women were excluded from additional analysis.
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In addition, the BMI in GDM participants was considered in order to divide this
group into gestational diabetic lean or normal weight (pre-pregnancy
%0,NJP2 but <25 kg/m2; hyperglycaemic; n=14), gestational diabetic
RYHUZHLJKW SUHSUHJQDQF\%0,NJP2 but <30 kg/m2; hyperglycaemic;
Q  JHVWDWLRQDO GLDEHWLF REHVH SUHSUHJQDQF\ %0, NJP2;
hyperglycaemic; n=11). This allowed the effect of gestational diabetes per se
and associated with an increase in body mass to be considered separately.
2.3. Maternal questionnaires
At the time of recruitment, each participant was asked whether she received
multivitamin and mineral tablet supplements, such as iron, iodine and folate,
during the first trimester.
Pre-pregnancy diet was evaluated with food frequency questionnaires, which
were completed by each mother after instruction were given, and returned at
the first antenatal visit at 24th week of pregnancy. However, in this study
dietary intake was estimated using a 7 day food records (SDDR) given to the
participants during the second visit at 34 gestational weeks, allowing
information about folate and nutrient intake before delivery to be collected.
Despite food-frequency questionnaires having been validated for determining
food intake in a variety of populations, food records are considered the gold
standard for dietary intake assessment in measuring actual food intake due to
their higher accuracy and minor estimation errors [411].
Each subject was given verbal and written instructions by the investigator on
how to record everything she consumed during the 7 days recording period
(week 34-36). At the time of delivery or after a week of giving birth, food
records were reviewed with each mother by a dietician for completeness and
accuracy of food description and amount. For this purpose, a booklet of
common food items and mixed dishes was used to facilitate the estimation of
portion sizes.
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Nutritional data were then analyzed for nutrient intake by using a nutritional
software program (CESNID 1.0, Barcelona University, Spain) based on
validated Spanish food tables (Tablas de composición de alimentos del
CESNID) [412, 413].
2.4. Collection of biological samples
A chronological diagram of the study reflecting collection of biological samples
from the mother as well as anthropometry of both pregnant women and
newborns is illustrated in Figure 2.3.
Figure 2.3: Programme of evaluations in the Preobe study.
Maternal examinations during gestation and after delivery. Measurements and
collection of samples are reported in white boxes whereas greyed out boxes represent
time before, during and after pregnancy.
Maternal pre-gestational weight was self-reported by the participants at the
day of recruitment (approximately 20 weeks of gestation). During gestation,
each mother attended two medical examinations, at 24 and 34 gestational
weeks respectively, and anthropometry measurements were undertaken by a
gynaecologist as well as maternal blood collected by a nurse.
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At delivery, additional maternal biological samples as well as the placenta and
cord blood were collected. At this stage, self-reported maternal weight was
annotated, whereas newborn weight and height measured by a midwife.
Maternal anthropometry was evaluated at 6 months post-delivery and infant
anthropometry was measured at 3, 6 and 12 months of age respectively by a
paediatrician.
Food records questionnaires were handed to every subject at 34 weeks of
gestation in order to be completed approximately one week before delivery
and returned to the investigator at the next visit.
2.4.1. Blood sampling
All blood samples were collected after written consent was obtained from the
mother. Maternal venous blood samples (25 ml) were collected at 24, 34
weeks of pregnancy and during labour for haematological and biochemical
analysis, which was performed by the Clinical Analysis Service of San Cecilio
Clinical Hospital. As mothers with gestational diabetes were recruited after 24
gestational weeks, their samples were collected by the second revision at 34
weeks. After birth, umbilical venous blood samples were taken (where
possible) from cord double-clamped section, immediately after a small aliquot
was used for blood gas analysis to record the fetal pH at birth.
An aliquot of each blood sample was immediately transferred into 7.5% EDTA,
3.0 ml chilled collection tubes (ref. 368857, Vacutainer®) for hematologic
assessment and 8.5 ml chilled heparin collection tubes (ref. 367953,
Vacutainer®) for biochemical analysis. Once collected, the heparinised plasma
samples were centrifuged at 900 g for 10 minutes at 4°C and the plasma
fraction was then transferred into sterile blood collection tubes (Vacutainer®)
and stored at 4°C until performing biochemical analysis the following day.
The serum samples were left at 4°C for 15 minutes to allow the blood to clot
fully and then they were centrifuged at 900 g for 10 minutes at 4°C. The
resulting serum fraction was carefully transferred into fresh sterile blood
collection tubes and stored at 4°C until use.
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Haematological parameters were analyzed using a haematologic counter
(Roche Diagnostic, model and serial number: Sysmex XE-2100 Sysmex
XE=5000) and citometers BAYER (model and serial number: ADVIA 120-
160858. ADVIA 120-160529. ADVIA 120- 162136).
Serum folate was evaluated by using the automatic analyser Elecsys 2010
with modular analytics E170 (Roche, Neuilly sur Seine Cedex, France). Serum
leptin concentrations were measured using a sensitive ELISA kit (Biosource
Kap 2281, Denmark), whereas cytokines were quantified by using eBioscience
human Th1/Th2 ELISA Ready-Set-Go kit, according to the manufacturers
instructions.
2.4.2. Tissue sampling
All placentas samples were collected within 20-30 minutes of delivery, placed
in a sterile tray, and carefully inspected for any visible abnormalities. Wet
placental weights and diameter were immediately recorded before a triangular
segment of the placenta was excised using a sterile scalpel and re-inspected
for any visible abnormalities. Both the decidual layer along the basal plate as
well as the chorionic surface and membranes were removed by sharp
dissection and the remaining tissue was then divided into two portions along
the long axis. A set of three samples (200 mg) of approximately two cm2 in
length was excised from the medial to the lateral edge of the placenta (Figure
2.4), rinsed twice in physiological saline (NaCl 0.9%) and then divided in two
0.5-1 cm2 specimens. Those samples were immediately collected into labelled
sterile 1.5 ml tube (Greiner®) containing RNAlater solution (Qiagen®,
Cat.Nr.76106), a reagent which immediately stabilizes RNA in tissues to
preserve the gene expression profile eliminating the need for dry ice or liquid
nitrogen. The remaining portions of the placental tissue were also sampled
and, like the ones in RNA later, kept frozen under RNase free conditions first
at -20°C and then at -80°C awaiting analysis.
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Where delivery occurred overnight, the placentas were stored in the same
way as described above although the time of collection sometimes was
delayed by up to 1 hour due to circumstances beyond our control.
Figure 2.4: Diagram of placental sections taken after delivery.
One set of three samples was taken and kept frozen in RNAlater solution at -80°C.
2.5. Tissue analysis
Frozen placental samples and samples stored in RNAlater solution were
shipped in dry ice to the Early Life Nutritional Academy department in the
Queens Medical Centre (University of Nottingham) where all laboratory-based
techniques and protocols for tissue analysis were conducted. The selected
tissues were immediately placed at -80°C while an accurate record of location
and usage was created using validated software database (Pro-curo software
Ltd, Bethesda, MD 20814-3993, USA). In order to minimise the risks of
possible contamination and degradation of RNA, all equipment was autoclaved
and sterilized prior to all experimental work as well as working areas cleansed
of ribonucleases using RNaseZap® (Ambion, California, USA), 70% denatured
ethanol (Ecolabs, Surrey, UK) and 1% Virkon disinfectant (Antec
International, Suffolk, UK). In addition, all reagents were RNase and
ribonuclease free while special care was taken to set up reactions and
maintaining samples on ice wearing gloves.
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To further avoid RNA contaminations by handling human samples, all tissue
and molecular work was carefully performed under a UV cabinet (UV4PCR,
Scientific Laboratories Supplies, UK) and a laminar flow cabinet was used
when working with hazardous biological agents. All placental tissues and RNA
samples were stored at -80°C until needed whereas DNA samples and some
reagents were kept at -20°C.
2.6. Ribonucleic acid analysis
The number of copies of a gene transcript, expressed as messenger
ribonucleic acid (mRNA), in a cell or tissue is determined by the rates of its
expression and degradation. A common method for amplifying DNA is the
polymerase chain reaction (PCR) [414], which allows specific detection and
quantification of gene expression from small amounts of RNA. According to
this, the RNA sample is first extracted from cells or tissues and then reverse
transcribed into cDNA through a reverse transcription (RT) reaction in order to
be measured and amplified during PCR at each cycle. The data thus generated
can be analysed by computer software to calculate relative gene expression
(or mRNA copy number) in several samples.
2.6.1. RNA extraction
Isolation of RNA of extremely high integrity must be performed cautiously as
RNA can rapidly be degraded by the ubiquitous presence of ribonuclease
enzymes [415]. Total RNA was extracted from placental tissues following an
adapted version of the Chomczynski and Sacchi method [416] before further
purification using RNeasy Plus Mini kit (Qiagen Ltd., Crawley, UK) according to
the manufacturers instructions [417]. A single step using Tri Reagent®
(Sigma Chemical Co. Poole, UK), which contains guanidinium thiocyanate and
phenol, ensures both tissue lysis and protein denaturation, thus allowing
inhibition of any RNase activity [418].
74
Subsequent addition of chloroform to the lysate leads to three phase
separation by centrifugation resulting in an upper aqueous phase containing
total RNA, an interphase with most of the dissolved DNA and a lower organic
SKDVHZLWKSURWHLQV,QWKHILQDOVWHSWRWDO51$ǋJLVUHFRYHUHGIURP
the aqueous phase by precipitation with either isopropanol or ethanol while
passing to an RNAeasy mini column. After appropriate binding of total RNA,
the RNAeasy membrane is washed with buffers of ethanol and guanidium salt-
based to remove any contaminants and RNA is finally eluted using nuclease-
free water.
Extracted RNA yields are unknown and can contain proteinaceous impurities;
therefore, the concentration and purity of extracted samples was determined
spectrophotometrically (Nanodrop® Technologies, Wilminton, USA). Since
nucleic acids absorb UV light at 260 nm, the concentration and purity of
extracted RNA yields was estimated through relative wavelength absorption
(1 OD unit = 40 µg RNA/ml) [419]. In addition, protein absorbs UV light at
280nm therefore the presence of protein contamination in the sample was
measured through a ratio of absorption between wavelengths 260nm:280nm;
optimal absorbance between 1.8 and 2 indicated good quality RNA [420].
2.6.1.1. RNA extraction procedure
Total RNA was extracted from 100 mg placental samples with 1 ml TRI
Reagent® and then homogenised at 800 g using a Dispomix homogeniser
(Medic Tools, Zurich, Switzerland) and centrifuged for 1 minute at 800 g.
Samples were left at room temperature for 5 minutes to ensure complete
dissociation of nucleoprotein complexes and the supernatant was transferred
to a sterile 1.5 ml eppendorf tube.
1H[WǋODQDO\WLFDOJUDGHFKORURIRUP)LVKHU6FLHQWLILF/HLFHVWHUVKLUH8.
was added followed by vortex for 15 seconds. Incubation at room
temperature for 15 minutes then allowed phase separation.
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After centrifugation at 12500 g for 15 minutes at 4°C the upper aqueous
SKDVH § ǋO ZDV FDUHIXOO\ WUDQVIHUUHG WR VSHFLDOO\ GHVLJQHG JHQRPLF
deoxyribonucleic acid (gDNA) columns and centrifuged at 8000 g for 30
seconds at room temperature to allow efficient removal of any remaining
gDNA contamination. The supernatants were then centrifuged at room
temperature for 1 minute at 8000 g and the gDNA columns discarded before
RQHYROXPH§ǋORILFHFROGHWKDQROZDVDGGHGWRWKHIORZWKURXJK
providing appropriate binding conditions for RNA. RNeasy Plus Mini extraction
kit (Qiagen, West Sussex, UK) was used to extract RNA from each individual
sample according to manifacturers instructions.
The solution was pipetted to an RNeasy spin mini column allowing total RNA
binding to the membrane after centrifugation at 8000 g for 15 seconds at
room temperature. All contaminants were washed away by discarding the
IORZWKURXJK5:EXIIHU ǋOZDVXVHG WRZDVK WKHFROXPQZKLFKZDV
centrifuged at 8000 g for 15 seconds at room temperature before discarding
WKHIORZWKURXJK53(EXIIHUZDVWKHQDGGHGǋOWRWKHFROXPQIROORZHG
by centrifugation at 8000 g for 2 minutes at room temperature and discard of
the flow-through before transferring the minispin column to a sterile 2 ml
collection tube. Further centrifugation at 12500 g for 1 minute ensured
elimination of any RPE buffer carry-over, which could interfere with future
RNA applications. The minispin column was transferred to a sterile 1.5 ml
collection tube and high-quality RNA was then eluted in 50 µl RNase-free
water after centrifugation at 8000 g for 1 minute. RNA concentration and
purity were determined using a Nanodrop®ND-1000 (Nanodrop Technologies,
Wilmington, USA) spectrophotometer by pipetting 1.5 µl each RNA
SUHSDUDWLRQ ,Q RUGHU WR EH XVHG LQ WKH TXDQWLWDWLYH 573&5 DQDO\VLV  ǋO
aliquots from each extracted RNA stock were then diluted with RNase-free
ZDWHUWRǋJǋO LQD ILQDOYROXPHRIO$OOH[WUDFWHG51$VDPSOHVZHUH
labelled with an individual sample identification code (ID) and stored in 0.3 ml
microcentrifuge tube at -80°C until further analysis.
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2.6.2. RNA integrity
The integrity of total RNA was assessed by running an aliquot of 2 µl from 13
random samples stored in RNA later solution on a denaturating agarose gel
stained with 0.01 % ethidium bromide. Visualization of sharp and clear 28S
and 18S rRNA bands on the gel as shown in Figure 2.5 (samples 1-5, 7-8, 10-
13, lane 1 and lane 2 respectively) confirmed the integrity of the sample. A
2:1 ratio (28S should be twice as intense as 18S) is a good indication that the
RNA is completely intact [419], whereas a partially or completely degraded
RNA would show a smeared appearance or lacking in sharp rRNA bands
(partial degradation, Figure 2.5, sample 6), or it would appear as a very low
molecular weight smear (complete degradation, Figure 2.5, sample 9).
Figure 2.5: Purity of RNA samples.
2 µl total RNA were run beside DNA marker ladder on a 2% denaturing agarose gel.
From top to bottom: two intense bands corresponding to 28S and 18S ribosomal RNA
bands respectively are clearly visible in all intact RNA samples (1-5, 7-8, 10-13)
whereas partially degraded (6) and completely degraded samples (9) do not show
well-defined bands.
In the case of RNA, a sample containing no protein would be expected to have
a 260nm/280nm ratio of approximately 2 [421]; however in the two samples
above mentioned, a 260/280 ratio of 1.65 (sample 6) and 1.52 (sample 9)
was detected, indicating sample contamination. Therefore, all samples with a
260nm/280nm ratio below 1.8 were excluded from further analysis.
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2.6.3. Reverse transcription polymerase chain
reaction
Following extraction, the single stranded RNA template must be first reverse
transcribed into a double stranded complementary DNA (cDNA). This
molecular process is known as reverse transcription PCR (RT-PCR) which
allows the detection of a low copy number of mRNA molecules by using a DNA
primer sequence and a reverse transcriptase. This enzyme is provided with
both RNA and DNA polymerase activity ensuring efficient transcription,
elongation and synthesis of the single stranded RNA template into a double
stranded cDNA which is then ready for standard PCR and further amplification.
RT-PCR is widely used in the diagnosis of genetic diseases and in the cellular
determination of the abundance of specific mRNA molecules as a measure of
gene expression [422].
In this work, cDNA was created using the High Capacity RNA-to-cDNA kit
(Applied Biosystems, CA 94404, USA) which has the advantage to require
fewer pipetting steps thus reducing reverse transcription time since it
consolidates all the components of the reaction into two tubes, one RT buffer
containing deoxyribonucleotide triphosphates (dNTPs) and an enzyme mix
containing MuLV reverse transcriptase and RNase-free inhibitor protein.
2.6.3.1. RT-PCR procedure
A set of RNase-free 0.2 ml eppendorf tubes were labeled for every sample,
which was run concurrently with a no-reverse transcription enzyme control
(NRTC) to ensure transcription efficiency and a negative control without RNA
template (NTC), replaced with nuclease-free water. The reaction consists of
pipetting 2 µl the 1 µg/µl RNA samples (or nuclease-free water) into the RT
and controls labelled tubes placed on Eppendorf PCR Cooler (Sigma Aldrich)
before adding 18 µl each master mixes to reach a final volume of 20 µl as
described below:
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Volume (µl) Reagent
2 RNA 1µg/µl (or water)
10 2x RT buffer mix
1 20x RT enzyme mix
7 RNase-free water
After centrifugation for 1 minute at 12500 g, the tubes were then transferred
to the PCR machine (Techne Thermal Cycler, Stone, Staffordshire, UK) using
the RT for the the RT reaction to proceed for 60 minutes at 37°C. After the
reaction was stopped and cooled at 8°C the samples were stored in a freezer
at -20°C.
2.6.4. Classical polymerase chain reaction
The PCR technique allows isolation and amplification of a specific region of a
small chosen DNA sequence using a pair of complementary primers in an
enzymatic reaction. The method relies on thermal cycling which uses repeated
cycles of heating and cooling to denature and replicate the two strands of
DNA. During the DNA melting step the doubled stranded DNA is physically
separated subsequently allowing primers to anneal to the DNA sequence at
lower temperature. These short DNA oligonucleotides (primers) are
complementary to the target DNA and ensure selectivity of the PCR process
enabling its amplification under specific thermal cycling conditions [423].
Adequate design of primers, by considering their length and sequence,
annealing and melting temperatures, is critical for a successful PCR reaction
as poorly designed primers can result in a decreased product yield and/or
formation of primer dimers. The sequence that is amplified during PCR is
called amplicon or PCR product and corresponds to the part of the gene
between the two primers.
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7KHERXQGSULPHULVHORQJDWHGE\ELQGLQJIUHHSKRVSKRQXFOHRWLGHVLQWKHʦWR
ʦ GLUHFWLRQ E\ D WKHUPRVWDEOH '1$ SRO\PHUDVH XVXDOO\ 7DT 3RO\PHUDVH
extracted from the bacteria Thermus aquaticus) which maintains its activity at
high temperature (>105°C) for a long period of time [414]. Subsequently,
both DNA strands  the original template and the newly synthesised strand
including the primer  are denatured allowing the primers to bind to both of
them again. Following each PCR cycle, the DNA product is doubled, leading to
an exponential amplification of the target sequence for the number of cycles
(2n, n = number of cycles). In the case of cDNA, the final amount of amplicon
copies is representative of the number of intact mRNA molecules for this gene
present in the target tissue at the time of RNA isolation.
2.6.4.1. Classical PCR procedure
Conventional PCR method was performed to amplify target cDNA, which was
then used to prepare standards dilutions for the Q-PCR reaction. A set of
sterile 0.2 ml eppendorf tubes was labelled on ice for each sample and
reaction mixture added per tube as follows:
Volume (µl) Reagent
2 cDNA
10 Thermo start PCR master mix
1 Forward primer (1:10)
1 Reverse primer (1:10)
6 RNA-free water
Negative controls containing no template cDNA and no primers were run
concomitantly to ensure the integrity of the prior RT-PCR reaction, and to
confirm quality controls against genomic DNA contamination.
As shown above, 2 µl cDNA or nuclease free water was then pipetted into the
each 0.2 ml tube respectively before 18 µl PCR master mix was added to
reach a final volume of 20 µl.
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Tubes were then centrifuged for 1 minute at 12500 g before being loaded into
the Techne thermal cycler (Scientific Laboratories Supplies Ltd, Nottingham,
UK) and run on a 60°C hot start PCR program (Table 2.3). The thermo-start
master mix (Thermo Scientific, Abgene, Epsom, UK) includes the thermo-start
Taq DNA polymerase and all the components to perform a rapid and
reproducible PCR. The enzyme is completely inactive at room temperature,
preventing the formation and subsequent amplification of non-specific
products, and requires an activation step at 96°C for 15 minutes.
Table 2.3: Hot start PCR program conditions.
Step Temperature (°C) Duration
Initiation 105 4 min
Enzyme activation 96 15 min
PCR cycles (n=35)
Denaturation 94 30 sec
Primer annealing 60 30 sec
Primer Extension 72 60 sec
Final Extension 72 7 min
Hold 4 Indefinitely
81
2.6.5. Design of primers for RT-PCR
Primer sequences for RT-PCR were designed with Beacon Designer 4.0
software (Premier Biosoft, Palo Alto, USA) and Primer3 Input 4.0 software
(available online http://frodo.wi.mit.edu/primer3/) which automatically
interpret the homology by using the human genome sequence from the
National Centre for Biotechnology Information (NCBI) online database. To
avoid amplification of contaminating genomic DNA, primers were designed
ensuring that one half of the primer hybridizes to the 3' end of one exon and
the other half to the 5' end of the adjacent exon with an annealing site that is
at least 300400 bp apart. The software also guarantees greater specificity to
the target gene by creating primers that flank exon boundaries containing at
least one intron sequence, resulting in products amplified from cDNA (no
introns) being smaller than those amplified from genomic DNA (with introns).
Similar optimum annealing temperatures, guanine-cytosine base pair content
and length of the primers designed conferred ideal reaction conditions. The
target sequence was then tested using the NCBI basic nucleotide BLAST
search engine (http://blast.ncbi.nlm.nih.gov/Blast.cgi) ensuring that each
primer was amplifying the correct sequence without cross-hybridising with
other gene sequences within the genome.
All oligonucleotides were developed and purchased from Sigma-Aldrich UK,
resuspended in an appropriate volume of RNase-free H2O and stored at -20°C
at a stock concentration of 100 µmol/l. Primers details for each gene analysed
in this thesis are reported in Table 2.4.
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Table 2.4: Oligonucleotide primer sequences used for quantification of target
and endogenous control gene cDNA by real time PCR.
NCBI sequence Target Gene Sense primer sequence (5-3) Anti-sense primer sequence (5-3)
NM_001014432 Akt1 TCACCATCACACCACCTGACCAAG CGCCTCTCCATCCCTCCAAGC
NM_001130823.1 DNMT1 TTCTTCGCAGAGCAAATTGA CCATGAAGGAGGCAGATACG
10B '107Į $$*&&7&$$*$*&$*7**$$ $$*&$*$&&777$*&&$&*$
NM_058186.3 FAM3B GCCAAAATCTGCTTTGAGGA CACCATGAAGAGCAGGGATT
10B )5Į &$&7&&&7*&&7*7&7&& 7&7*&7&7*&7&7$&$&7&&
NM_001080432 FTO TGGAAGCACTGTGGAAGAAGATGG TGTTCGGGCAATTCGTGACTGG
NM_001134945 GHRL GGCAGAGGATGAACTGGAAG GAGGTGAGTAAGGCTTGTGG
10B *5Į **$$7$**7*&&$$**$7&7* *&77$&$7&7**7&7&$7*&7
NM_000196 HSD11B2 ACTCATGGACACATTCAGCT CCACGTTTCTCACTGACTCT
NM_000875 IGF1R CCTTGCTGCTGCTCCATCC GACTCTGCTCCTGCGTGTG
NM_005544 IRS1 CAGTCCTAACCGCAACCAGAGTG CGCTGCTGCTGCTGCTACC
NM_000230 LEP TCCTGAGACCTGACAAGCACTG CCCAAACCTCCTCTTTCATCTTCC
NM_002303 LEPR GCTAAGGTCGGAGTTCTGC CTGAAGGATAATGCCACGAGAG
NM_017898.3 MOSC2 GACAGGTTTTGGCTGGTGAT TTTGTTTGAGGAAGGCTGCT
NM_005957 MTHFR TCCCGTCAGCTTCATGTTCT TGTCGTGGATGTACTGGATGA
NM_004958 mTOR CGAGGGCAGCAACAGTGAGAG ACAAGGAGATGGAACGGAAGAAGC
NM_003161 p70S6KB1 GACGCACTGAGCCTAAGC CCAGGTCTATGTCAAACACTCC
NM_015869.4 *33$5Ǆ 77&$*$$$7*&&77*&$*7* &&$$&$*&77&7&&77&7&*
NM_022551.2 18S GATGGGCGGCGGAAAATAG GCGTGGATTCTGCATAATGGT
NM_001142498 SIRT1 TACCGAGATAACCTTCTGTTCG GTTCGAGGATCTGTGCCAAT
NM_006996.2 RFC CAGCATCTGGCTGTGCTATG TGATGGTCTTGACGATGGTG
NM_080669.4 PCFT ATGCAGCTTTCTGCTTTGGT GGAGCCACATAGAGCTGGAC
NM_001135930.1 TLR4 AAGCCGAAAGGTGATTGTTG CTGAGCAGGGTCTTCTCCAC
NM_001033611.1 *UCP2 CCCGAAGCCTCTACAATGGG CTGAGCTTGGAATCGGACCTT
NM_003391.2 Wnt2 GTGGATGCAAAGGAAAGGAA AGCCAGCATGTCCTGAGAGT
*Human primers were used for all genes except for UCP2 and TLR4 which were
analysed using sheep primers after homology was tested with the BLAST database
[424].
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2.6.6. Agarose gel electrophoresis and DNA
extraction
PCR products can be analysed and resolved using a matrix gel (either agarose
or polyacrylamide) by electrophoresis. DNA molecules are negatively charged
and can be separated according to their size by applying an electric field
through the gel which will make the smaller fragments migrate further and
quicker towards the positive electrode [425]. A DNA dye, ethidium bromide, is
added to the gel matrix to visualise the DNA fragments using ultra-violet (UV)
fluorescence. The unknown DNA band size can be estimated by running a DNA
marker ladder alongside the samples before proceeding with their extraction
from the agarose gel using a commercial gel extraction kit.
In this study, the DNA gel fragments were isolated with the QIAquick® Spin
extraction kit (QIAGEN) which combines spin-column technology with the high
DNA affinity of a silica membrane which selectively binds DNA in the presence
of a high concentration of salt. Washing steps with different buffers provided
by the kit also ensure the elimination of any possible contamination or
residual agarose before eluting the purified DNA using either nuclease-free
water or elution buffer.
2.6.6.1. Agarose gel electrophoresis & DNA extraction
procedure
A 2% (w/v) agarose gel was prepared by dissolving 2% agarose
electrophoresis grade (Invitrogen Life Technologies) in 50ml of 1x Tris-
acetate-EDTA (TAE) buffer, from a 50x stock solution of 2M tris
(hydroxymethyl) aminomethane base (tris), 1M glacial acetic acid (Fisher
Scientific), 50mM Na2 EDTA buffer. After heating, the solution was mixed with
ǋO PJPO HWKLGLXPEURPLGH IRU YLVXDOL]DWLRQ DQG WKHQ FRROHG WR IRUPD
gel.
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Following, each PCR product (20 µl) was mixed with 5 µl glycerol blue dye
(2.5% Ficoll® - 400 11mM, EDTA 3.3mM, Tris-HCl 0.017%, SDS 0.015%,
bromophenol blue) and was loaded into separate lanes together with a DNA
marker ladder (100 bp Blue eXtendec, Bioron, Ludwigshafen, Germany).
Electrophoresis was run at constant voltage (100 V) for about 45 minutes for
small gels (V=50 ml), 60 minutes for medium gels (V=100 ml) or 75 minutes
for large gels (V=150 ml). After DNA separation, the PCR product was
visualised under a UV trans-illuminator CCD camera (Fuji film luminescent
image analyzer LAS-1000 V1.01) with an ultra violet lens for imaging and its
size estimated by comparison to the ladder. Fluorescent target bands were
cut out of the gel, transferred into sterile 1.5 ml eppendorf tubes and weighed
before proceeding to DNA purification using the QIAquick® gel extraction kit
4LDJHQ7KHGLVVHFWHG'1$EDQGVZHUHUHGLVVROYHGLQǋO*4EXIIHUSHU
 ǋJ RI JHO XVLQJ D WKHUPREORFN DW & IRU  PLQXWHV DQG WKLV ZDV
IROORZHGE\DGGLWLRQRIǋOLVRSURSDQRO)LVKHU6FLHQWLILFSHUǋJRIJHO
to ensure DNA precipitation. The mixture was then pipetted into a sterile
QIAquick spin column and centrifuged at 12500 g for 1 minute in order to
discard the GQ buffer and isopropanol filtrate. To remove any remaining trace
RI DJDURVH DQRWKHU  ǋO *4 EXIIHU ZDV DGGHG WR WKH VSLQ FROXPQ DQG
centrifuged at 12500 g for 1 minute before discarding the filtrate. An
DGGLWLRQDO ZDVK ZDV SHUIRUPHG ZLWK  ǋO 3( EXIIHU FRQWDLQLQJ HWKDQRO
followed by 5 minutes of incubation and 1 minute of centrifugation at 12500 g
with final discard of the filtrate. The empty column was centrifuged again at
full speed for 1 minute to ensure removal of any residual PE buffer and the
spin column was then transferred to a fresh 1.5 ml eppendorf tube. Elution of
'1$ZDVREWDLQHGE\FDUHIXOO\SLSHWWLQJǋOHOXWLRQEXIIHU(%GLUHFWO\RQWR
the column membrane which was centrifuged at 12500 g for 1 minute and
then discarded. Before storing all purified DNA samples at -20°C until needed,
their concentration and purity were measured using the Nanodrop
spectrophotometer and the resulting values were used to set the standard of
the Q-PCR reaction.
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Newly designed primer products were sent for sequencing at the University of
Nottinghams Centre for Genetics and Genomics (Queens Medical Centre,
Nottingham UK) and the resulting sequences were cross-referenced using the
NCBI online database (BLAST).
2.6.7. Real-Time polymerase chain reaction
Quantification of a target DNA sequence can now be achieved in real time
through advanced PCR technologies which by including additional analysis
steps ensure a reduction of time expenditure and the chance of having
contamination [426]. Quantitative PCR (Q-PCR) detects and quantifies a PCR
product by using a fluorescent signal whose intensity is correlated to the
amount of DNA template (the greater the intensity, the higher the DNA
concentration detected). The level of fluorescence emitted by the dye is
normally detected at a crossing point (Cp) or threshold point (Ct) that reflects
the number of cycles after which the signal has crossed certain level of
background fluorescent [427]. As the cycle threshold is correlated to the
initial concentration of the DNA template this parameter is used for the
quantification of the targeted gene expression.
The increase in the signal fluorescence is graphically represented by the
instrument as a sigmoidal curve reflecting the fact that the amplification of
the targeted sequence within the PCR reaction is exponential. The linear
section of the curve can be compared to signals from other samples run
within the same experiment. Figure 2.6 shows the magnitude of normalised
fluorescence generated by the software at each PCR cycle that is expressed as
Ʃ5Q ZKHUH 5Q LV WKH IOXRUHVFHQFH RI WKH UHSRUWHU G\H GLYLGHG E\ WKH
fluorescence of a passive reference dye (i.e. ROX).
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Figure 2.6: Example of amplification curves for a gene of interest in Q-PCR.
Fluorescent signal crosses a threshold and increases exponentially until a plateau from
expenditure of reagents or cycle number. Amplification plot shows the variation of log
Ʃ5QZLWK3&5F\FOHQXPEHUFDOFXODWHGDWHDFKF\FOHDVƩ5QF\FOH 5QF\FOHí
Rn (baseline). Rn is the fluorescence of the reporter dye divided by the fluorescence of
a passive reference dye (i.e. ROX).
Red lines represent external standard dilutions (10-3 to 10-8) while colored lines
correspond to the unknown samples, which fall within the standard curve. Samples
that fell outside the last standard (10-8) were run again using a more diluted standard
(10-9 or 10-10) to avoid false estimation of gene expression.
The unknown cDNA concentration is calculated by interpolation using a
standard curve. Gene standards are prepared from serial dilutions of cDNA
amplicon of the measured gene (i.e. 10-3 to 10-8 ng/ml or 10-4 to 10-9 ng/ml if
the gene is low expressed) and are run with the samples into a 96-well plate.
A standard curve is produced by plotting the log concentration of each
standard against their Ct value resulting in a straight line equation.
This reflects the coefficient of correlation (R2) and the efficiency of the
reaction (E), which is calculated by the following formula derived from the
basic equation describing PCR amplification [428]:
E = 10 (-1/slope)  1
Measurements are only considered successful if the standard curve shows an
R2 of >0.95 and an efficiency of between 1.95 and 2.05.
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An efficiency of 2 indicates the ideal amplification (i.e. a doubling of the
number of amplicon molecules with each thermocycle).
Normalisation of target gene expression levels must be performed to
compensate intra- and inter-kinetic variations of RT-PCR reactions (sample-
to-sample and run-to-run variations) [429]. To quantify any variations in the
abundance of a target gene between samples, mRNA expression levels are
normalised to a reference gene, which is highly expressed in all cells or
tissues at relatively constant levels [430]. This gene is used to compare the
expression of the target gene in the same sample allowing quantification of its
expression (see section 2.6.8 for details of housekeeping genes used in this
study). Results can then be analysed assuming an efficiency of 2 based on the
ƩƩ&WPHWKRGGHYHORSHGE\3IDIIO >@$V LOOXVWUDWHG LQ WKH IRUPXODEHORZ
the amount of a target gene (QT) is normalised to a reference control, where
Ʃ&WLVWKHGLIIHUHQFHEHWZHHQ&WRIWDUJHWJHQHDQG&WRIUHIHUHQFHJHQHRI
the same sample):
QT = 2 -(Ct target  Ct reference)
In this mathematical model, the relative expression ratio of a target gene is
calculated based on the efficiency (E) of the reaction and on the difference in
threshold cycles (Ct) between an unknown and a control sample in
comparison to a reference gene. The method assumes that the efficiency of
the PCR reaction is 100%, indicating that primer concentrations have been
properly optimized and cDNA strands replicate entirely within each cycle,
hence 2^. This assumption of efficiency is verified by the standard curve,
whereby general accepted efficiency range from 90-105% [431].
Q-PCR reaction can be affected by a number of variables including length of
the amplification, secondary structure of the product and primer quality
[432]. As with standard PCR, primer design is a key component to
amplification of specific region of a sequence. One disadvantage of using
fluorescent dyes, such as SYBR Green, is the generation of false positive
signals which can be originated from non-specific DNA bindings of the dye.
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Therefore, to ensure that the amplified PCR product specifically corresponds
to the targeted sequence, a melt curve stage is performed following the PCR
cycles. The plot of data collected generates a melt curve (or dissociation
curve) for every sample where the peaks display the melting temperature
(Tm) at which 50% of the cDNA is double-stranded and 50% of the cDNA is
dissociated into single-stranded DNA. A specific PCR amplification should be
identified by only one peak in the melt curve whereas a double- or multi-
peaks melt curve would reflect a primer dimer or non-specific double stranded
DNA bindings. Further qualitative analysis can be performed by DNA
sequencing after the product has been extracted by gel electrophoresis.
2.6.7.1. Q-PCR procedure
Following DNA gel extraction, serial dilutions (1:10) up to and including 1 x
10-9ZHUHSUHSDUHGIURPQJǋOF'1$VWDQGDUGWHPSODWHIRUDOOWDUJHWJHQHV
(housekeeping genes included). A standard curve was first tested in the Q-
PCR instrument together with two samples and a no-reverse transcription
enzyme control to ensure transcription efficiency. In addition, a negative RNA
template control, replaced with nuclease-free water, was also run in the same
reaction. When primers annealing was not optimal, different conditions of
primer concentrations (pilot concentration=250nM), i.e. 100, 300 and 500
nM, or primer annealing temperature (pilot temperature=60°C), i.e. 58, 62
and 64°C, were modified to improve reaction conditions.
For gene expression analysis, all unknown samples were measured with
housekeeping gene 18S to normalise all unknown cDNA samples. Following
primers optimisation, samples, standards and negative controls were run for
HDFK RSWLPLVHG JHQH LQ D WRWDO YROXPH RI  ǋO SHU 43&5 UHDFWLRQ  ǋO
samples, standards and negative controls were loaded into a 96 well PCR
SODWH $EJHQH DQG VXEVHTXHQWO\  ǋO PDVWHU PL[ FRQWDLQLQJ WKH
following reagents was added:
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Volume (µl) Reagent
4.5 cDNA (1:10)
7.5 SYBR® green (Thermo Scientific)
1.5 Forward primer (250 nM)
1.5 Reverse primer (250 nM)
Samples and standards were run in duplicate to calculate the coefficient of
variation within each experiment. For each gene analysed, negative controls
for no template cDNA and no primers were also run. The enzyme SYBR®
green (Thermo Scientific, ABgene Ltd. Epson, UK) contains Taq DNA
polymerase, magnesium chloride and dNTP mix in optimised buffer.
After sealing the Q-PCR plate using an Abgene plate sealer and thermal seals
(Alpha Laboratories, Hampshire, UK), samples were placed in the Quantica®
Q-PCR instrument (Techne) or the StepOne Plus Real Time PCR System
(Applied Biosystems). Q-PCR relies on the same reactive principles as a
regular PCR, although the reactions are carried out without an extra
temperature step for primers extension because the polymerases used in Q-
PCRs are less temperature-sensitive than the polymerase used in regular PCR
(Fifure 2.7). In the sample mix, the extension of short amplicons occurs in the
time the machine needs to heat up from the annealing temperature (60°C) to
72°C. During the cycling, fluorescence is measured at the end of each
annealing step. After completion of the cycling, a ramp is carried out with
the temperature steadily rising in 1°C from 65°C to 95°C with a 10 second
hold and a measurement of fluorescence on each step.
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Figure 2.7: Q-PCR program conditions.
The programme starts with a denaturation at 95°C for 20 minutes followed by 40
cycles of 95°C for 3 seconds and a gene-specific annealing temperature of 60°C for 30
seconds. During the cycling, fluorescence is measured at the end of each annealing
step, and, after the cycling is completed, a melt curve stage is carried out to test
product specificity. During this step, the temperature steadily rises in 1°C increases
from 65°C to 95°C with a 15 second hold and a measurement of fluorescence on each
step is performed. Range of optimal temperatures for genes analysed were used
according to specific primers binding.
Q-PCR analysis was performed by using the Quansoft® (Techne) or the
StepOne v2.2 (Applied Biosystems) software packages respectively and
gene expression of each target gene was calculated as described above
(section 2.6.7).
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2.6.8. Housekeeping genes
The reliability of any relative RT-PCR experiment is improved by including an
invariant endogenous control (reference gene) in the assay to correct for
sample-to-sample variations as well as errors in sample quantification which
can result in misinterpretation of the derived target genes expression profile
[433]. Therefore the abundance of each gene of interest was normalised
relative to endogenous reference genes, known as housekeeping genes, which
by definition have a relatively higher expression than other genes of interest
maintaining a constant level of expression across samples, physiological
states, and treatments [434].
However, reference genes are not stably expressed in all scenarios as
numerous studies have been shown as certain experimental conditions can
influence their expression leading to incorrect findings if inappropriate
housekeeping gene is used [435]. This discovery pointed out the critical
importance of validating them within the specific tissue and biological
conditions.
To address this issue, seven candidate housekeeping genes (18S, ACTB, B2M,
GAPDH, YWHAZ, SF3A1, UCB), previously validated as reference genes within
the placenta [436], were investigated using RT-PCR for their expression
stability in placentas from pregnancies complicated by overweight (n=10),
obesity (n=10), gestational diabetes (n=10) and control pregnancies (n=10).
While the primers set for 18S was designed as previously described (section
2.6.5), endogenous control genes provided and already optimised by Primer
Design (geNormTM reference gene selection kit) were used as additional genes
of reference (Table 2.5).
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Table 2.5: Human GeNorm housekeeping genes (Primer Design geNormTM
reference gene Selection).
NCBI sequence Target Gene GeNorm Reference Gene
NM_001135702.1 YWHAZ Homo sapiens phospholipase A2
NM_031144.3 ACTB2 Homo sapiens actin, beta
NM_004048 B2M Homo sapiens beta-2-microglobulin
AF261085.1 GAPDH Homo sapiens glyceraldehyde-3-phosphate dehydrogenase
NM_005877.4 SF3A1 Homo sapiens splicing factor 3a, subunit 1
NM_021009.5 UBC Homo sapiens ubiquitin C
These genes were used to identify the most stable reference/s gene/s in a random
selection of human placental samples.
The most stable reference genes were determined from an experimental
database (Cotton Est Database) using a web-based comprehensive tool
(RefFinder), available at http://www.leonxie.com/referencegene.php, which
integrates the data from four of the currently major statistical approaches
JH1RUP1RUPILQGHU%HVW.HHSHUDQGWKHFRPSDUDWLYHƩ&WPHWKRG>@
2.6.8.1. Housekeeping genes analysis procedure
After re-suspending the lyophilised primer mix in 200 µl of RNA-free water, a
reaction mix using the PrimerDesign 2xqPCR Mastermix also provided by the
kit, was made up for each reference gene according to the protocol below.
3 µl of cDNA from each sample was pipetted onto a 96-well plate before
adding 17 µl of the reaction mix to reach a final volume 20 µl.
Volume (µl) Reagent
3 cDNA (1:10)
1 Resuspended primer mix *
10 PrimerDesign 2X PrecisionTM Mastermix
6 RNA-free water
*using RNA-free water
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All 40 placental samples were run in duplicate for each reference on the same
plate. In this analysis, no standard curve was used to compare samples as all
the genes have been already optimised either by the company or in the
course of this work. The most stable housekeeping genes (ACTB, 18S,
GADPH, B2M) were validated with RefFinder (Figure 2.8 A-B).
Figure 2.8: Evaluation and screening of seven reference genes expression
from Cotton Est Database using RefFinder software, a user-friendly web-
based comprehensive tool which is fully available online from
http://www.leonxie.com/referencegene.php
A) Ranking order of the tested reference genes according to each computational
program. The first and second entries provided by Genorm are equally good and
correspond to 18S and B2M. B) Graph of the comprehensive gene stability for each of
the tested reference genes, the most stable of which resulted to be ACTB and 18S.
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This database integrates data from the geometric mean calculated for each
individual gene using the algoritms from four of the major computational
programs; a lower geometrical mean value reflects higher stability.
Gene expression levels were first normalised relative to 18S whereas,
subsequently, the arithmetic mean of the best housekeeping genes above
reported was used. However, using different housekeeping genes did not
influence the outcome of gene expression analysis in this study, hence, gene
expression levels were finally reported only relative to 18S, which represents
a good reliable control gene [436].
2.7. Triglycerides extraction
Higher triglycerides have been associated with pregnancies complicated by
maternal high BMI and diabetes [438] so lipids were isolated and extracted
from human placental samples using a modified method previously validated
by Folch et al. in different animal tissues [439]. This procedure is based on
partitioning chloroform-methanol organic solvents with water or salt solutions
(8:4:3) to separate the lipid and no-lipid components by dissolution,
centrifugation and filtration. Tissue homogenisation with 2:1 chloroform-
methanol and gravity filtration result in lipids extraction and solubilisation in
the solvent phase whereas washing the filtrate with at least a fifth of either
distilled water or 0.9% saline solution allows elimination of non-lipid
substances. The pure lipid extract is then obtained from evaporation of the
samples under nitrogen steam to ensure the removal of the solvent mix and
the triglyceride concentration can be measured with a commercial assay after
re-suspending each sample in another solvent. In this study the Randox
triglycerides assay kit (Cat. No: TR212, Randox laboratories Ltd, Crumlin, UK)
was used to determine triglycerides concentration by spectrophotometric
absorbance after converting them into quinoneimine as described in Figure
2.9. Interpolation of measured values from an internal control standard curve
allows calculating triglyceride concentrations for unknown samples.
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Figure 2.9: Principle enzymatic chemical reactions involved in triglyceride
analysis reaction.
2.7.1. Triglycerides extraction procedure
A total of 149 placentas were removed from -80ºC, weighed (500mg) and
homogenised in 50ml dispomix tube with 2ml cold chloroform-methanol (2:1)
solvent previously prepared. Samples were gently centrifuged (200 g) at
room temperature for 1 minute to ensure complete exposure of all
homogenised tissue to the solvent before being agitated at for 20 minutes at
room temperature using an orbital shaker (Shaker incubator SI50, Stuart
Technology, Staffordshire ST15 0SA, UK). The mixture was then filtered under
gravity through a 150mm Whatman filter paper (Scientific Laboratory
Supplies, Nottinghamshire, UK), placed on a funnel, into a 15ml centrifuge
tube (Greiner bio-one, Cat.No:188261, Stonehouse, Gloucestershire, UK) to
recover the liquid phase. One ml solvent solution was used to wash the inside
wall of the dispomix tube whereas additional 8ml same homogenization
solution were applied to wash the filter paper ensuring all available lipids in
the homogenate were collected. After removing the funnel and filter paper,
2ml distilled water was added to the filtrated samples, which were vortexed
for 5 seconds and then centrifuged at low speed (800 g) for 10 minutes at
room temperature allowing the separation of the organic and aqueous phase
of the solution.
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The upper phase (aqueous phase) containing the non-lipid contaminants was
removed with a Pasteur pipette by siphoning and 2ml lower phase containing
the purified lipid was collected into 2ml eppendorf tube. Then it was vortexed
for 5 seconds and centrifuged at low speed (400 g) for 10 minutes at room
temperature. If impurities were still present, the top layer and any remaining
gel-like interphase were discarded and samples containing the solvent mix
were evaporated under nitrogen steam using a Driblock DB-3 (Techne) for 15-
20 minutes. After complete evaporation of the aqueous phase samples were
UHGLVVROYHGLQǋOWHUWEXWDQRO%'+DQGǋOWULWRQ;DQGVWRUHGDW
4ºC in a spark-free fridge until further analysis. Standards were prepared by
diluting the provided triglyceride standard (CAL) in a 60:40 ratio of tert-
EXWDQROWULWRQ;EHIRUHSLSHWWLQJǋOHDFKVDPSOHFRQWURODQGVWDQGDUG
was into the a 96 well microplate (Grenier Bio-one, Gloucestershire, UK). The
HQ]\PH UHDJHQW VXSSOLHG E\ WKH NLW ZDV WKHQ DGGHG  ǋO DYRLGLQJ
formation of bubbles and the plate was incubated at 37°C for 5 minutes for
FRORUGHYHORSPHQW$EVRUEDQFHZDVPHDVXUHGXVLQJDǋ4XDQWSODWHUHDGHUDW
500 nm and triglyceride content expressed as a ratio of milligrams (mg) of
triglyceride per gram (g) of placental tissue (mg/g). All samples analyzed
were performed in triplicate with a 10% intra-assay coefficient of variance
(calculated as standard deviation/mean X 100). Analyses were repeated for
samples outside this CV% value.
A serial dilution calibration curve was prepared fresh each time whilst the
internal standards were used to minimize inter-plate variability and optimize
accuracy.
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2.8. Thiobarbituric acid reactive substances
analysis
The oxidative degradation of lipids, known as lipid peroxidation, has been
implicated in the pathogenesis of several diseases and clinical conditions
including chronic inflammation, diabetes and premature birth disorders [440].
Progression of lipid peroxidation generates a large number of unstable
biproducts which are highly detrimental to the structure of biological
membranes thus to cell functioning and survival [441]. Some of these
reactive compounds of major toxicological interest include malondialdehyde
(MDA) and 4-hydroxynonemal (4-HNE) and measuring their levels in vitro is
one of the most widely accepted assays for oxidative damage [442]. The
thiobarbituric acid reactive substances (TBARS) method is based on the
reaction between MDA and thiobarbituric acid (TBA) at 95°C under acidic
conditions with the formation of an adduct (MDA-TBA) which can be measured
spectrophotometrically or fluorometrically (Figure 2.10).
Figure 2.10: Malondialdehyde-thiobarbituric acid (MDA-TBA) adduct
formation.
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The Oxiselect TBARS Assay kit (Cell Biolabs Inc, CA, USA) determines lipid
peroxidation through the formation of MDA-TBA adducts, a reaction that
produces a pink chromagen which can be measured colorimetrically at
532nm. In recent years, however, the development of a large number of
assays for lipid peroxidation measurement have questioned the specificity of
TBARS reaction as TBA and MDA can both react with additional compounds
such as aldehydes, DNA and amino acids to form similar colorimetric products
[443-445]. Hence, it is suggested the reaction measures TBARS rather than
MDA concentration. Despite this, the assay is still being used in many
laboratories for its rapid and easy protocol and remains one of the most
extensively employed format for screening and monitoring secondary
products of lipid peroxidation in biological samples [443, 444].
2.8.1. TBARS procedure
Placental tissues of 139 samples, reagents and all experimental tubes were
prepared the day before to ensure running the experiment in the most
efficient way. Each sample was weighed (approximately 100mg), resuspended
and homogenised in 1ml 1X butylated hydrotoluene kit reagent (BHT)
dissolved in phosphate buffered saline (PBS). Adding the anti-oxidant BHT to
the sample prevents further oxidation of lipid during sample processing and
must be performed quickly. Samples were initially centrifuged for 1 minute at
2000 g at room temperature in a 50 ml dispomix tube and the supernatant
was transferred to 1.5ml labelled eppendorf tubes. Centrifugation was
repeated at 10000g for 5 minutes at 4°C before transferring the supernatant
to clean 1.5ml tubes to ensure removal of any remaining cell debris. Samples
were then stored at -20°C until performing the TBARS assay or total protein
concentration analysis. Oxiselect TBARS assay kit was used for TBARS
analysis as per the manufacturers instructions; analysis of both standards
and samples were performed in duplicate.
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7HQ 0'$ VWDQGDUGV ǋO ZHUH SUHSDUHG UDQJLQJ IURP PJGOPJGO
XVLQJ WKH 0'$ UHDJHQW SURYLGHG DQG GLVWLOOHG ZDWHU ǋO RI VWDQGDUG
negative control or unknown sample was added to a fresh 1.5ml eppendorf
WXEH 6XEVHTXHQWO\ ǋO RI VRGLXP GRGHF\O VXOSKDWH 6'6 O\VLV VROXWLRQ
was added to each tube and incubated at room temperature for 5 minutes.
ǋO RI 7%$ UHDJHQW ZKLFK PXVW EH SUHSDUHG IUHVK HYHU\ WLPH ZDV QH[W
added and tubes were incubated in a water bath at 95°C for 60 minutes. After
this, samples were removed and cooled on ice for a further 5 minutes.
&HQWULIXJDWLRQRIVDPSOHVZDVSHUIRUPHGDWJIRUPLQXWHVZLWKǋO
RIVXSHUQDWDQWWUDQVIHUUHGWRDIUHVKHSSHQGRUIWXEH1H[WǋORIQEXWDQRO
was added to the samples to prevent interference of haemoglobin and its
derivatives. Samples were vortexed for 1-2 minutes and centrifuged for 5
minutes at 10000g at room temperature to allow for phase separation. The n-
butanol layer, which is the top layer of the solution, was then decanted into
DQRWKHU HSSHQGRUI WXEH IRU VSHFWURSKRWRPHWULF DQDO\VLV DQG ǋO RI HDFK
sample and standard was pipetted into a 96 well microplate to measure
absorbance at 532nm using the Nanodrop (Nanodrop® Technologies,
Wilminton, USA). Unknown sample concentrations of MDA/TBARS were
determined against the MDA standard curve and normalised against total
protein content using the bicinchoninic acid (BCA) method (sub-section
2.8.2). The protein content of the samples is an indicator of how efficiently
the cellular contents were extracted; therefore, normalisation of the data
against protein content was performed to compensate for differences in the
extraction efficiency. Analysis of each standard and sample in both TBARS and
BCA assays was performed in duplicate to ensure the most reliable reading
DQGUHVXOWVZHUHH[SUHVVHGDVSPROǋJ
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2.8.2. Bicinchoninic acid total protein determination
Total protein concentrations were determined using the BCA assay method,
which relies on a colourimetric reaction between proteins, BCA and copper
sulphate [446]. Peptide bonds in proteins reduce Cu2+ to Cu1+ ions when
incubated at room temperature, which are then chelated by BCA reagent to
form a purple coloured compound [446]. The colour development from green
to purple is in proportion to the amount of protein present in the sample, the
absorbance of which can be measured at 562nm with the Nanodrop
(Nanodrop® Technologies, Wilminton, USA). Unknown sample concentrations
can then be referenced against a standard curve.
2.8.2.1. BCA assay
Reagent A containing 1% bicinchoninic acid, 2% sodium carbonate, 0.16%
sodium tartrate and 0.4% sodium hydroxide was made up to 50 ml with
distilled water and 10% sodium bicarbonate was used to reach a pH of 11.25.
Reagent B (50 ml) was made up with 4% copper sulphate solution dissolved
in 50 ml distilled water. The two reagents (A+B) were mixed well in a ratio of
100ml:2ml to form a third reagent (Reagent C) which was stored at 4°C until
needed (no more than a month).
Eight standard concentrations of 1 mg/ml bovine serum albumin (BSA)
ranging from 1.0-0.00 mg/ml were made up in 0.9% saline solution and 2.5
ǋO RI HDFK XQNQRZQ SURWHLQ VDPSOH ZHUH GLOXWHG E\  LQ  VDOLQH WR
PDNHDILQDOYROXPHǋO1H[WǋOHDFKVWDQGDUGQHJDWLYHFRQWURO51$
free water) or unknown sample was pipetted into a 96-well microplate and
ǋO UHDJHQW&ZDVDGGHGWRHDFKZHOO$IWHUPLQXWHVRI LQFXEDWLRQDW
37°C in an orbital shaker to allow color development, absorbance was
measured spectrophotometrically at 562 nm. A 10% coefficient of variance
(calculated as standard deviation/mean X 100) was accepted between
duplicate samples and analyses for samples outside this CV% value were
repeated.
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Samples were run with their own calibrators for the standard curve on
multiple assay plates. The interassay coefficient of variation, calculated from
the mean values for the standards on each plate, was used as an expression
of plateǦtoǦplate consistency. A 20x multiplication factor was then applied to
all recorded absorbance results to account for the initial 1:20 dilution factor.
2.9. Histological analysis
Microscopic analysis was performed by using histological techniques to study
the cellular differences that might contribute to different size and structure of
the placenta. Tissues were fixed in neutral-buffered formalin (10%), which
introduces cross-links that preserve peptides of the cellular structures from
protein degradation [447]. Following tissue fixation, each sample was encased
and embedded in a holding matrix (paraffin wax) to maintain its structural
DQGFHOOXODUFRPSRVLWLRQEHIRUHVHFWLRQLQJILYHǋPXVLQJDVOHGJHPLFURWRPH
[448]. As paraffin wax is immiscible in water, a dehydration step followed by
immersion in ethanol and xylene was performed on any tissue before
embedding in the wax. To allow visualization and/or differential identification
of microscopic structures, histological stains were applied in each sample
section followed by examination under a light microscope.
2.9.1. Histological tissue processing
A subset of 40 frozen placental samples was selected for histological
sectioning from each group (10 C, 10 OV, 10 OB, 10 GDL, 10 GDOV and 10
GDOB) after selecting them by maternal age, BMI, parity, smoking during
pregnancy and newborn gender. Half a gram of placental tissues was weighed
and treated with 10% formalin (10% v/v formaldehyde in 0.9% w/v sodium
chloride/distilled water (Fisher Scientific) saline solution) overnight. Each
sample segment was loaded into a Histosette II (Simport, Quebec, Canada)
30 mm x 27 mm x 5 mm cassette and processed through six stages of
ethanol dehydration.
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This was followed by three stages of xylene (Fisher Scientific) for ethanol-
clearing. After three stages of paraffin wax using the Shandon Excelsior
tissue wax processor (Thermo Scientific) at 60°C, samples were then allowed
to solidify overnight. This step ensured to fix in paraffin each sample segment
which was then sectioned using a sledge microtome (Anglia Scientific,
&DPEULGJH8.OHDGLQJWRVOLGHVDWǋPVDPSOH
After rinsing each slide in 70% ethanol and floated in 45°C water to stretch
them out by surface tension, sections were transferred to Superfrost Plus
slides (Menzel-Gläser Inc, Braunchweig, Germany), dried on a heat rack for
15 minutes and stored in a drying oven at 37°C for 24 hours.
2.9.2. Haematoxylin and eosin staining
The application of Haematoxylin and Eosin staining (H&E), a basic aluminium
salt dye was used to visualize the main microscopic cellular structures.
Haematoxylin is oxidised to haematein by the chemical agent mercuric oxide,
which forms a strongly colored complex with the addition of an aluminium salt
mordant by binding acidic structures, i.e. nucleic acids. It is generally used as
a regressive dye and its intensity is reduced and blued off by washing with a
weak alkali [449]. The nuclear staining is thus followed by counterstaining
with an aqueous solution of eosin, which colors other eosinophilic structures
surrounding the nuclei (cytosol, muscle fibres, collagen and erythrocytes) in
various shades of red, pink and orange. Differentiation of the eosinophilic
formations occurs through washing with water.
2.9.2.1. H&E staining procedure
One slide from each sample was blinded by assignation of a random identifier
and placed in a slide rack. The slides were then dewaxed by immersion in two
consecutive xylene washes for 3 minutes which was followed by rehydratation
through two steps of 100% ethanol immersion and one stage of 70%
ethanol/distilled water immersion, before a final wash with distilled water.
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The sections were nuclear-stained in a trough of Harris haematoxylin (VWR
Ltd, Lutterworth, UK) for 5 minutes and then rinsed in tap water for 5 minutes
to remove all excess dye. The haematoxylin stain was reverted by immersion
in an acid-alcohol solution (1% conc. hydrochloric acid in 70% ethanol) for 5
seconds, rinsed in tap water and blue stain was hed off in alkaline Scotts tap
water (a 0.2% sodium bicarbonate and 20% magnesium sulphate distilled
water solution) for 1 minute. This solution performs rapide and precise
blueing of nuclear cromatin and nuclear membranes ensuring minimum loss of
tissues sections and cells from glass slides. Subsequently, the sections were
washed in tap water and transferred to a 1% Eosin Yellowish (VWR Ltd)
counter stain for 3 minutes. Tap water was used once more to wash the slides
of any excess of staining allowing the differentiation of eosinophilic structures.
Sections were then dehydrated in two stages of 100% ethanol immersion for
2 minutes and ethanol cleared in two 3 minute immersions of xylene. Sections
were mounted with coverslips (VWR) using DPX mounting medium (Fisher
Scientific), and left to dry overnight.
2.9.2.2. Placental H&E analysis
H&E-stained slides were visualised through a Leica DRM microscope (Leica
Microsystems, Wetzlar, Germany) at 4x and 10x magnification and
photographed for analysis using a Hamamatsu digital camera (Hamamatsu,
Hertfordshire, UK). A total of 45 out of 60 frozen placental samples showed
poor tissue integrity due to tissue deterioration during collection, and this did
not allow a powerful and complete analysis.
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2.10. Immunohistochemistry
Immunohistochemistry (IHC) refers to a technique that allows the detection of
specific antigens in a histological section by selective antibody binding and
also the determination of their morphological localization and distribution in
different parts of a biological tissue. The interaction antibody - target antigen
produces a signal which can be visualised in a direct or indirect method of
staining by using a conjugated signaling marker, commonly an enzyme (e.g.
peroxidase) or a fluorophore (e.g. fluorescein or rhodamine) [450]. The most
common enzyme conjugated to the secondary antibody used in the indirect
IHC method is the horseradish peroxidase (HRP) which through catalytic
conversion develops a brown precipitate in the presence of 3,3
diaminobenzidine (DAB), a chromogenic substance.
Prior to antibody exposure, all sections were dewaxed and rehydrated in order
to allow access of all reagents to the tissue although many antigen sites can
be masked after formalin fixation as a result of the cross-linking of proteins.
This can happen, for instance, if the secondary antibody is conjugated to
biotin molecules resulting in recruitment of avidin-biotin-enzyme complexes
which leads to nonspecific binding and high staining.
Therefore, to break these protein cross-links and unmask all hidden antigen
sites samples should be treated with a heat-induced epitope retrival (HIER)
step (usually heating with citrate buffer).
2.10.1. IHC procedure
Immunohistochemical analysis was performed in order to elucidate and
quantify the amount of fibronectin deposits and also markers of macrophages
accumulation often observed in complicated pregnancies [451].
Recommended primary antibody dilutions for each human antibody used in
this study (Table 2.6) were tested for optimisation using both an automated
system and hand staining.
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Table 2.6: Antibodies used for detection of tissue macrophages (CD68, CD14)
and fibronectin.
Antibody Supplier Type
Primary antibody
dilution factor
Incubation time
and temperature
Anti-CD68 Abcam
Mouse
monoclonal
1/200
1/400
1/800
30-60 minutes at RT,
overnight
Anti-CD14
Millipore
Chemicon
Mouse
monoclonal
1/200
1/400
1/800
1/1600
30-60 minutes at RT,
overnight
Anti-
Fibronectin
Abcam
Mouse
monoclonal
1/100
1/200
1/400
30-60 minutes at RT,
overnight
RT: room temperature
In the automated method, one slide for each tested dilution and a negative
control were labelled, placed in a slide rank and loaded in into a Leica
BondMax IHC slide processor (Leica Microsystems) before being run on an
automated software program (Vision Biosystems Bond version 3.4A).
Primary antibody binding to tissue sections were visualized using BOND
Polymer Refine Detection (no-vision biosystem antibody, Leica), which
contains a peroxide block, post primary, polymer reagent, DAB chromogen
and hematoxylin counterstain. Slides were washed twice in xylene and
ethanol for one minute each and finally incubated at 95°C with epitope
retrieval solution before being treated with peroxide block for 5 minutes at
room temperature. Following exposure of all tissue, sections (except the
QHJDWLYHFRQWUROWRǋOGLIIHUHQWSULPDU\GLOXWLRQVIRUPLQXWHVǋO
HRP conjugated secondary anti-mouse and rabbit antibody polymer were
applied to all samples for 8 minutes. Subsequent exposure to 3,3 DAB (DAB
peroxidise substrate kit, Vector Labs, Cat.Num.SK-400) for 10 minutes results
in a brown precipitate development, after which all samples were stained with
H&E for 5 minutes for nuclear visualisation (Kiermnan, 2000). Bondwash
buffer and distilled water were applied to the slides for washing after each
Bondmax stage.
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Tissue sections were mounted with coverslips using DPX mounting medium
and dried overnight before being visualised at 5x, 10x and 20x magnification
and photographed for analysis. After visualisation on the microscope the
villous structure of both frozen and RNA later placenta were not well
delineated and clear probably due to tissue damage during sample collection.
Additionally, non-specific brown staining was still detected at higher antibody
dilutions therefore it was not possible to proceed to quantification of antigen-
antibody complex (Figure 2.11).
)LJXUH  5HSUHVHQWDWLYH &' LPPXQRKLVWRFKHPLVWU\ ǋP VWDLQHG
microscopic sections at 4x magnification in frozen placental sample from
obese subject.
A) Negative control; B) 1:400 primary antibody dilution with diffuse brown staining; C)
1:1600 primary antibody dilution still indicating non-specific staining of the antibody.
Villous membrane is not well defined (blue arrow) reflecting a partial degradation of
those samples which were not suitable for histological analysis. Brown staining
represents positively staining of the primary antibody.
A second attempt aiming to eliminate this non-specific staining and eventually
detect the correct antigen-antibody binding was undertaken by using the hand
staining procedure. After deparaffinization and hydratation of all tissues, an
antigen retrival step (Dako EnvisionTM+ system) was performed by
microwaving samples for 15 minutes in a citrate buffer solution, pH 6.0 [452].
After immersion in a solution of 0.5% H2O2 in water/methanol for 30 minutes
to quench endogenous peroxidase activity, samples were washed in Tris-
buffer saline (TBS) (containing 20 mM Tris base, 500 mM sodium chloride) for
5 minutes.
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Each section was then marked using a PAP pen for immunostaining (Sigma-
Aldrich) to prevent the waste of reagents by keeping liquid pooled in a small
droplet. Sections were incubated in diluted normal blocking serum using the
Vectastain® Universal Elite® ABC kit (Vector Laboratories, Cat. Num. PK-600)
for 20 minutes. The excess liquid was blotted from slides, which were then
rinsed with TBS 1:10. Incubation with different primary antibody dilutions was
carried out overnight at 4ºC, following which excess of liquid was blotted and
sections rinsed 3 times in TBS for 5 minutes. Slides were then incubated at
room temperature for 30 minutes with diluted biotinylated secondary antibody
diluted in blocking buffer according to manufacturer's instructions
(Vectastain® Universal Elite® ABC kit). An additional wash in TBS for 5
minutes was followed by 30 minutes application of a preformed Avidin and
Biotinylated horseradish peroxidase macromolecular Complex (Vectastain®
Universal Elite® ABC kit) for peroxidase substrate development. Samples
slides were washed 5 minutes in TBS before being exposed to 3,3 DAB for 10
minutes until brown precipitate development. Sections were then
counterstained with H&E for 5 minutes for nuclear visualisation, mounted with
coverslips using DPX mounting medium and dried overnight at room
temperature before being visualised at 5x, 10x and 20x magnification.
Once more, non-specific brown staining for each antibody was still diffused all
over the sections, despite several attempts with higher antibody dilutions than
recommended by manufacturer were performed.
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2.11. Western blot analysis
Western blot also known as protein immunoblot is one of the most widely
used analytical techniques to detect specific proteins in a tissue [453].
Depending on the source, the protein has to be brought into solution by
breaking the tissue (e.g. homogenization and lysis) and can be separated
from other cell components (membranes, DNA, etc.) by centrifugation.
Tissue preparation is undertaken at cold temperature to avoid protein
denaturation and degradation as well as protease and phosphatase inhibitors
added to the lysate to prevent digestion of the sample by its own enzymes.
After extraction, the proteins need to be denatured by heating with an ionic
detergent in order to be separated by molecular weight through gel
electrophoresis. Reducing agents like 2-mercaptoethanol are added to
remove the proteins secondary and tertiary structure by cleaving proteins
disulfide bonds whereas the addition of SDS maintains the polypeptide in a
denatured state and covers it with a negative charge.
Sampled proteins can then migrate to the positively charged electrode
through the 2-D polyacrylamide gel according to their isoelectric point (pH at
which they have neutral net charge) and molecular weight (the smaller the
faster). The use of a greater acrylamide concentration in the gel is
recommended for resolution of lower molecular weight proteins whereas
decreasing acrylamide concentration ensures resolution of higher molecular
weight proteins.
A protein marker ladder (Biorad Precision Plus Protein Standards, Biorad,
California, USA) with defined protein molecular weights is run in each gel
alongside the samples to enable the estimation of the protein size and
monitor the progress of the electrophoresis run. A negative control, i.e. non-
immune rabbit serum, known not to express the target protein, is used to
check for non-specific binding and false positive results.
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A positive control, i.e. a lysate from a cell line (HeLa, COX) known to express
the target protein, is also used to demonstrate the efficiency and reliability of
the protocol showing that the antibody recognises the target protein, which
may not be present in the experimental samples. A positive result from the
positive control, even if the samples are negative, will indicate that the
procedure is optimized and working. An additional way to test the validity of
the protocol and the results is loading an internal control, such as beta-actin
[454], which is normally expressed in cells at very high concentrations.
In order to make the protein accessible to antibody detection they are
transferred from the gel matrix to an electrostatic membrane using an
electroblotting method [455]. This uses an electric current to pull proteins
from the gel into the membrane ensuring the maintenance of the same
organization they had within the gel. In wet transfer, the gel and membrane
are carefully sandwiched between sponge and paper and all are clamped
tightly together. The sandwich is then submerged in transfer buffer to which a
small electrical field is applied, drawing the negatively-charged proteins from
the gel onto the membrane, by a combination of capillary action and
electrostatic attraction. After blotting, the membrane is stained using a
reversible protein dye (Ponceau red) to ensure completion of protein transfer
and each molecular weight is marked with a HRP-conjugated secondary
antibody pen in order to be visualised following immunodetection.
Before proceeding to incubation with a primary antibody specific to the target
protein the membrane is first incubated in a blocking reagent (usually non-fat
milk or BSA) to block any non-specific binding sites of the primary and/or
secondary antibodies to the membrane. Optimised dilutions of primary and
secondary antibody, and an adequate incubation time will then ensure the
formation of the target antigen-antibody protein complex. Detection of the
HRP-conjugated secondary antibody occurs by incubation in a
chemiluminescent reagent (luminol and peroxide solution), which emits a
signal in proportion to the abundance of target antigen present.
110
Exposing the blot to a suitable X-ray film for an appropriate duration will
detect the chemiluminescent signal which can be quantify through analysis of
protein band density using densitometry software.
Primary antibodies for folate transporters used in this study are shown in
Table 2.7.
7DEOH  $QWLERGLHV XVHG IRU GHWHFWLRQ RI IRODWH UHFHSWRU DOSKD )5Į DQG
reduced folate carrier (RFC).
Ab: antibody; RT: room temperature.
2.11.1. Protein extraction procedure
The extraction of protein from frozen placental tissue was performed using
CelLytic MT reagent from Sigma-Aldrich which consists of a dialyzable mild
detergent, bicine, and 150 mM NaCl, resulting in minimal interference with
protein interactions and biological activity. A volume of 20 ml of lysis buffer is
sufficient for 1 g of tissue. To increase the yield of proteins in the extracts a
protease inhibitor cocktail (Sigma-Aldrich) containing a number of inhibitors
with a broad specificity for serine, cysteine, acid proteases, and
aminopeptidases was also added to the lysate (0.05 ml per 1g tissue / 20 ml
CelLytic MT).
Protein extraction from frozen samples stored in RNA later solution was
performed using radio-immunoprecipitation assay (RIPA) buffer.
Target Type Supplier
Catalogue
number
Protein
size
Primary Ab
dilution
Incubation
time and
temperature
)5Į Rabbit
polyclonal
Aviva
System
Biology
OAAB00710 38 kDa
1/250 1/500
1/1000
3-4h at RT
)5Į Rabbit
polyclonal
Santa
Cruz
Biotec
sc-28997
36-39
kDa
1/200 1/400
1/800
3-4h or
overnight at RT
)5Į Rabbit
monoclonal
Insight
Biotec
5420-1
37-42
kDa
1/1000
1/5000
1/10000
3-4h or
overnight at RT
RFC
Rabbit
polyclonal
Alpha
Diagn Int
RFC11-A 28 kDa
1/150 1/200
1/400
3-4h or
overnight at RT
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This solution enables efficient cell lysis and protein solubilization while
avoiding protein degradation and interference with the proteins
immunoreactivity and biological activity and also results in low background in
immunoprecipitation and molecular pull-down assays.
2.11.1.1. Protein extraction from frozen tissue
Half a gram of frozen tissue was weighed in a dispomix tube and 10 ml of
CelLytic MT (C3228) lysis reagent (Sigma-Aldrich) and 0.0025 ml protease
inhibitor cocktail P8340 (Sigma-Aldrich) were added. After homogenisation at
800 g for 30 seconds the homogenised samples were transferred to Sorvall
tubes and centrifuge in a refrigerated superspeed centrifuge (Sorvall RC-5B,
Thermo Life Science) for 10 minutes at 4°C at 12000 - 14000 g to pellet all
tissue debris. Protein containing supernatant was then aliquoted in fresh 2 ml
eppendorf tubes and lysate stored at -20°C until further analysis. BCA assay
(see TBARS section 2.8.1.2, p.33) was used to measure protein concentration
of each placental sample.
2.11.1.2. Protein extraction from RNA later tissue
A total of 50 ml RIPA buffer was prepared using 1x TBS and stored at 4ºC.
7KH SURWHDVH LQKLELWRUV SKHQ\OPHWK\OVXOIRQ\O IOXRULGH 306)  ǋOPO
DSRSURWHLQ  ǋOPO DQG P0 VRGLXP RUWKRYDTQDGDWH  ǋOPO ZHUH
added to the lysis buffer at the time of the extraction. Three frozen RNA later
samples were weighed (0.1 g) in dispomix tubes and homogenised 3 times for
30 seconds with 1 ml RIPA buffer mix each until no clumps of tissue were
visible. Care was taken to not cause foaming during the process as it can
GDPDJH SURWHLQV $GGLWLRQDO  ǋO 306) ZDV DGGHG WR HDFK KRPRJHQDWH
which was then incubated on ice for 30 minutes without vortexing. After
centrifugation at 8000 g for 10 minutes at 4°C the supernatant was collected
and stored at -20°C until further analysis.
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As repeated freeze, thawing is not recommended for RIPA samples small
aliquots of each were prepared instead. Concentration of placental extracts
was performing using BCA protein assay.
2.11.2. Sample preparation procedure
After measurement at 562 nm, protein concentration was multiplied by the
dilution factor used in the BCA assay (1:20) and samples diluted to the
GHVLUHG FRQFHQWUDWLRQ  PJPO XVLQJ &HO/\WLF 07 GLOXHQWV  ǋO GLOXWHG
VDPSOHV ZDV WKHQ PL[HG ZLWK  ǋO SURWHLQ GLVVRFLDWLRQ EXIIHU FRQWDLQLQJ
50mM Tris, 10% glycerol, 2% SDS, 5% beta-mercaptoethanol and distilled
ZDWHU S+  EHIRUH VDPSOHV ZHUH PDGH XS WR  ǋO E\ DGGLQJ  ǋO
glycerol-bromophenol dye (containing 0.01 g bromophenol blue, 14.9 g
sodium hydroxide and 23.5 ml distilled water). Incubation for 5-10 minutes at
95-100°C in a water bath allows denaturation of samples proteins without
need to re-heat sample after the first time. As freezing can lead to samples
degradation, a stock solution of protein mix for each sample was prepared
and stored at -20°C until use or ready for electrophoresis (see below).
2.11.3. Protein detection procedure
The detection of the target protein abundance is based on the immunoblotting
technique which encompasses two main steps. First, the proteins are
denatured and separated according to their molecular weight by gel
electrophoresis before being transferred to a membrane (typically
nitrocellulose and PVDF) [453]. Next, the membrane is probed for the protein
of interest with a modified primary antibody which is linked to an enzyme
(either alkaline phosphatase or horseradish peroxidase) - conjugated
secondary antibody [456]. The generation of a chemiluminescence signal in
proportion to the amount of protein is then generated allowing for protein
quantification. To prove the reproducibility of the assay, each Western blot
was performed in duplicate.
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2.11.4. Gel electrophoresis procedure
After assembling the slab gel unit using the BioRad glass plates 8 cm x 7 cm,
spacers and clamp sets (BioRad Lab, Life Science Research, UK), a 12%
polyacrylamide-resolving gel containing 3.3 ml 30% polyacrylamide (Severn
Biotech, Worcestershire, UK), 4 ml distilled water, 2.5 ml 1.5 M Tris pH 6.8,
0.1 ml 10% SDS, 0.1 ml 10% ammonium persulphate (APS) and 0.004 ml
tetramethylethylenediamine (TEMED) (Acros Organics, New Jersey, USA) was
prepared. The gel was immediately cast in gel chamber by syringe injection
allowing 3 - 4 cm space from the top for stacking gel and loading comb.
Before gel polymerization, which usually takes an hour at room temperature,
water-saturated butanol was poured onto the gel to level the resolving gel
surface and prevent the gel from drying out.
After the butanol was poured off (corresponding to completion of gel
polymerization), the resolving gel was washed with distilled water and a 3%
stacking gel (containing 1.7 ml polyacrylamide, 6.8 ml distilled water, 1.25 ml
1.0M Tris pH 6.8, 0.1 ml 10% SDS, 0.1 ml 10% APS and 0.01 ml TEMED) was
then prepared and injected in the gel chamber on top of the former gel. A
loading comb was inserted in the stacking gel and allowed to polymerise for 1
hour at room temperature. After removal of the loading comb, distilled water
was used to wash each gel well before filling the gel chamber with 1x running
buffer (containing 5 mM tris, 50 mM glycine (Fisher Scientific), 2% SDS and
GLVWLOOHGZDWHUUHDG\IRUHOHFWURSKRUHVLV(DFKVDPSOHǋODORQJVLGHZLWK
DSURWHLQPDUNHUODGGHUǋODQHJDWLYHFRQWUROQRQLPPXQHUDEELWVHUXP
ǋODQGDSRVLWLYHFRQWURO+H/DFHOOVO\VDWHǋOZHUHUDQGRPO\ORDGHG
LQGXSOLFDWHRQWRWKHJHOHQVXULQJWRORDGDQ\HPSW\ZHOOVZLWKǋOJO\FHURO
bromophenol dye solution to allow even running during electrophoresis.
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The gel chamber was attached to the upper and lower electrophoresis
chambers, which were filled with 1x running buffer before electrophoresis was
run at 150200 V (20 mA) for 60 minutes or until the desired band reached
the bottom of the gel.
2.11.5. Immunoblotting procedure
Two sheets of 1 mm whatman filter paper and one piece of nitrocellulose
membrane (Hybond-C Super, GE Healthcare) were cut for each gel to
approximately the same size before soaking them in Towbin blotting buffer
(containing 25 mM Tris, 192 mM glycine, 20% v/v methanol, and distilled
water, p.H 8.3). Following electrophoresis, the gel apparatus was
disassembled and the gel carefully unloaded. The stacking gel was removed
and the resolving gel was placed directly on top of the nitrocellulose
membrane in order to form a sandwich between the two sheets of soacked
whatman paper as shown in Figure 2.12.
Figure 2.12: Sandwich of polyacrylamide gel and nitrocellulose membrane.
From cathode (-) to anode (+): sponge | sheet of filter paper (whatman) soaked in
transfer buffer | polyacrylamide gel | nitrocellulose membrane | sheet of filter paper
(whatman) soaked in transfer buffer | sponge.
After trimming the edges of excess of whatman paper and nitrocellulose
membrane, the top left corner of the gel was cut off in order to orientate it in
the following analysis.
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Since current applied and samples move from the negatively-charged cathode
to the positively-charged anode, the membrane was located between the gel
and the anode to ensure transfer of proteins from gel to membrane. Any
excess of liquid and air bubbles were carefully rolled out of the gel sandwich,
which was then placed into the transfer system (BioRad 8 cm x 7 cm) for 60
minutes at 80V. When possible, blotting was performed overnight at a lower
voltage (25 V) to ensure a more efficient protein transfer from gel to
membrane.
2.11.6. Immunodetection procedure
Following protein transfer, the blot was dismantled and the nitrocellulose
membrane was briefly washed in 50 ml Tris-tween buffer saline (TTBS)
containing 0.2% tween in TBS solution. Efficiency of protein transfer from
polyacrylamide gel to nitrocellulose membrane was assessed by washing the
gel in Coomassie Brilliant Blue dye for 1 hour. To visualise protein band
location 50 ml 1:10 Ponceau S red stain dilution (containing 0.2 g Ponceau S,
3 g trichloroacetic acid (Fisher Scientific), 3 g sulphosalicylic acid (Acros
Organics) and distilled water) was applied to the membrane for 10 minutes.
After the Ponceau S stain was poured off, excess of staining was washed with
distilled water until visualization of the protein bands.
The membrane was then placed on cling film, quickly dried with tissue and
wrapped to keep it wet before photographing. A rabbit primary
antigen/antibody pen (Alpha Diagnostic Int, San Antonio, TX, USA) was
applied to the membrane to highlight the marker bands allowing subsequent
visualization of the protein size under chemiluminescence. To prevent non-
specific binding and prevent any speckling the membrane was placed
overnight at 4°C in 50 ml blocking solution using 10% Marvel dried milk
powder and TTBS. The following day the membrane was further blocked for
30 minutes at room temperature with shaking before being rinsed twice in 50
ml TTBS and cut in different strips according to the number of dilutions
tested.
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)5Į SULPDU\ DQWLERG\ DQG D QRQLPPXQH UDEELW VHUXP QHJDWLYH FRQWURO
(1:1000) were diluted in 10 ml of 3% Marvel / TTBS before incubating each
sample membrane for 3 hours (or overnight) at room temperature (see Table
2.7 for details). The membranes were then washed 3 times with TTBS for 10
minutes and incubated with 1:2000 HRP conjugated secondary antibody
(rabbit to goat polyclonal IgG, Biorad) diluted in 10 ml 3% Marvel / TTBS.
After one hour of incubation at room temperature, 15 minute washes in 50 ml
TTBS were performed four times followed by two further washes (30 and 45
minutes) in TBS. Chemiluminescent visualisation of the target protein 
antibody complex was ensured by applying 1 ml chemiluminescent solution (3
ml of hydrogen peroxide and 3 ml of luminol) onto each membrane
(Immobilon Western Chemiluminescent HRP Substrate, Millipore,
Massachusetts, USA) which was incubated for 5 minutes before being drained
and wrapped in cling film. Protein bands were visualised using a CCD digital
camera after exposing the membrane for 1-5-10 minutes under visible light
(EPI) and chemiluminescence.
2.11.7. Western blot troubleshooting
7KUHHGLIIHUHQWDQWLERGLHVIRUIRODWHUHFHSWRUDOSKD)5ĮDQGRQHIRUUHGXFHG
folate carrier (RFC) were used (see table 2.7, page 110). However, none of
them detected bands specific for the target antigen showing non-specific
binding in the negative control (NRS) samples, whilst a specific band of 37
kDa was detected by the HeLa positive control. At this point, the integrity of
frozen samples was questioned and three samples stored in RNA later solution
were used for protein extraction using RIPA buffer (instead of cell lytic buffer)
in order to investigate whether those tissues were better preserved than the
frozen ones. After gel electrophoresis, proteins resolution was better in RNA
later samples than in frozen samples as shown in the Ponceau red stain
)LJXUH  7KLV OHDG WR WKH DVVXPSWLRQ WKDW WKH HSLWRSH RQ )5Į SURWHLQ
would have been specifically recognised by the antibody.
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Figure 2.13: Example of Ponceau red staining (1:10) of nitrocellulose
membrane.
Left side: protein separation of placental samples from three RNA later samples;
middle: protein separation of HeLa cells lysate; right side: protein separation of
placental samples from three frozen placental samples. A marker (blue bands) is
loaded alongside the samples for estimation of protein size.
7KLV WLPH VSHFLILF ELQGLQJ IRU )5Į LQ WKH WKUHH 51$ ODWHU VDPSOHV ZHUH
detected, however the molecular weight of the protein band was almost
doubled (68 - 73kDa) compared to the original one (38-42 kDa) and this was
once more highlighted by the HeLa positive control.
2.11.8. Protein interactions and urea treatment
The detection of a specific band with a very high molecular weight compared
to the expected protein size can have different causes, such as glycosylation,
cross reactivity to a contaminant, and protein aggregation. Protein
glycosylation can be removed by treating samples with the peptide N-
Glycosidase F (PGNase), an amidase which specifically cleaves N-linked
oligosaccharides. Albumin (68 kDa) is a typical contaminant of the sample and
often can specifically bind the antibody hiding the other protein bands. This
can be eliminated by immunoprecipitation (RIP) or using a centrifugal filter
Centricon with a molecular weight cutoff of 40-50kDa in order to separate
soluble protein from the aggregated one.
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Finally, if protein aggregation occurred, the interaction can be broken by
adding a reducing agent, such as anti-ubiquitin or urea 4-8M, after sample
incubation. In this work, it is likely that the 6873 kDa protein recognised by
WKHDQWLERG\UHVXOWVIURPDQLQWHUDFWLRQRIWKHWDUJHWSURWHLQ)5ĮZLWKDQRWKHU
PROHFXOH SUHVHQW LQ WKH VDPSOH DQG WKLVZRXOG LPSHGH )5Į DELOLW\ WR IUHHO\
migrate through the polyacrylamide gel. Therefore, a further procedure using
urea 4M to separate the aggregate was carried on. Following brief heating of
RNA later placental extracts at 95°C, urea 4M was added to each sample
which was then incubated at RT for 30 minutes. To remove remaining
aggregates centrifugation of the samples was also performed. The resulting
protein bands resolution was improved after treatment with urea 4M.
However, after immunodetection, the target protein was not recognised by
the antibody which once more gave similar non-specific bindings.
2.12. Methylation analysis
Recent experimental advances to detect DNA methylation at genome-scale
levels have brought DNA methylation to the vanguard of epigenetics
contributing to the development of a large range of experimental techniques
[457]. Each of these allows the analysis of DNA methylation at different
levels, spanning from genome-wide methylation content to methylation of
single residues in specific genes. Global methylation analysis is performed by
methods (i.e. chromatography) which can measure the overall level of methyl
cytosines in the genome [458]. On the other hand, techniques for gene-
specific methylation analysis require the development of computational
approaches since they involve the interpretation and comparison of large-
scale methylation profiles [459]. While analysis of global DNA methylation
content can be determined directly on crude DNA preparations, initial
amplification of the target sequence is required when performing the gene-
specific analysis.
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Because DNA polymerases cannot discriminate between methylated and
unmethylated sites, it is necessary to pretreat the DNA with enzymes or
chemicals according to the technique applied (i.e. enzyme digestion, affinity
enrichment, sodium bisulfite). The most widely used chemical reagent is
sodium bisulfite which introduces differences between methylated and
unmethylated sites allowing single-base discrimination. Treating the target
DNA with sodium bisulfite deaminates unmethylated cytosine to uracil while a
lower reactivity with bisulfite protects methylated cytosine from this
conversion [460, 461]. DNA pretreatment can then be combined with different
detection techniques like high density arrays to detect methylation. Among
these, Illumina Infinium Human-Methylation BeadChips [462], have become a
popular and reliable high-throughput method to quantitatively measure
methylation levels at specific single-base resolution in the human genome
[463].
2.12.1. DNA isolation
DNA extraction is a critical first step in the experimental workflow of DNA
sequencing and fragment analysis. The overall quality, accuracy and length of
the DNA sequence read can be significantly affected by characteristics of the
sample itself, and the method chosen for nucleic acid extraction. Efficient
genomic DNA isolation was achieved by thorough disruption and digestion of
placental tissues which were then purified using QIAamp DNA Mini Kit (50)
(QIAGEN). To guarantee homogeneity of the population, a set of 24 placental
samples were selected from 5 of the groups (C, n=5; OV, n=4; OB, n=5;
GDL, n=5; GDOB, n=5) by maternal age (between 25 and 35 years ), BMI
(no borderline BMIs), smoking during pregnancy (only no smokers),
nulliparity (only first pregnancy) and newborn weight (only AGA).
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2.12.1.1. DNA isolation procedure
Each placental sample was chopped from the previously excised samples (see
Section 2.4.2, Figure 2.4), and carefully weighed (25 mg) before being cut
into small pieces and placed into sterile DispoMix tubes in which 80 ml PBS
was added. Samples were then homogenized making sure that any residual
deposit was not left in the tube nor any foam produced during the process.
Following mechanical disruption 100 µl buffer ATL was added to the
homogenate to allow lysis. This buffer cannot be used during the
homogenization step as it contains a detergent (for breaking cell membrane).
The further addition of 20 µl proteinase K digested the proteins associated
with DNA and guaranteed complete digestion of the tissue by vortexing.
During incubation at 56oC, to complete the lysis, repeated vortexing was
ensured to disperse the sample and after 1-3 hour, the microtube was briefly
centrifuged to remove drops from inside the lid. Next, 200 µl buffer AL was
directly included into the mixture which was vortexed for 15 seconds and
incubated at 70oC for 10 minutes.
Briefly, centrifugation of the microtube to remove any drops from inside the
lid was followed by mixing the sample with 200 µl 100% ethanol allowing
formation of a white precipitate after vortexing for 15 minutes and pulse-
centrifuging. Sample, buffer and alcohol were mixed thoroughly to achieve a
homogeneous solution which was carefully applied to a QIAamp Mini spin
column placed in a 2 ml microtube. After centrifugation at 5000 g for 1
minute, which was repeated if the solution had not completely passed through
the membrane, the spin column was placed in a clean 2 ml collection tube
while the filtrate was discarded. Two buffer washes were performed, firstly
AW1 (500 µl) followed by centrifugation at 5000 g for 1 minute and filtrate
discarding, then AW2 (500 µl) with centrifugation at full speed (12500 g) for 3
minutes. To eliminate the chance of possible buffer AW2 carryover a further
step using new 2 ml collection tube was carried out with centrifugation at full
speed for 1 minute and discarding of the filtrate.
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The QIAamp spin column was immediately placed in a clean 1.5 ml
microcentrifuge tube before carefully adding 200 µl buffer EL; the sample was
then incubated at room temperature for 5 minute and centrifuge at 5000 g for
another minute. This step was repeated to increase DNA yield, which, for 25
PJRIWLVVXHXVXDOO\FRUUHVSRQGVWRDSSUR[LPDWHO\ǋJRI'1$LQǋO
EL buffer. The use of this buffer other than water guaranteed long-term
storage of DNA since DNA stored in water is subject to acid hydrolysis. DNA
concentration was then measured at the NanoDrop resulting in a range
EHWZHHQ±QJǋOZLWKDQ$$UDWLRRI±DQGVWRUHGDWoC.
2.12.1.2. DNA methylation detection
Purified DNA extracts were sent to Gen-Probe (Manchester, UK) for
quantification of DNA methylation while the data analysis was performed in
Nottingham using the Numerical identification of Methylation Biomarker Lists
(NIMBL) software developed by Emes and Wessely [402].
DNA methylation levels were detected by using the Infinium array from
Ilumina (Infinium Human Methylation450 Bead Chip) which features more
than 485,000 methylation sites per sample at single-nucleotide resolution
[464, 465]. Methylation analysis of all 24 samples was conducted over two
arrays since each array can analyse 12 samples in parallel requiring only 500
ng of input (1 µg with automation). Unmethylated and methylated CpG sites
were differentiated by pre-treating DNA sample (1 ug) with sodium bisulfite,
which converts unmethylated cytosines to uracils allowing single-base
discrimination. Following, the bisulfite treated DNA is subjected to whole
genome amplification using random hexamer priming and a DNA polymerase
with higher proofreading activity compared to the Taq polymerase. The final
product is then enzymatically fragmented, purified from dNTPs, primers and
enzymes, and ready to apply to the Illuminas high density array [466].
122
2.12.1.3. Principle of the assay
The molecular principle of the Illumina Infinium assay is based on the
immobilization of a single stranded 50 bases DNA oligonucleotides to each
bead type and this is followed by specific hybridisation of the probe to the
downstream region of the interrogated CpG site. In order to enhance the
depth of coverage for methylation analysis, the Infinium HumanMethylation
BeadChip450 is provided with two different design types of probe (Infinium I
and II) for each CpG (Figure 2.14) [465].
The Infinium I model uses two different probes to differentiate between the
unmethylated and methylated bisulfite-converted DNA. Each of the bead types
are attached to a single stranded 50 DNA oligonucleotides that differ in
sequence only at the free end. One of the bead types corresponds to the
methylated cytosine locus whilst the other corresponds to the unmethylated
cytosine locus. The latter has been converted into uracil during bisulfite
treatment and later amplified as thymine during whole genome amplification.
Once the bisulfite converted amplified DNA products are denatured into single
strands and hybridized to the chip and allele specific annealing to either the
methylation specific probe or the non-methylation probe occurs [400].
Hybridization is followed by single base extension with hapten labelled
dideoxynucleotides, among which the ddCTP is labelled with biotin while
ddATP, ddUTP and ddGTP are labelled with 2,4-dinitrophenol (DNP) [467].
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Figure 2.14: Infinium I and II probe design.
Hybridisation and extension of the two different probes in the Infinium I array (A)
according to the unmethylated (U) or methylated (M) status of the target DNA (see
text for details). Hybridisation and extension of the degenerate probe in the Infinium II
array (B) in which the methylation status is unknown (grey color). An R within the
probe indicates either a G or an A complementary to the unknown CpG site. Assays
were designed using Infinium II chemistry whenever possible.
On the other hand, only one beadtype per locus, which is complementary to
both unmethylated and methylated target region, is required in the Infinium
II. This is the main beadtype adopted in these assays allowing the use of
degenerate oligonucleotides to design for every possible combination of
methylation status across up to three CpG sites falling within a probe
sequence (for a total of 23 possible combinations). For Infinium I assays, all
underlying CpG sites were assumed to have the same methylation status as
the query base.
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After hybridisation, the same single nucleotide labelled with a green
fluorophore is used for the extension of both Infinium I probes (2.14-A) at the
next position upstream of the interrogated C. On the other hand, single base
extension is used to differentiate the methylation state in Infinium II (2.14-B)
resulting in labelling an A with a red fluorophore for unmethylated CpG site,
whereas a G labelled with a green fluorophore is incorporated at the
methylated CpG site.
2.12.2. Quantification of DNA methylation levels
The raw data are analyzed by the software, and the ratios of the fluorescence
intensitiy between the two bead types are calculated allowing quantification of
the methylation levels of each CpG site. A ratio of 0 equals to non-
methylation of the locus whereas a value of 1 equals to total methylation; a
ratio value of 0.5 means that one copy is methylated and the other is not, in
the diploid human genome. Since the array contains multiple copies of each
EHDGDUHODWLYHPHWK\ODWLRQOHYHODOVRNQRZQDVEHWDYDOXHǃLVFDOFXODWHG
to express the average of the intensity (sum of methylated and unmethylated
probe intensities) measured for the same bead type (Equation 2.1). Each
beta-values can be intuitively interpreted as the proportion of methylation at
a given CpG site with values ranging from 0 (CpG site always found
unmethylated in sample DNA) to 1 (CpG site always found methylated in
sample DNA).
Įimax(U+,0)imax(M
,0)imax(M=iǃ
(TXDWLRQ0HWK\ODWLRQOHYHOH[SUHVVHGDVEHWDYDOXHǃ
Mi and Ui represent the averaged intensities measured for the methylated and
unmethylated status of CpG site i, respectively. To avoid negative values after
background adjustement, any negative value will be reset to 0. A constant offset (by
GHIDXOWĮ LVDGGHGWRUHJXODULVHǃZKHQERWKSUREHVLQWHQVLWLHVDUHORZĮKDV
only a minor effect for the majority of methylation levels because the sum of
intensities is generally large compared to this [468].
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2.12.3. Analysis of methylation data
A comprehensive annotation file (TAB-delimited), including gene and gene
region information, was retrieved by using the
HumanMethylation450_15017482_v.1.1 manifest from Illumina [469] and
genomic information on DNA sequence and coordinates of gene coding
regions were obtained from the UCSC Genome Browser database. Annotation
data were then analysed using the NIMBL package, which has been
implemented and tested in Matlab release version 7.11 (R2010b) 64-bit
[470]. This represents a straightforward approach to identify differential
methylation sites and corresponding genes between two groups of samples.
The data files includes beta values and corresponding p values (p>0.05),
which estimate the quality of the measurement as detected by a Kolmogorov-
Smirnov test. This p-value reflects the probability that the resulting CpG site
signals are significantly different from the signals of the negative controls on
the array, which gives an estimate of the background level. Hence, array sites
with one or more of the 24 samples having a p value of less than 0.05, and
sites with missing beta values measurements, were excluded from further
analysis. The differential methylation settings used for NIMBL are based on a
constant level of beta value inter-group distance (i.e. default setting d=0.2
corresponding to 20% minimum difference between groups). Therefore,
differentially methylated sites were identified as sites with the largest
difference in methylation levels between two groups with a minimum beta
value distance (d) between non-overlapping groups (Figure 2.15). In each
analysis, one sample was allowed to be an outlier and was masked (m=0),
whilst the rest were compared to identify those CpGs with the greatest
discrimination between groups.
The NIMBL input script for the complete methylation analysis of the test data
can be obtained from the example directory within the NIMBL package and
are publicly available.
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Figure 2.15: Detection of differential methylation by NIMBL.
Each site is tested for a minimum distance of beta values (d) between two groups
(corresponding samples are depicted as circles and squares). If no samples are
masked (m=0), only non-overlapping sites separated by at least a value of d are
identified (A). If samples are masked (marked as x), sites with previously overlapping
groups (B) or low discrimination (C) are additionally identified and flagged (B*, C*).
Various directories comparing one group to the other were generated within
NIMBL, each of them including different files representing differential
methylated CpG per gene and the top 50 differential methylated sites. Gene
centric plots of the sites of methylation changes relative to the gene were also
generated for those genes with the most differential methylation level and
their expression determined by QPCR.
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2.13. Statistical analysis
Statistical analysis of data was performed using IBM SPSS v20.0 statistical
software for Windows package (IBM Corp. Armonk, NY, USA).
Before proceeding to statistical analysis, the distribution of data collected was
tested for normality by performing a Kolmogorov-Smirnov normality test. A
YDOXH RI S LQGLFDWHG WKDW WKH GDWD ZDV QRUPDOO\ GLVWULEXWHG DQG
according to this, appropriate tests (parametric or nonparametric) were used
for further analysis [471].
If data were normally distributed, analysis of variance using one-way ANOVA
for parametric data was undertaken with a multiple comparison of contrasts
between groups (i.e. Bonferroni post-hoc test).
If data were not normally distributed, their logarithm transformation (base
10) was tested for normal distribution. In the case data were still not normally
distributed, comparable groups were assessed using Kruskal-Wallis one-way
analysis of variance for non-parametric data. To avoid a family-wise error
rate, which is the probability of making one or more Type I errors in a family
of comparison, a Dunns test using multiple Mann-Whitney tests was
computed for each desired comparison. The resulting p value was then
adjusted with the Bonferroni correction, which divides the expected p value
(0.05) by the number of paired comparisons to be made (i.e. if n=3,
p=0.016).
The effect of maternal obesity was compared between overweight (OV), obese
(OB) and lean control (C) groups. In addition, the influence of gestational
diabetes independently and combined with high BMI was assessed between
gestational diabetic lean (GDL), gestational diabetic overweight (GDOV),
gestational diabetic obese (GDOB) and lean control (C) groups. Association
between two continuous variables was assessed using the Pearson correlation,
whereas correlation between more than two variables was examined using
linear and multiple linear regression analysis.
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Categorical data were analysed using Pearsons chi-square test of
LQGHSHQGHQFH,IWKHWHVWZDVVWDWLVWLFDOO\VLJQLILFDQWSSRVWKRFWHVWV
using the standardised residual (converted to a z-score) computed for each
cell variable, were performed. The residual is the difference between the
observed and the expected frequency of the counts. As SPSS does not
produce the probability, the size of standardised residuals was compared to
the critical values that correspond to an alpha of 0.05 (±1.96). Statistical
difference between two cell variables was detected when standardised
UHVLGXDOVUHVXOWHGRU
For consistency and easier reading, continuous parametric data presented in
this study were expressed as mean average ± standard error of the mean
(SEM) whereas for non-parametric data percentages or ratios were used. All
statistical graphs produced using Microsoft Office Excel 2010 software
(Microsoft Corporation, Berkshire, UK). Further details of any statistical test
used are provided in the relevant results Chapters.
Sample size and retrospective power calculations were executed using Minitab
v16 statistical software (Minitab Ltd, Warwickshire, UK). This reduced the
probability of performing a type I or II error, i.e. by rejecting or accepting the
null hypothesis respectively, and enabled to calculate the tests power based
on the sample size and the additional number of samples needed to detect
the desired difference.
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Chapter 3 - Nutritional and
biochemical influence of
maternal BMI and diabetes on
maternal health and newborn
growth
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3.1. Introduction and hypotheses
The incidence of obesity and type-2 diabetes (T2DM) in women of
childbearing age is rising dramatically in western countries [472]. Both
conditions in pregnancy are associated with adverse metabolic adaptations in
the mother compromising fetal and newborn survival and well-being [473].
Obese pregnant women experience an increased risk of miscarriage,
preeclampsia, gestational diabetes mellitus (GDM) [24], Caesarean section
[474] and stillbirth as well as both intrauterine restriction (IUGR) and
macrosomia [475]. Similarly, women who develop diabetes in pregnancy are
at increased risk of perinatal morbidity and show higher incidence of obesity,
abnormal insulin secretory function [72, 80, 413] as well as large for
gestational age (LGA) newborns who have a higher risk of developing obesity,
insulin resistance and hypertension in childhood and early adulthood [70, 81,
413]. It is currently estimated that 50-60% of women are overweight or
obese at the start of their pregnancies [79, 476] and, overall, 10-25% of
pregnant women develop GDM [77, 78]. High pre-pregnancy BMI is also
associated with the development of GDM, as 65-75% of women with GDM are
overweight or obese [75, 79]. Therefore, the relative impact of pre-pregnancy
BMI and maternal hyperglycaemia during gestation on adverse maternal and
perinatal outcomes can be difficult to separate.
Overweight and obese women with gestational diabetes are recommended to
consume low glycaemic index diets to lower their risk of accelerated fetal
growth and LGA [49]. In addition to the adverse effects of hyperglycaemia
and obesity, an unbalanced nutrient supply increases the risk of gestational
diabetes [477] and a high fat (HF) and low-carbohydrate diet doubles the risk
of small for gestational age (SGA) birth [49]. Recently, the beneficial effect of
a Mediterranean diet in preventing preterm delivery ensuring adequate fetal
development has been proposed [478, 479].
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The participants of this study were of Spanish-Caucasian origin consuming a
Mediterranean-type diet, which is based on different nutritional components
than those routinely consumed in Northern Europe and America [478, 480]
and this raises the possibility of evaluating a populations diet and quality by
considering specific lifestyle and eating habits [407, 481].
In addition to obesity and GDM, excess gestational weight gain (GWG)
complicates a large number of pregnancies and it is highly correlated with
high maternal BMI [48] as well as with the development of GDM [65].
Although there is a growing knowledge about increases in the risk of adverse
outcomes with increasing GWG [62, 63], many studies examining the effects
of maternal obesity and/or gestational diabetes have not accounted for this
important factor. The novel approach of my study allows analysis of each
condition separately aiming to establish the independent contribution of high
BMI, GDM and GWG on pregnancy outcomes.
The consumption of an unhealthy diet in pregnancy is often associated with
increased GWG with negative repercussions on maternal, fetal and newborn
outcomes [47, 58, 59]. As described in Chapter 1 (Sections 1.4.2), excessive
GWG can also occur in women with a lean BMI [66] and has been strongly
associated with a higher risk of adverse pregnancy outcomes and childhood
obesity. Nonetheless, the relative contribution of maternal diet and weight
gain to the complications associated with maternal obesity is still uncertain.
The IOM acknowledged the imprecision of the estimates on which the
recommended weight gain ranges are based and the many additional factors
that might need to be considered for an individual woman. Therefore, in 2009
new IOM guidelines were published based on the WHO cut-off point for the
BMI categories [61]. Additionally, a specific narrow range of recommended
weight gain for obese women was included. In this Chapter, I focus on the
two critical points tightly linked to high BMI, which are maternal diet and
GWG, investigating their association with birth outcome.
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Therefore, the aims of this Chapter are to investigate whether:
1. high BMI and diabetes in pregnant women are associated with
complications in pregnancy, such as Caesarean section, preterm
delivery [46] and incidence of macrosomic offspring [33, 34], who are
at increased risk of gaining more weight later in life [226]. I
hypothesised that these outcomes would also be enhanced with the
combined effect of both obesity and GDM
2. lower educational achievement is associated with the consumption of
high energy diets and exceeding the IOM recommended gestational
weight gain resulting in overweight and obesity in pregnancy [41, 46,
51, 64]
3. insulin resistance in pregnancies complicated by obesity and GDM
reflects altered plasma concentrations of maternal metabolites, such as
glucose and insulin, which is associated with fetal hyperinsulinaemia
and consequent increased fetal growth in obese [216, 227-229] and
diabetic [169, 186] pregnancies.
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3.2. Methods
A description of the study design and all materials and methods used is
provided in Chapter 2. Briefly, pregnant women participating in the Preobe
study (P06-CTS-02341) were recruited in the 20th week of pregnancy and
classified according to their BMI. At 28th weeks of gestation, they were further
classified on the basis of BMI and glucose tolerance, making six groups
(Chapter 2, Section 2.2, Figure 2.2). Maternal and fetal anthropometries were
evaluated at 24 and 34 weeks of pregnancy for women in the BMI group
whereas those of participants with gestational diabetes were measured only at
the 34th gestational week (Chapter 2, Section 2.4, Figure 2.3). A similar
procedure was carried on for collection of maternal venous blood for women in
the BMI groups (at 24, 34 and 40 weeks of gestation) and for women with
gestational diabetes at pregnancy weeks 34 and 40. After birth, umbilical
venous blood samples were collected and placentas were snapped frozen and
stored at -80oC for further analysis in Nottingham. Information about
maternal nutrient intake before delivery (between 34-40 gestational weeks)
was collected using 7 day estimated food intake records. Nutritional data were
then analysed for nutrient intake by using a nutritional software program
(CESNID 1.0, Barcelona University, Spain) based on validated [412] Spanish
food tables (Tablas de composición de alimentos del CESNID).
Maternal pre-pregnancy BMI was calculated as weight in kilograms divided by
height in metres2 by using self-reported pre-pregnancy weight, as recorded
from maternal questionnaires, and height, measured at the first antenatal
clinic visit. Weight gain during pregnancy was calculated using clinical data
recorded at gestational week 24 and 34 as the maternal weight at 40 weeks
of gestation was not measured directly but reported by the mother either at
the time of delivery or by telephone. Therefore, the measurement of total
weight gain in pregnancy and post-gestational weight loss were calculated
referring to the last recorded weight (34 gestational weeks).
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Maternal weight gain was calculated as the difference between pre-gestational
weight and maternal weight at the 34th week. Maternal weight loss was
defined as the difference between maternal weight at 34 gestational weeks
and 6 months after pregnancy. Weight change was compared to the 2009 IOM
guidelines calculated for the 34th week of pregnancy [61] and categorised as
inadequate, adequate, or excess weight gain. As described in Chapter 2,
Section 2.2.1, adequate GWG range until the first 34 gestational weeks was
defined as 9.8-13.6 kg for women of normal BMI, 5.9-9.8 kg for overweight
women and 4.2-7.6 kg for obese women. Inadequate and excessive GWG
were considered as less, and more, than adequate GWG, respectively. In the
infants, a birth weight of less than 2.5 kg was considered low birth weight,
whereas high birth weight was considered higher than 4.0 kg. Large (LGA),
average (AGA) and small for gestational age (SGA), defined as >90th, 10-90th,
<10th birthweight population centile respectively [25], were calculated using
the Lubchenco growth curves [405] adjusted for newborn weight and
gestational age. Infant anthropometry was evaluated by a paediatrician at 3,
6 and 12 months of age respectively and maternal anthropometry at 6
months post-delivery. To determine whether changes in placental weight and
gene expression were reflected in modification of placental phenotype,
histological analysis and immunohistochemistry for fibronectin, an
extracellular matrix molecule, were performed. However, these analyses were
hampered by degradation of a large number of frozen placental samples
caused by delays in fixing the tissue samples at the time of delivery (see
Chapter 2, Section 2.9.2.2 and Section 2.10.1, for details). Finally, placental
triglycerides (TG) were isolated and extracted with chloroform and methanol
(2:1) following the adapted Folch method [439] (Section 2.7, Chapter 2). The
Randox triglycerides assay kit (Cat. No: TR212, Randox laboratories Ltd,
Crumlin, UK) was used to determine triglycerides concentration by
spectrophotometric absorbance. After filtration, samples were dissolved in
BDH and triton X-100 and placental TG concentrations calculated by
interpolation of measured values from an internal control standard curve.
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3.3. Results
The relative effects of maternal BMI and GDM for each outcome has been
analysed both separately and combined, as shown in the following
subsections.
3.3.1. Maternal socio-economical outcomes
As illustrated in Table 3.1 high BMI in pregnancy was associated with having
undertaken professional studies compared to control mothers, who were more
likely to enrol higher educational studies (University).
Table 3.1: Sociological characteristics of control (C), overweight (OV) and
obese (OB) pregnant women at the time of recruitment (20 gestational
weeks).
Maternal highest education
attainment
C (n=59) OV (n=28) OB (n=22)
Primary school 8 4 4
Secondary school 12 4 4
Professional level 14 6 9*
University 24 11 5
*
PhD 1 1 0
Maternal employment
status
C (n=59) OV (n=28) OB (n=21)
Unemployed 16 4 7
Not working outside the
home
2 4* 1
Temporary employment 13 5 7
Permanent employment 28 15 6
Data represents number of women per group (n); Statistical differences denoted by ŵ
correspond to p<0.05 compared to control and overweight respectively (Chi-square
test).
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Overweight women were more likely to work within the domestic environment
compared to lean mothers.
On the other hand, a significant proportion of overweight and obese mothers
with GDM did not continue studying after primary school (Table 3.2). The
highest educational achievement of lean control women was to university
degree level. This was significantly lower in obese mothers with GDM, who
were also associated with the highest level of not working outside the home.
Table 3.2: Sociological characteristics of control (C), gestational diabetic lean
(GDL), gestational diabetic overweight (GDOV) and gestational diabetic obese
(GDOB) pregnant women at the time of recruitment (20 gestational weeks).
Maternal highest education
attainment
C
(n=59)
GDL
(n=14)
GDOV
(n=13)
GDOB
(n=10)
Primary school 8 2 5* 4*
Secondary school 12 5 1 1
Diploma 14 1 1 4
University 24 5 6 1
*
PhD 1 1 0 0
Maternal employment
status (%)
C
(n=59)
GDL
(n=14)
GDOV
(n=13)
GDOB
(n=9)
Unemployed 16 2 1 4
Not working outside the
home
2 0 0 2*
Temporary employment 13 1 4 2
Permanent employment 28 11 8 1
*
Data represents number of women; n: women/group; Statistical differences denoted
by * correspond to p<0.05 compared to lean control (Chi-square test).
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3.3.2. Maternal dietary intake
Only 86 mothers out of the 149 participants completed, and returned, the 7
day food record questionnaire. Nutritional analysis of those food records
available indicated that the only difference in reported major macronutrient
intake between BMI groups was in total carbohydrate intake as illustrated in
Table 3.3.
Table 3.3: Maternal energy and macronutrient intake during late gestation
(34 gestational weeks) in control (C), overweight (OV) and obese (OB)
pregnant women.
Energy and
macronutrients
C (n=37) OV (n=16) OB (n=8)
Energy (kcal/day) 2086.8±52.8 1933.1±150.1 1927.2±200.6
Total carbohydrates
(g/day)
228.4±7.0 207.9±15.9 183.8±20.8
Monosaccharides 116.6±5.6 103.7±11.1 86.2±13.6
Polysaccharides 110.9±4.7 104.6±5.7 97.6±10.9
Total lipids (g/day) 90.3±3.3 84.3±8.6 93.6±10.4
SFA 30.2±1.7 30.0±3.6 31.6±3.4
MUFA 33.9±2.2 34.4±3.4 39.2±5.3
PUFA 12.6±0.8 12.4±1.4 15.0±2.1
Cholesterol (g/day) 0.33±0.01 0.36±0.04 0.37±0.03
Total proteins
(g/day)
88.5±3.5 83.7±5.4 82.9±7.7
Animal protein 63.1±3.3 59.7±4.6 60.5±5.3
Vegetal protein 25.4±0.8 23.9±1.6 23.5±3.2
Total fibre (g/day) 19.9±0.7 17.5±1.0 18.3±3.0
Data represents means ± S.E.M. n: women/group; SFA: saturated FA; MUFA:
monounsaturated FA; PUFA: polyunsaturated FA.
Although there was a trend at decreasing energy (p=0.1) and total
carbohydrate (p=0.08) intake in obese mothers compared to lean women, the
difference did not reach statistical difference.
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Another trend in decreased total proteins, mainly of vegetable origin
(p=0.08), was observed among obese women. Total lipids, saturated FA
(SFA), monounsaturated FA (MUFA) and polyunsaturated FA (PUFA) intake as
well as cholesterol and total fibre consumption were not different between
BMI groups. Obese women with GDM had a significantly lower reported total
energy intake compared to lean healthy mothers without GDM (Table 3.4).
Table 3.4: Maternal energy and macronutrient intake during late gestation
(34 gestational weeks) in control (C), gestational diabetic lean (GDL),
gestational diabetic overweight (GDOV) and gestational diabetic obese
(GDOB) pregnant women.
Energy and
macronutrients
intake
C
(n=37)
GDL
(n=11)
GDOV
(n=8)
GDOB
(n=6)
Energy
(kcal/day)
2086.8±52.8 1900.3±120.1 1762.9±140.7 1565.1±117.5
**
Total
carbohydrates
(g/day)
228.4±7.0 174.0±11.9
**
189.4±20.6 155.2±13.4
**
Monosaccharides 116.6±5.6 85.9±6.8* 89.9±10.8 73.6±9.2*
Polysaccharides 110.9±4.7 88.3±7.3 99.4±11.0 81.7±8.2
Total lipids
(g/day)
90.3±3.3 90.2±7.3 70.8±6.7 66.1±7.9*
SFA 30.2±1.7 29.0±5.1 22.0±2.4
*
19.6±2.1
**
MUFA 33.9±2.2 38.5±3.5 30.7±3.7 29.2±4.9
PUFA 12.6±0.8 14.4±2.5 11.7±1.2 11.0±2.3
Cholesterol
(g/day)
0.33±0.01 0.36±0.04 0.28±0.03 0.29±0.03
Total proteins
(g/day)
88.5±3.5 96.8±7.1 90.1±7.7 85.5±4.6
Animal protein 63.1±3.3 74.5±6.9 62.1±6.1 61.9±4.6
Vegetal protein 25.4±0.8 22.4±1.1 28.1±2.8 22.4±2.3
Total fibre
(g/day)
19.9±0.7 20.8±1.2 26.3±3.4
*
19.6±3.0
Data represents means ± S.E.M. Statistical differences denoted by *, ** correspond to
p<0.05 and p<0.01 respectively compared to control group (1-way ANOVA; Bonferroni
post-hoc test); n: women/group; SFA: saturated FA; MUFA: monounsaturated FA;
PUFA: polyunsaturated FA.
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This was reflected by diminished total intake of carbohydrates, particularly
monosaccarhides, total lipid and saturated fatty acid (SFA), in those women.
Similarly, total carbohydrate and monosaccharide consumption was lower in
lean mothers with GDM compared to lean controls. However, their lipid and
SFA intake was not different than that in the control group, reflecting similar
energy intake. Total protein, both of animal and vegetable origin, were
consumed in the same amount in all groups. Fibre intake was also similar
among participants, although overweight mothers with GDM consumed the
highest proportion compared to their healthy counterparts. When
micronutrient intake was considered, 130 participants out of 149 reported
daily intake of folate and iodine supplements at 24th week of pregnancy,
whereas only 62 out of 130 mothers consumed iron supplements (Table 3.5).
Table 3.5: Maternal micronutrient intake during late gestation (34 gestational
weeks) in control (C), overweight (OV) and obese (OB) pregnant women.
Ion intake
(mg/day)
C (n=37) OV (n=16) OB (n=8)
Sodium 2760.6±129.8 2792.6±224.7 2451.9±258.3
Potassium 3441.0±94.5 3013.1±181.4 2784.4±314.2
*
Calcium 1006.3±34.2 888.6±64.3 747.3±64.9
**
Magnesium 328.4±7.7 296.6±16.5 271.9±30.0
*
Phosphorus 1413.7±44.7 1322.3±89.2 1251.5±98.6
Iron 12.5±0.4 11.03±0.8 11.8±1.6
Vitamin intake
(mg/day)
C (n=37) OV (n=16) OB (n=8)
Vitamin A 0.95±0.06 0.83±0.08 0.84±0.15
Vitamin D (x 10
-3
) 2.20±0.21 1.70±0.21 2.70±0.59
Vitamin B1 1.57±0.07 1.45±0.10 1.36±0.13
Vitamin B2 1.88±0.06 1.71±0.13 1.54±0.12
Vitamin B6 2.02±0.07 1.83±0.12 1.74±0.23
Vitamin C 162.2±12.8 133.7±16.0 115.8±31.0
Data represents means ± S.E.M. Statistical differences denoted by *, ** correspond to
p<0.05 and p<0.01 respectively compared to control group (1-way ANOVA; Bonferroni
post-hoc test); n: women/group.
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As expected [41, 45, 46], higher BMI was associated with lower reported
intake of ions compared to healthy controls. Obese mothers reported
significantly lower daily intake of calcium, potassium and magnesium
compared to women with lean BMI.
Table 3.6 illustrates that vitamin D consumption in lean mothers with GDM
was significantly higher compared to their healthy counterparts, although no
other major differences in other vitamins or ion intake were found between
GDM groups.
Table 3.6: Maternal micronutrient intake during late gestation (34 gestational
weeks) in control (C), gestational diabetic lean (GDL), gestational diabetic
overweight (GDOV) and gestational diabetic obese (GDOB) pregnant women.
Micronutrients
intake (mg/day)
C (n=37) GDL (n=11) GDOV (n=8) GDOB (n=6)
Sodium 2760.6±129.8 2791.6±276.8 2606.6±217.0 2348.2±217.1
Potassium 3441.0±94.5 3539.3±163.5 3804.2±401.3 3195.6±377.6
Calcium 1006.3±34.2 931.2±75.1 1102.2±131.0 931.7±102.6
Magnesium 328.4±7.7 309.4±16.2 370.9±36.8 328.9±33.2
Phosphorus 1413.7±44.7 1403.3±86.2 1482.1±129.7 1322.5±93.2
Iron 12.5±0.4 13.0±0.9 12.7±0.9 12.5±1.5
Vitamin intake
(mg/day)
C (n=37) GDL (n=11) GDOV (n=8) GDOB (n=6)
Vitamin A 0.95±0.06 1.35±0.17 1.13±0.14 0.91±0.15
Vitamin D (x 10
-3
) 2.20±0.21 3.81±0.66
* 2.01±0.65 3.01±0.67
Vitamin B1 1.57±0.07 1.52±0.10 1.57±0.13 1.44±0.14
Vitamin B2 1.88±0.06 2.04±0.18 2.05±0.17 1.80±0.17
Vitamin B6 2.02±0.07 2.22±0.14 2.28±0.23 2.10±0.20
Vitamin C 162.2±12.8 178.5±10.6 211.1±31.5 139.5±16.2
Data represents means ± S.E.M. Statistical differences denoted by * correspond to
p<0.05 compared to control group (1-way ANOVA; Bonferroni post-hoc test); n:
women/group.
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3.3.3. Maternal clinical characteristics and
anthropometry
The majority of women in this study were experiencing their first pregnancy
(Table 3.7, Table 3.8). Maternal age and gestational age at delivery did not
differ between BMI groups (Table 3.7). Overweight was associated with
increased smoking during pregnancy (24%) compared to healthy controls
(12%) and obese mothers (9%).
Table 3.7: Clinical characteristics of control (C), overweight (OV) and obese
(OB) pregnant women.
Maternal clinical
characteristics
C (n=59ƺ) OV (n=29ƺ) OB (n=22ƺ)
Maternal age (yr) 30.4±0.6 31.9±0.8 29.0±1.0
Gestational age (wk) 39.2±0.1 39.4±0.3 39.3±0.4
Smoking status (yes/no) 7/51 7/22
ʋ
2/20
Parity (PP/MP)
33/24 13/14 12/7
Type of delivery (S/C)
50/7 20/7 13/7
*
Delivery (P/T/O)
0/52/6 1/21/7 2/13/7*
Data represents means ± S.E.M.; n: women/group; ƺ some data are missing due to
lack of recorded information; yr: years; wk: weeks; PP: primiparous; MP: multiparous;
S: spontaneous; C: Caesarean P: preterm; T: term; O: overdue; gw: gestational
weeks; m: months. Statistical differences denoted by ŵ correspond to p<0.05
compared to control and obese respectively (Chi-square test).
All mothers gave birth to healthy offspring although obese women were 1.3
and 2.9 times more likely to experience Caesarean sections than overweight
and healthy control mothers, respectively. Women in the highest BMI group
had a trend (p=0.09) to increased risk of giving birth before 37 weeks of
gestation (32%) followed by overweight (24.1%) and lean (10.3%) mothers.
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Similarly, women who were obese had 3.1 and 1.3 times higher risk of
experiencing an overdue pregnancy than overweight mothers and lean
counterparts respectively.
Clinical characteristics of pregnant women with GDM, the majority of whom
did not smoke during pregnancy, are shown in Table 3.8. Obese mothers with
GDM were older than their lean counterparts without GDM.
Almost all mothers with GDM delivered at term (37-40 gestational weeks),
whereas one preterm birth was observed among women with both overweight
and GDM (<37 gestational weeks), who also gave birth post-term once (>40
gestational weeks). The highest proportion of women experiencing Caesarean
section was observed among obese mothers with GDM (0.5 times) compared
to lean controls.
Table 3.8: Clinical characteristics of control (C), gestational diabetic lean
(GDL), gestational diabetic overweight (GDOV) and gestational diabetic obese
(GDOB) pregnant women.
Maternal clinical
characteristics
C
(n=59ƺ)
GDL
(n=14ƺ)
GDOV
(n=14ƺ)
GDOB
(n=11ƺ)
Maternal age (yr)
30.4±0.6
33.1±1.1 33.5±0.9 34.7±1.3**
Gestational age (wk)
39.2±0.1
39.2±0.4 38.5±0.7 38.9±0.4
Smoking status
(yes/no)
7/51 0/13 1/10 0/7
Parity (PP/MP) 33/24 5/5 5/5 6/3
Type of delivery (S/C) 50/7 9/3 8/2 5/5**
Pregnancy (P/T/O)
0/52/6
0/10/2 1/9/1 0/9/1
Data represents means ± S.E.M.; n: women/group; ƺ some data are missing due to
lack of recorded information; yr: years; wk: weeks; PP: primiparous; MP: multiparous;
S: spontaneous; C: caesarean; P: preterm; T: term; O: overdue; gw: gestational
weeks; m: months. Statistical differences denoted by ** correspond to p<0.01
compared to control group (1-way ANOVA; Bonferroni post-hoc test for continuous
variables; Chi-square test for categorical data).
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Women with higher BMI in pregnancy, independently of GDM, showed
reduced weight gain compared to lean control group without GDM (Figure 3.1
A). The combined effects of higher BMI and GDM were associated with
considerably less weight gain during the first 34 weeks of pregnancy (Figure
3.1 B).
Figure 3.1: Maternal weight gain during first 34 weeks of gestation and
maternal weight loss from 34 gestational weeks to 6 months post-delivery.
A) control (orange bars; n=59), overweight (green bars; n=29) and obese (light blue
bars; n=22) women and in (B) control (orange; n=59), gestational diabetic lean (red;
n=14), overweight (aqua; n=14) and obese (blue; n=11) mothers. Data represents
means ± S.E.M. Statistical differences denoted by *, **, *** correspond to p<0.05,
p<0.01, p<0.001 respectively (1-way ANOVA; Bonferroni post-hoc test).
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Interestingly, maternal weight loss from 34 gestational weeks to 6 months
after pregnancy decreased with BMI, and the highest weight retention was
observed in obese women with or without GDM.
Similarly, for each IOM category (Low, Adequate, High), women with
increased BMI gained less weight during gestation compared to healthy and
lean mothers (Table 3.9 and 3.10). By definition, BMI was significantly higher
in overweight and obese groups with (Table 3.9) or without (Table 3.10) GDM
before, throughout and 6 months after gestation.
Table 3.9: Anthropometrical characteristics of pregnant women in the control
(C), overweight (OV) and obese (OB) BMI groups.
Maternal BMI (kg/m
2
) C (n=59) OV (n=29) OB (n=22)
Pre gestational BMI 21.8±0.2 27.4±0.3
***
32.5±0.5
***
Gestational BMI 24 weeks 24.9±0.3 29.7±0.4
***
33.6±0.4
***
Gestational BMI 34 weeks 26.6±0.3 31.3±0.4
***
35.4±0.5
***
BMI 6 months post-delivery 23.5±0.4 28.5±0.6
***
32.5±0.4
***
Maternal GWG 0-34 weeks (kg)
Ǔ
C (n=59) OV (n=29) OB (n=22)
Low 7.7±0.4 2.7±0.9 2.5±0.6
Adequate 12.1±0.2 8.1±0.4 5.9±0.4
High 16.1±0.6 13.4±0.6 12.3±1.1
Data represents means ± S.E.M.; n: women/group; BMI: body mass index; GWG:
gestational weight gain during the first 34 gestational weeks (Ǔ) based on 2009 IOM
guidelines for each category[61]:
Low: <9.8 kg for control, <5.9 kg for overweight and <4.2 kg for obese women;
Adequate: 9.8-13.6 kg for control, 5.9-9.8 kg for overweight and 4.2-7.6 kg for obese
women; High: >13.6 kg for control, >9.8 kg for overweight and >7.6 kg for obese
women. Statistical differences denoted by *** correspond to p<0.001 compared to
control group (1-way ANOVA; Bonferroni post-hoc test).
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Table 3.10: Clinical characteristics of control (C), gestational diabetic lean
(GDL), gestational diabetic overweight (GDOV) and gestational diabetic obese
(GDOB) pregnant women.
Maternal BMI
(kg/m
2
)
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
Pre gestational BMI 21.8±0.23 22.4±0.5 26.98±0.4
***
35.52±1.5
***
Gestational BMI
34 weeks
26.6±0.3
25.9±0.7 29.67±0.7
**
36.4±1.2
***
BMI 6 months
post-delivery
23.5±0.4
23.2±0.8 27.1±0.5
***
35.2±1.4
***
Maternal GWG 0-34
week(kg)
Ǔ C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
Low 7.7±0.4 5.2±1.2
*
- 0.81±2.1
***
- 3.4±2.1
***
Adequate 12.1±0.2 11.4±0.6 7.2±0.3
**
5.2±0.4
**
High 16.1±0.6 17.0±0.6 15.6±1.0
*
11.3±1.9
*
Data represents means ± S.E.M.; n: women/group; BMI: body mass index; GWG:
gestational weight gain during the first 34 gestational weeks Ǔ based on 2009 IOM
guidelines[61]:
Low: <9.8 kg for control, <5.9 kg for overweight and <4.2 kg for obese women;
Adequate: 9.8-13.6 kg for control, 5.9-9.8 kg for overweight and 4.2-7.6 kg for obese
women; High: >13.6 kg for control, >9.8 kg for overweight and >7.6 kg for obese
women. Statistical differences denoted by *,**,*** correspond to p<0.05, p<0.01 and
p<0.001 respectively compared to control group (1-way ANOVA; Bonferroni post-hoc
test).
Despite overweight and obese mothers without GDM gaining the least weight
compared to their healthy counterparts, a great proportion of them exceeded
the 2009 IOM recommendations (Figure 3.2 A).
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Figure 3.2: Frequency of low (Low), adequate (Ade) and excessive (High)
gestational weight gain according to the 2009 IOM recommendations during
the first 34 weeks of gestation [61].
A: control (C; n=59), overweight (OV; n=29) and obese (OB; n=22) pregnant women;
B: control (C; n=59), gestational diabetic lean (GDL; n=14), overweight (GDOV;
n=14) and obese (GDOB; n=11) mothers.
Overall, those who entered pregnancy with a normal BMI were 1.4 and 1.7
times more likely to show adequate GWG, based on 2009 IOM guidelines,
compared to overweight and obese mothers respectively (C: 40.4%; OV:
2%ƹ2= 5.24, p=0.026; Std. Residual=2.1).
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Interestingly, overweight women were 1.4 and 1.3 times more likely to
exceed the IOM recommended GWG compared to their lean counterparts and
REHVHPRWKHUV UHVSHFWLYHO\ & 29  2% ƹ2= 5.24,
p=0.046; Std. Residual=1.7). Nonetheless, among obese women a similar
proportion gained less than adequate weight throughout the first 34 weeks of
gestation (OB low GWG: 36.4%; OB high GWG: 40.9%). On the other hand,
the effect of GDM was associated with lower than recommended GWG
compared on IOM guidelines (Figure 3.2 B). The proportion of lean women
with GDM who gained less GWG than recommended by IOM was 2.5 higher
FRPSDUHGWROHDQKHDOWK\FRQWURO&*'/ƹ2=9.6; p=0.034;
Std. Residual=1.5). This was accompanied by lower weight gain throughout
pregnancy (Figure 3.1 B). The effect of BMI combined with GDM was similar
to that of GDM alone (GDOV: 42.9%; GDOB: 54.5%), although not
statistically significant between GDM groups.
3.3.4. Maternal plasma metabolites
Physiological and clinical characteristics of mothers without GDM at different
times of gestation are summarised in Table 3.11. Increased glucose
concentrations in maternal plasma were detected at 40 gestational weeks in
obese mothers compared to lean controls. However, these values were
measured post-prandially, whilst fasting plasma glucose from an OGTT had
revealed that these women were not having glucose intolerance or gestational
diabetes.
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Table 3.11: Physiological characteristics of maternal plasma at 24, 34 and 40
gestational weeks (gw) in control (C), overweight (OV) and obese (OB)
pregnant women.
Maternal metabolites C (n=59) OV (n=29) OB (n=22)
Glucose (mg/dl)
24 gw 78.2±1.6 85.0±3.1 80.6±3.9
34 gw 84.6±1.9 86.7±4.4 86.7±3.3
40 gw 77.4±3.1 82.9±4.6 97.5±10.2*
Triglycerides (mg/dl)
24 gw 166.3±9.2 190.4±13.8 171.9±17.8
34 gw 231.6±10.6 248.4±13.4 245.2±14.3
40 gw 210.5±9.9 237.2±15.3 223.8±18.1
Cholesterol (mg/dl)
24 gw 243.1±5.2 246.4±8.4 242.4±13.98
34 gw 256.1±5.8 261.3±9.7 246.6±10.72
40 gw 246.4±7.3 254.0±9.8 247.2±15.67
Data represents means ± S.E.M.; n: women/group; Statistical differences denoted by *
correspond to p<0.05 compared to control group (1-way ANOVA; Bonferroni post-hoc
test).
Similarly, women with GDM had enhanced plasma glucose concentrations at
both 34 and 40 weeks of gestation. Overweight women with GDM showed no
difference in glucose concentrations at 34th gestational weeks (Table 3.12).
Surprisingly, no differences in maternal serum TG and cholesterol were
observed in women in the highest BMI group in either presence, or absence,
of GDM.
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Table 3.12: Physiological characteristics of maternal plasma at 34 and 40
gestational weeks in control (C), gestational diabetic lean (GDL), gestational
diabetic overweight (GDOV) and gestational diabetic obese (GDOB) pregnant
women.
Maternal metabolites
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
Glucose (mg/dl)
34 gw 84.6±1.9 98.7±4.4
**
87.4±4.4 98.5±8.9
*
40 gw 77.3±3.1 109.0±11.3
**
112.1±10.3
**
110.9±10.9
**
Triglycerides (mg/dl)
34 gw 231.6±10.6 255.4±32.5 233.3±21.2 247.7±26.0
40 gw 210.5±9.9 237.1±15.3 215.8±16.4 221.4±18.9
Cholesterol (mg/dl)
34 gw 256.1±5.8 253.4±14.1 257.5±10.0 254.5±15.6
40 gw 246.4±7.3 229.5±16.2 241.1±8.5 228.8±19.1
Data represents means ± S.E.M.; n: women/group. Statistical differences denoted by
*,** correspond to p<0.05 and p<0.01 respectively compared to control group (1-way
ANOVA; Bonferroni post-hoc test).
Insulin concentrations in maternal plasma were greater in the obese (BMI)
group at 40 gestational weeks than in the lean comparison group regardless
of GDM (Figure 3.3). By definition, insulin plasma levels at term were higher
in women with GDM (Figure 3.4), although they were diet-treated.
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Figure 3.3: Plasma insulin concentration at 34th gestational week in control
(C; n=59), overweight (OV; n=29) and obese (OB; n=22) pregnant women.
Data represents means ± S.E.M. Statistical differences denoted by * correspond to
p<0.05 (1-way ANOVA; Bonferroni post-hoc test).
Figure 3.4: Plasma insulin concentration at 34th gestational week in control
(C; n=59), gestational diabetic lean (GDL; n=14), gestational diabetic
overweight (GDOV; n=14) and gestational diabetic obese (GDOB; n=11)
pregnant women.
Data represents means ± S.E.M. Statistical differences denoted by * correspond to
p<0.05 (1-way ANOVA; Bonferroni post-hoc test.
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3.3.5. Fetal and placental outcomes
Physiological characteristics of metabolites measured in cord blood in the
three BMI groups and in the gestational diabetic groups are illustrated in
Table 3.13 and 3.14 respectively.
Table 3.13: Cord blood and placental characteristics in control (C),
overweight (OV) and obese (OB) women.
Cord blood metabolites C (n=33) OV (n=15) OB (n=12)
Cord blood glucose (mg/dl) 71.2±3.1 66.1±6.2 59.3±6.6
Cord blood triglycerides (mg/dl) 47.5±2.9 46.4±4.0 45.6±6.8
Cord blood cholesterol (mg/dl) 32.3±2.5 26.1±2.3 29.9±4.1
Placental TG C (n=50) OV (n=26) OB (n=14)
Total placental TG*placental
weight (mg)
19.9±1.4 19.7±3.1 21.4±4.8
Data represents means ± S.E.M; n: women/group; TG: triglycerides.
Although glucose concentrations in cord blood had a trend to decrease as a
consequence of obesity (p=0.1), it did not reach statistical significance (Table
3.13). Similarly, triglycerides and cholesterol concentrations in cord blood did
not differ between BMI groups as did total placental TG per placental weight.
On the other hand, overweight women with GDM showed a trend (p=0.17) to
increased glucose concentrations in cord blood compared to lean controls
without GDM (Table 3.14). Nonetheless, after running an independent t-test
between cord blood glucose concentrations in GDOV group compare to control
a statistical significance (p=0.035) was reached. Overall, a sample size
calculation indicated that 40 participants from each group were required to
detect a significant difference in cord blood glucose at an 80% power.
Unchanged cord blood TG and cholesterol concentrations were accompanied
by similar concentrations of total placental TG per placental weight in GDM
groups compared to the lean control without GDM.
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A sample size calculation showed that 63 samples from each group were
required to detect the significance warranted at a power of 80%.
Table 3.14: Cord blood and placental characteristics in control (C), gestational
diabetic lean (GDL), gestational diabetic overweight (GDOV) and gestational
diabetic obese (GDOB) pregnant women.
Cord blood and placental
outcomes
C
(n=33)
GDL
(n=7)
GDOV
(n=12)
GDOB
(n=7)
Cord blood glucose (mg/dl) 71.2±3.1 71.1±4.7 88.8±7.9 71.9±8.5
Cord blood triglycerides (mg/dl) 47.5±2.9 39.1±5.2 42.3±3.4 44.3±10.7
Cord blood cholesterol (mg/dl) 32.3±2.5 35.4±4.5 34.6±4.3 30.0±6.2
Placental TG
C
(n=50)
GDL
(n=12)
GDOV
(n=4)
GDOB
(n=5)
Total placental TG*placental
weight (mg)
19.9±1.4 19.7±3.1 21.4±4.8 30.8±9.7
Data represents means ± S.E.M.; n: women/group; TG: triglycerides.
Anthropometric characteristics of the fetus and placenta of pregnant women
without GDM indicated similar fetal weight at 24 and 34 gestational weeks
(Table 3.15). Interestingly, increased placental weight, but not diameter
(measured at the widest point), was observed in obese women compared to
lean controls.
Table 3.15: Anthropometric characteristics of the fetus, based on ultrasound
scan (USS) at 34 gestational weeks (gw), and placenta in control (C),
overweight (OV) and obese (OB) women.
Placental and fetal
anthropometry
C (n=59) OV (n=28) OB (n=22)
Estimated fetal weight at
34 gw (g)
2357±23 2360±56 2433±87
Placental diameter (cm) 19.1±0.3 19.6±0.4 20.2±0.6
Placental weight (g) 469±16 495±25 520±29
*
Data represents means ± S.E.M. Statistical differences denoted by * corresponds to
p<0.05 (1-way ANOVA; Bonferroni post-hoc test); n: women/group.
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The effect of GDM alone and combined with BMI did not influence fetal weight
at 34 gestational weeks nor placental weight or diameter (Table 3.16).
Table 3.16: Anthropometric characteristics of the fetus, based on ultrasound
scan (USS) at 34 gestational weeks (gw), and placenta in control (C),
gestational diabetic lean (GDL), gestational diabetic overweight (GDOV) and
gestational diabetic obese (GDOB) pregnant women.
Placental and fetal
anthropometry
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
Estimated fetal weight at
34 gw (g)
2357±23 2593±116 2641±92 2612±213
Placental diameter (cm) 19.1±0.3 19.7±0.4 18.4±0.5 18.8±0.4
Placental weight (g) 469±16 497±38 491±31 462±36
Data represents means ± S.E.M.; n: women/group; m: months.
Attempt to look at placental morphology through microscopic analysis in 60
placental samples (10 C, 10 OV, 10 OB, 10 GDL, 10 GDOV, 10 GDOB) was
executed. However, the analysis showed that a large number (n=30) of these
frozen placental samples was degraded, probably due to delay in fixing the
tissue samples at the time of delivery (Figure 3.5).
Figure 3.5: 5HSUHVHQWDWLYH KDHPDWR[\OLQ 	 HRVLQ +	( ǋP VWDLQHG
microscopic sections at 4x magnification.
A) On the left: section corresponding to placental sample from control (C).
B) On the right: section of placental sample from obese with gestational diabetes
group (GDOB). The pink coloured stain represents connective tissue, red blood cells
and non-nucleated cellular material. Villi surface were either deteriorated (3.9-A) or
surrounded by maternal blood (3.9-B).
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Few placental sections (10 out of 60) were better preserved, but the amount
of frozen tissues available for quantification was limited and did not allow
meaningful comparison between observational groups. Therefore, the analysis
could not be completed.
3.3.6. Newborn outcomes and postnatal growth
All women without GDM gave birth at term and to healthy neonates, whose
anthropometric characteristics are reported in Table 3.17.
Table 3.17: Newborn anthropometric characteristics in control (C),
overweight (OV) and obese (OB) women.
Newborn anthropometry C (n= 59) OV (n=29) OB (n=22)
Newborn gender (M/F) 31/28 11/17 13/8
Newborn weight (kg) 3.29±0.53 3.27 ± 0.95 3.42 ± 0.12
Newborn length (cm) 50.2±0.2 50.5±0.3 50.5±0.7
Ponderal index (g/cm
3
x 100) 2.62±0.04 2.63±0.05 2.58±0.07
Placental weight/Birthweight 0.14±0.0 0.15±0.01 0.16±0.01
Infant weight gain 0-3m (kg) 2.76±0.10 2.76±0.20 2.87±0.15
Infant weight gain 3-6m (kg) 1.58±0.08 1.64±0.14 1.56±0.12
Total infant weight gain 0-12m (kg) 6.32±0.16 6.25±0.17 6.15±0.22
Data represents means ± S.E.M. n: women/group; m: months.
Neonatal ponderal index, a measure of their leanness calculated by
normalising the mass with the third power of body height, did not differ
between BMI groups. Despite their bigger placentas, obese mothers gave
birth to neonates of similar weight to that of their lean counterparts. This may
have result from the sample size being lower than expected.
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In fact, the studys actual power was only 18% and, in order to detect a
statistically significant difference, it would have needed 287 subjects in each
group to have a target power of 80%.
After birth, infant postnatal growth at three, six and twelve months was
similar between groups showing analogous weight gain in the first year of age
(Table 3.17). Although women in each BMI group gave birth to newborns in
the normal range of recommended weight (2.5<birth weight<4.0kg), obese
women had the highest percentage of large for gestational age (LGA) infants
(defined as > 90% birthweight population centile) compared to the other BMI
groups. This was, in fact, more than twice the rate of LGA infants born to the
lean group (Figure 3.6).
Figure 3.6: Frequency of delivering small (SGA < 10th birthweight population
centile), adequate (AGA 10-90th birthweight population centile) or large (LGA
> 90th birthweight population centile) for gestational age newborns in control
(C; n=59), overweight (OV; n=29) and obese (OB; n=22) women.
Furthermore, when obese pregnant women gained more weight (10.1-14 kg)
than the 2009 IOM recommendation (4.2-7.6 kg) during the first 34
gestational weeks, they delivered bigger infants compared to lean controls
mothers (Figure 3.7).
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Figure 3.7: Birth weight trend based on maternal weight gain during the first
34 weeks of gestation in offspring from control (C), overweight (OV) and
obese (OB) pregnant women.
Data represents means ± S.E.M. Statistical differences denoted by ** corresponds to
p<0.01 (1-way ANOVA; Bonferroni post-hoc test). Orange, green and blue bars
represent infants from C (n=59), OV (n=29) and OB (n=22) mothers respectively.
Unexpectedly, the effect of GDM did not influence newborn weight, length or
ponderal index as reported in Table 3.18. Infant postnatal growth at three, six
and twelve months was similar with all groups showing no significant
influence of GDM alone, or combined with BMI, on postnatal weight gain over
the first year of age (Table 3.18).
157
Table 3.18: Newborn anthropometric characteristics in control (C),
gestational diabetic lean (GDL), gestational diabetic overweight (GDOV) and
gestational diabetic obese (GDOB) pregnant women.
Newborn
anthropometry
C
(n= 59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
Newborn gender (M/F) 31/28 8/7 3/4 8/3
Newborn weight (kg) 3.29±0.05 3.37±0.11 3.23±0.15 3.42±0.17
Newborn length (cm) 50.2±0.2 50.6±0.5 50.6±0.9 50.9±1.0
Ponderal index
(g/cm
3
x100)
2.62±0.04 2.61±0.09 2.58±0.08 2.60±0.13
Placental
weight/Birthweight
0.14±0.0 0.15±0.01 0.16±0.01 0.14±0.01
Infant weight gain
0-3m (kg)
2.76±0.10 2.75±0.23 2.83±0.31 2.76±0.31
Infant weight gain
3-6m (kg)
1.58±0.08 1.61±0.12 1.83±0.18 2.04±0.47
Total infant weight gain
0-12m (kg)
6.32±0.16 6.40±0.20 6.30±0.25 6.60±0.45
Data represents means ± S.E.M.; n: women/group; M: male; F: female; m: months.
A linear regression model was undertaken in order to investigate the change
in birth weight associated with BMI, GDM, GWG and other potential
confounding factors (Table 3.15). In the first model, maternal pre-gestational
BMI was used as the main predictor and this only resulted in an increased
newborn weight of 22 grams. The second model took into account the
combined effect of BMI and GWG and revealed a stronger influence of BMI on
birth weight. The effect of both BMI and GWG were then combined with that
of GDM in the third model, which indicated a similar influence of BMI and GDM
with GWG having the weakest influence on neonatal weight. Lastly, additional
confounders including newborn gender, maternal age, smoking status and
parity, were added to the third model. This resulted in a negative contribution
on the prediction of birth weight (Model 4), due to the gender effect as,
surprisingly, males from these women weighed less than females.
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Table 3.19: Association between changes in birth weight and different
predicting factors in control, overweight and obese mothers with and without
GDM.
Linear regression model
(n=149)
Increase in birth weight (kg) p value
MODEL 1
Ǔ
Maternal BMI 0.022 (0 to 0.044) 0.071
MODEL 2
ǓǓ
Maternal BMI 0.024 (0.006 to 0.043) 0.011
Maternal GWG 0.016 (0.001 to 0.032) 0.033
MODEL 3
ǓǓǓ
Maternal BMI 0.024 (0.006 to 0.043) 0.011
Maternal GWG 0.017 (0.001 to 0.033) 0.038
Maternal GDM 0.021 (-0.190 to 0.232) 0.845
MODEL 4
ǓǓǓǓ
Maternal BMI 0.022 (0.002 to 0.041) 0.041
Maternal GWG 0.016 (0.00 to 0.032) 0.032
Maternal GDM 0.020 (- 0.196 to 0.236) 0.236
Other confounders - 0.175 (-0.173 to 0.103) 0.287
ǓAdjusted for the a priori confounder BMI; ǓǓadjusted for the a priori confounders
BMI and GWG; ǓǓǓadjusted for the a priori confounders BMI, GWG and GDM; ǓǓǓǓ
Adjusted for the a priori confounders BMI, GWG, GDM and additional factors (newborn
gender, maternal age, maternal smoking status, maternal parity, type of delivery).
Numbers in brackets are 95% confidence intervals.
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3.4. Discussion
3.4.1. Maternal BMI and diabetes influences
maternal socio-economic status and dietary choices
There is increased awareness that high BMI and GDM have effects on
pregnancy outcomes with the potential to compromise newborn health in the
long-term [482, 483]. Therefore, appropriate and sustainable intervention
strategies for pregnant women need to be optimised. To my knowledge, only
a few investigations have attempted to discern the relative influences of
overweight, obesity and GDM [474, 484, 485] on pregnancy outcomes. The
novel contribution of my study was to consider the relative effects of different
BMI categories in pregnancy in the presence and absence of GDM. In addition,
the large amount of data available allowed me to widely analyse and interpret
the adverse consequences related to these conditions. Therefore, the aim of
this chapter was to focus on different critical aspects related to these diseases
and their contribution on maternal and newborn outcomes.
Current evidence from epidemiological and animal investigations has
highlighted the crucial contribution of maternal diet and weight gain on the
development of obesity and hyperglycaemia in pregnancy [39, 486].
Unquestionably, ethnic differences play a significant role in the prevalence of
obesity and GDM [61]. For instance, in Europe, GDM has been found to be
more common among Asian women than among European women [487] and,
in the USA, Native Americans, Asians, Hispanics, and African-American
women are at higher risk for GDM than non-Hispanic white women [488-490].
In my study, the majority of the subjects were of Hispanic European white
origin (95-98%) with a minor prevalence of other ethnicities as American-
Indian (0-1.7%), Arabic (0-1.7%) and Romani (0-1.7%). Hispanic and
Southern European culture is associated with a lifestyle and social behaviour
that diverges from those of Northern European and American [491-493].
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For instance, consuming an excess of saturated fat and processed food
coupled with mental stress and inequality, a common feature in countries like
the UK and USA [490, 493, 494], might represent factors contributing to
increased obesity and diabetes in those countries [38, 495, 496]. On the
contrary, Scandinavian diet is more reach in polyunsaturated fatty acids, fruit
and vegetables and physical activity is a predominant part in their daily life
[493, 497]. Mediterranean diet follows similar principles and it has been
characterised by a less stressful life along with more homemade food [498,
499]. Furthermore, low socioeconomic status along with high levels of stress
has been recognised as a frequent cause predisposing the mother to
imbalanced and inadequate diets [51, 490]. More healthy women with a BMI
in the normal range participating in the study had a university degree and a
permanent job whereas obese mothers with or without diabetes were less
likely to have continued their education to University level. In addition,
obesity in pregnancy was associated with a high percentage of unemployment
and not having paid work outside the home. It is possible that those women
have invested less in fitness and high quality food and they could have been
more stressed about their economic situation [51, 490, 493].
After analysis of the nutritional questionnaires returned by participants,
however, the outcomes did not reflect what was expected, that is, a high
energetic and caloric diet in women with high BMI [52]. In fact, overweight
and obese mothers reported similar high caloric food consumption resulting in
similar energy and total carbohydrate intake than lean women (Table 3.3).
Mothers with both enhanced BMI and GDM consumed a lower energy rich diet
with less total carbohydrate, lipid and SFA intake (Table 3.4). In addition,
these women reported higher intake of MUFA and PUFA reflecting healthier
nutritional choices [500]. A large body of evidence in both animals and human
cohorts supports the beneficial effects of dietary long chain PUFA
supplementation on placental and fetal development as well as birthweight
[501, 502].
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However, the benefits for the mother [503], as for the offspring in the long
term, remain to be confirmed [504]. It is plausible to assume that the
Mediterranean diet consumed by these Spanish participants played a key role
on protecting them from consuming excess of saturated fat and energy rich
food [479, 505]. Above all, the Mediterranean tradition of consuming
homemade food [503, 506], in contrast to the increased international
prevalence of fast and processed foods [490, 493, 494], may play a
significant role in lowering the incidence of high caloric diets.
Evidence from epidemiological studies [79] supports the beneficial effects of
higher intake of fruits and vegetables, whole grains, fish and moderate daily
consumption of alcohol on a healthy lifestyle and body weight. Also, the use
of olive oil as the major source of fat instead of butter and margarine that are
rich in SFA, has been associated with longer life expectancy [54] and this has
recently been substantiated in a larger study [491]. In this work, overweight
and obese women consumed lower ion intake (Table 3.5), supporting data
from epidemiological studies [38, 495, 496, 507]. Nevertheless, it is intriguing
to notice that there was an overall higher intake of major micronutrients
(Table 3.4) in the GDM group independent of BMI reflecting healthier food
choices [508, 509]. The fact that women with GDM were routinely attending
medical revisions, which included dietary recommendations for their
hyperglycaemia, might have contributed to this better dietetic outcome.
Researchers found that Mediterranean dietary principles are effective in
clinical practice, being associated with low rates of chronic diseases and high
adult life expectancy [478, 506].
Therefore, my findings substantiate that a good medical supervision in guiding
patients towards more conscious nutritional choices is important and might be
useful to counter-balance the adverse outcomes associated with obesity and
diabetes in pregnancy.
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3.4.2. Obesity, diabetes and maternal weight gain
in pregnancy
Increased total energy intake as well as a higher proportion of lipids of animal
origin are associated with enhanced GWG [66, 497, 510], an effect that
becomes even greater if the woman is obese [38, 478]. Fraser et al. [62]
studied the association between GWG, BMI and waist circumference on the
maternal outcomes 16 years after pregnancy, although they did not
differentiate between overweight and obesity. Not surprisingly, they observed
that women with higher GWG had increased odds of overweight and central
adiposity 16 years after pregnancy whereas reduced body weight and BMI
was associated with previous low GWG [62]. After the IOM revaluated the
GWG guidelines in 2009, more data are available for obese women based on
the severity of obesity [61], and a total GWG between 5-9 kg is currently
recommended. In this study, I considered GWG in the first 34 gestational
weeks, rather than up to delivery, as 34 weeks corresponds to the last weight
measured by professionals and not estimated. This method is supported by
current evidence [62, 482, 511] indicating that GWG is more strongly
associated with early and mid-pregnancy (0-28 gestational weeks), although
it remains difficult to compare across studies because of the various
populations, outcomes and definition of GWG.
In contrast to Mamun et al. [512] and Fraser et al. [62], but in agreement
with Bodnar et al. [513], my results revealed a lower GWG in all women in
higher BMI groups during the first 34 weeks of pregnancy. Nonetheless, it is
significant that overweight and obese mothers without GDM gained
considerably more weight up to the 34th gestational week than those with
GDM, indicating a less closer adherence to the IOM recommendations [61].
In the observational study by Bodnar et al. [513], an increase in the severity
of obesity was associated with a reduction in the levels of excessive weight
gain and higher levels of weight loss during pregnancy.
163
However, the authors were not able to address the causes as their database
lacked essential information such as maternal diet, socioeconomic status and
physical activity. The strength of my research reported here is that data on
these important variables was available, allowing wider interpretation of the
results. For instance, the lower GWG in overweight and obese women with
GDM in my study could reflect their lower macronutrient and energy intake
throughout late pregnancy. I am not aware of whether these women modified
their diet intentionally, before or during pregnancy, with the aim of limiting
weight gain or losing weight. If they did, it could have potentially adverse
consequences for their infants health in the long-term [46, 50]. However,
future research should explore the metabolic mechanisms behind weight loss
and/or low GWG in mothers wiyth high BMI. A follow-up of the study includes
analysis of newborn body composition data and it may assist in our
understanding of the relationship between BMI, GWG and newborn adiposity.
Although overweight and obese women gained, on average, less weight
during pregnancy than their normal weight counterparts, overweight mothers
did exceed the recommended weight gain for their BMI [3]. It must be
pointed out that adequate GWG ranges until the 34th gestational week
recommended to overweight (5.9-9.8 kg) and obese (4.2-7.6 kg) women are
lower than those recommended to lean mothers (9.8-13.6 kg) [61]. As such,
exceeding the IOM weight gain by overweight women might reflect a lack of
awareness or less adherence to the recommended weight gain [3, 66].
Overweight and obese participants seemed willing to improve their diet and
health condition and to be conscious of the negative consequences of gaining
too much weight [514, 515]. A major problem in self-reporting questionnaires
is that women with increased BMI are not very reliable when reporting their
food intake [406-408]. However, energy and macronutrient intake reported
by overweight and obese mothers in my study did not differ from that of lean
control women (Table 3.3), indicating that the lower weight gain of these
women may account for their metabolic adaptation during pregnancy.
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The group of Schebendach et al. observed that, 24 h after a measured
laboratory test meal, obese adults under-reported their food intake by 19%
[407]. Likewise, Poppitt et al. found that obese adult females under-reported
a 1 day observed and measured energy intake by 12.4% [408]. Conversely,
Conway et al. found that obese individuals accurately self-reported their
energy intake [516, 517], implying that diverse populations and study designs
could contribute to this discrepancy.
Reduced food consumption would explain the lower GWG and the significantly
minor proportion of women with GDM exceeding the IOM weight gain limits
compared with their healthy lean counterparts. The majority of overweight
(42.9%) and obese (54.5%) women with GDM gained less than adequate
weight recommended by IOM for their BMI categories and these proportions
were significantly lower than that of lean healthy women (22.4%). As
mentioned in the previous section, upon diagnosis of GDM, diabetic
participants had to undertake several routine medical examinations to control
their glycaemia and were constantly supervised throughout pregnancy.
Additionally, they were referred to a dietician for nutritional counselling in
order to develop appropriate meal plans. These findings support recent
studies about the importance for diabetic women of improving their lifestyle
including dietary pattern [508, 518] and moderate physical activity [483].
When abnormal glucose tolerance is first detected women tend to modify their
dietary habits towards healthier food choices [508, 509]. As the first line of
treatment of GDM was through nutrition and lifestyle advice in maternity
welfare clinics, my results illustrate that the dietary advice received by GDM
women can be effective. Nonetheless, few studies with the aim of improving
dietary intake and increasing physical activity in overweight and obese
pregnant women have been undertaken [486, 515]. Guelinckx et al. [486]
studied 195 obese pregnant women and observed that a lifestyle intervention
of group sessions combined with individual advice improves nutritional habits
without improving their physical activity or GWG.
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As such, a personal nutritional plan consisting of a balanced low caloric diet, a
diary of physical activity and monitoring energy expenditure might help
improve maternal diet thus avoiding excess GWG and GDM development.
3.4.3. Placental and neonatal anthropometry related
to maternal BMI, GDM and GWG
Women with increased BMI and GDM experience a higher incidence of
maternal and neonatal complications [31] as well as LGA (> 90th birthweight
population centile) offspring [33, 34]. This is of increasing public concern as
LGA neonates have a high risk of obesity, insulin resistance and hypertension
in childhood and early adulthood [70, 81]. The incidence of Caesarean
deliveries in my study increased with raised BMI and GDM reaching the
greatest ratio in primiparous obese women with (50%) or without (35%)
diabetes. My findings substantiate earlier reports, which showed a strong
association between BMI and GDM with the increased risk of Caesarean
delivery [31, 35, 519]. Additionally, preterm birth was more common in
participants with GDM with the greatest rate in women who were obese
(25%). Conversely, the effect of obesity per se on prematurity was lower
(9.5%) indicating that GDM combined with high BMI has stronger negative
influence on birth outcome. This is a common complication in women who
enter pregnancy with a high BMI [24, 31] and can be associated with the
development of preeclampsia [37], a condition that increases with the
severity of obesity [31].
Despite similar birth weight, obese patients without hyperglycaemia had
bigger placentas in agreement with previous investigations [14, 47, 93]. At
birth, newborn weight did not significantly differ between groups, although in
the literature obesity and GDM have been associated with enhanced birth
weight [14, 24, 169, 520]. GDM in my participants did not contribute to
greater placental or infant birth weight although current evidence from larger
studies established the additional contribution of maternal hyperglycaemia in
the development of macrosomia and heavier offspring [75, 478].
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In terms of LGA deliveries, the results of this study showed a higher
prevalence of these newborns with increasing pre-pregnancy BMI among
women with (9.1%) or without (19.1%) GDM. Once more, the effect of
hyperglycaemia did not seem to increase the odds of having a LGA infant
(>90th population percentile) as the incidence was higher for obese women
without GDM. These findings are in agreement with epidemiological studies
indicating obesity as a stronger risk factor for the increase risk of having a
LGA infant than GDM [474, 485, 521, 522]. In a large cohort of 12,950
deliveries, Ehrenberg et al. [475] reported the independent association of
high BMI and hyperglycaemia in pregnancy with a raised risk of LGA. In their
population, overweight and obesity in pregnancy exhibit the strongest
influence on the prevalence of LGA infant compared to diabetes, and
increasing BMI directly enhanced the risk of delivering a LGA infant. Similarly,
Ricart et al. [485] examined the relative contribution of pre-pregnancy BMI
and GDM in the development of adverse outcomes in a cohort of 9,270
Spanish women. Although their subjects were overweight, rather than obese,
they reported 13.4% of LGA infants in overweight women without
hyperglycaemia, whereas the contribution of GDM only counted for less than
1% of LGA infants [485]. Recently, Black et al. [1] observed that 21.6% of
LGA infants could be attributed to overweight and obesity without GDM, whilst
2.9% to GDM only. The contributions of both increased BMI and GDM in their
population were additive accounting for the highest proportion of LGA
(23.3%) [1]. Although women with GDM in Ricards study were treated for
hyperglycaemia during pregnancy, which could have reduced their probability
of a LGA birth, the trends of both investigations were similar.
In contrast, I observed that the combined effects of high BMI and GDM did
not increase the risk of having a LGA newborn, which was instead higher in
overweight and obese mothers without GDM. This may be explained by the
small sample size reported here, which significantly reduced the statistical
power.
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Similarly, the dietary treatment that those women with GDM monitored during
pregnancy could have been protective against substantial maternal
hyperglycaemia driving fetal weight gain [226].
Overall, these findings suggest that overweight and obesity in the absence of
GDM may have a more substantial impact on the development of adverse
maternal and perinatal outcomes than GDM itself. A healthy lifestyle along
with a balanced diet and reduced caloric intake might contribute to decrease
the risk of these consequences related to the combined effects of both BMI
and GDM.
Because overweight and obese mothers exceeded the IOM recommendation of
weight gain, I was interested in investigating the effect of GWG on birth
weight and eventually the contribution of each factor (BMI, GDM and GWG)
on this outcome. Weight gain in late pregnancy was positively correlated with
neonatal weight that increased when women were exceeding their
recommended GWG. Birth weight was significantly higher in obese mothers
without GDM when their weight gain at 34 gestational weeks was in the range
of 10.1-14 kg compared to the IOM recommended GWG to delivery (5-9 kg).
These results are consistent with other studies reporting a strong association
between excess weight gain and higher infant weight as well as pregnancy
complications in obese women [1, 62, 65, 474]. Mamun et al. [512] also
observed that the risk for a Caesarean section was more than doubled in their
population when obese women showed excess GWG. Similarly, in this study,
overweight (28.6%) and obese (25%) women without GDM, who gained
excess GWG, had an increased risk of Caesarean section compared to
mothers with healthy BMI. The increase in emergency caesarean sections in
these obese women may be related to the increased number of LGA infants,
or increased fat disposition in the soft tissues of the pelvis, which leads to
dystocia during labour [523]. This risk was further increased in women with
GDM, with the highest proportion of Caesarean section deliveries occurring in
obese mothers when their weight gain was more than recommended by IOM.
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Unfortunately, the low sample size of mothers with GDM did not permit
analysis of the trend of birth weight at different ranges of maternal GWG.
In a multi-linear regression analysis to investigate the odds of increased birth
weight depending on the separate effect of BMI, GDM and GWG, BMI was the
greatest contributor to a raise in birth weight of 22 g, followed by GDM (21 g)
and GWG (17 g). After adjusting for significant confounding variables [62,
486], the effect of each component on newborn weight was similar, whereas
the contribution of other predictors such as maternal age, maternal parity and
newborn gender, corresponded to a decreased in birth weight.
These results corroborate findings from larger human cohorts, which reveal
that high BMI in pregnancy is associated with increased GWG to a greater
extent than hyperglycaemia, resulting in a negative influence on birth weight
[485, 524]. In a retrospective study of 9,835 pregnant women [1], Black and
colleagues reported that the proportion of LGA infants born to overweight
mothers without GDM who gained < 40 pounds (18.14 kg) was similar to that
of women with a healthy BMI who gained the same gestational weight.
Nonetheless, the effect of pre-pregnancy BMI and GDM are additive as the
proportion of LGA infants among overweight mothers with GDM raised
substantially and significantly. Whether this is due to the development of GDM
or high BMI before pregnancy is not understood. Because maternal
overweight and obesity is more common than GDM, this condition could be
identified before pregnancy. As such, targeted interventions at overweight
and obese women to lose weight before getting pregnant and to avoid excess
GWG, regardless of GDM status, has the potential to decrease their high
incidence of LGA offspring and negative outcomes. Finally, the GWG of the
participants was accompanied by a similar trend of weight loss after delivery
(Figure 3.1-A), being significantly lower in overweight and obese mothers
compared to their healthy counterparts. Post-pregnancy weight loss was
halved in overweight and obese women with GDM (Figure 3.1-B), reflecting
their greater weight retention after pregnancy in agreement with previous
findings [48].
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GWG and post-pregnancy weight retention can increase the risk of long term
weight gain with important implications for maternal and offspring obesity
[59, 525]. Higher weight retention in obese women has been associated with
enhanced infant weight gain [59, 525]. Nevertheless, this study reported no
difference between infant weight gains during the first 12 months of life
among any of the observational groups. This is possibly due to the fact that
the study was under powered and did not allow substantiating epidemiological
data found in the literature. The aim of a follow-up study is to increase the
number of participants and investigate infants health in the long term
through measurement of body fat accumulation.
3.4.4. Insulin resistance in pregnancy influences
maternal but not neonatal glycaemia: protective role of
the placenta?
The development of maternal insulin resistance is associated with additional
maternal adipose tissue deposition in early pregnancy and increased feto-
placental nutrient availability in late gestation [121, 148]. Obese [130, 482]
and diabetic [33] gravidae are characterised by greater level of insulin
resistance exposing the fetus to enhanced nutrient availability and insulin
concentrations, which potentially result in fetal overgrowth [75]. My findings
support current literature since plasma glucose and insulin in the participants
increased with enhanced BMI and was significantly higher in obese mothers at
40 gestational weeks. Similarly, GDM mothers with high BMI reported
enhanced circulatory glucose and insulin at 40th gestational weeks. However,
in contrast to what found in the literature, I did not observe any significant
changes in birth weight with either increased maternal BMI or GDM despite
obese mothers having the highest frequency of LGA infants amongst all the
maternal groups. A reasonable explanation is, once more, the power of the
study, which was not strong enough to allow significant comparison between
groups, especially among mothers with GDM.
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Owing to limits on the blood volumes obtained from blood cord sampling, and
the number of other factors studied, there was insufficient blood remaining for
measurement of cord blood insulin. Therefore, it was not possible to
investigate whether maternal hyperglycaemia was associated with increased
levels of insulin in cord blood with potential negative effects in the newborn
[226].
In agreement with Catalano et al. [130], the combined effect of high BMI and
GDM further raised maternal blood glucose and insulin. Nonetheless, cord
blood glucose was comparable between all maternal groups indicating that
glucose transport across the placenta was modified with maternal
hyperglycaemia. Similarly, Desoye et al. found that placental glucose
transport in diet treated GDM is lower than that in normal pregnancies,
whereas insulin treated diabetes led to glucose uptake in the normal range
[295]. In addition, Ericsson et al. reported that insulin did not affect glucose
uptake at term [117] but was associated with enhanced glucose uptake in
primary villous fragments obtained at 68 weeks of gestation [203].
Jansson and colleagues have been investigating placental glucose transport
demonstrating increased glucose transport activity in pregnancies complicated
by type 1 diabetes (T1D) delivering LGA [198] but not GDM associated with
this outcome [200]. They have suggested that hyperglycaemia limits the
sensitivity of glucose transporters in early rather than late gestation leading
to macrosomia and LGA.
Placental weight in my study rose with obesity despite similar neonatal
weight, indicating lower placental efficiency [526] that could compromise fetal
nutrient supply [501, 527]. Placental hypertrophy across obese mothers [526]
could explain this finding, suggesting a difference in placental morphology and
function with obesity. Nevertheless, the lack of knowledge on the effect of
high BMI on placental growth and development triggers the need of further
investigation. Additionally, the HAPO study [528] related GDM with a higher
incidence of macrosomia despite an optimal glycaemic control and suggests
that different nutrients other than glucose can contribute to fetal overgrowth.
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Jansson also indicated that fetal macrosomia observed in GDM pregnancies
might depend on greater uptake of neutral amino acids rather than glucose
[179, 183]. However, opposite findings were reported by Kuruvilla [210],
illustrating, once more, that further studies are warranted.
Elevated lipid concentrations in obese pregnant women have also been related
to increased fetal growth and adiposity [529]. In contrast, my study showed
no differences in TG concentrations in either maternal or cord blood. These
results were confirmed by analysis of placental TG content, which were not
altered by either BMI or GDM. Di Cianni et al. [530] reported a significant
correlation between maternal TG concentrations in late pregnancy and fetal
growth/adiposity. These clinical observations were supported by Radaelli et al.
[215] who demonstrated that enzymes related to lipid metabolism, in contrast
to glucose, are increased in placenta of obese women with GDM.
Overall, lipid and protein metabolism in women with high BMI and GDM
participating in this study does not appear to be substantially modified and
does not contribute to negative pregnancy outcomes. On the other hand, a
positive correlation was found between maternal glucose at delivery and fetal
growth at late gestation, and between placental weight and cord blood
glucose in obese women with GDM. Glucose concentrations of either the
mother or the fetus, in obese mothers, might be, therefore, responsible to
their bigger placentas. However, it is not clear whether it is the placenta
driving fetal size or the fetus causing placental overgrowth.
A growing body of evidence on the effects of GDM on placental development
reports that GDM, even with optimal glycaemic control [168], is associated
with greater placental weights [186] and placental-birth weight ratios [169].
On the contrary, this study showed similar placental and placental-birth
weight ratios within GDM participants. Although placentas of obese mothers
with GDM had similar weight to that of their obese counterparts, no
statistically significant differences were observed in placental weight as a
consequence of obesity combined with GDM.
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This is probably due to the small sample size and their bigger variability,
which reduced the power of the analysis. Whether placental function is
influenced by maternal hyperglycaemia, through changes in its surface area,
vascularity and cell composition is unclear. Abnormal maternal glycaemia has
been associated with morphological abnormalities [174], including changes in
the villous surface area [171] and deposition of perivillous fibrinoid [172,
175]. As very few studies relating maternal obesity to placental morphology
can be found in the literature [153, 526, 531], an interesting comparison
could be the single and combined effect of both high BMI and GDM. Maternal
diet could potentially explain the lack of difference in placental or birth
weights, despite maternal hyperglycaemia, in women with GDM, who reported
to consume a low glycaemic index and healthy diet [486, 503]. To date, the
primary means to prevent the development of insulin resistance are lifestyle
measures of diet, activity and prevention of pre-pregnancy obesity [3, 532,
533]. Therefore, it appears sensible to stress the importance of lifestyle
measures in order to prevent the potential long-term implications of altered
fetal growth. Implementation of a low-GI diet may thus be a useful guideline
in the prevention of obesity among women of childbearing age [55, 486, 497,
534].
In conclusion, my findings illustrate critical points, which are of importance for
improving health and long term care in the population. Firstly, the adverse
outcomes of obesity in pregnancy may be ameliorated through good regular
clinical control where patients are educated towards healthy lifestyle choices
as highlighed participants with GDM. Secondly, as the introduction of physical
activity programmes and nutritional interventions in previous longitudinal
studies have shown beneficial effects, it might be advisable to include these
programmes in the health care of overweight and obese women. These
targeted interventions could avoid excess weight gain throughout pregnancy
and high post-delivery weight retention, thus reducing the high risk of deliver
of a LGA infant often observed in those women.
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Chapter 4 - Effect of BMI and
gestational diabetes on
placental metabolism
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4.1. Introduction and hypotheses
Altered placental function is a primary mechanism, which links maternal
nutritional status and the predisposition of metabolic disease as the placenta
represents the main nutritional interface between the mother and her fetus
[204, 205, 535]. This Chapter will further investigate the effect of entering
pregnancy with a high BMI and/or gestational diabetes on key mechanisms
regulating placental energy metabolism and potential implication for the
newborn.
As discussed in the Introduction (Chapter 1), maternal physiology in
pregnancy is further modified by obesity [263] and diabetes [252], resulting
in a greater degree of insulin resistance. This is associated with an imbalanced
store of nutrients and excessive release of inflammatory markers, such as
leptin and cytokines [95-97]. Consequently, fetal hyperinsulinaemia and/or
hyperleptinemia can stimulate fetal growth and has been associated with
insulin and leptin resistance during adulthood [255, 256]. The aim of this
Chapter is to examine links between maternal and fetal outcomes through
modifications in placental gene expression profile.
Changes in cellular energy levels not only promote internal pathways involved
in the regulation of energy metabolism and transport, they also stimulate
additional mechanisms, which, in turn, govern pro-inflammatory pathways
and cellular functions [535].
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1. My previous results showed that insulin resistance of obese and
diabetic pregnant women resulted in differences in glucose
concentration gradient between mother and fetus associated with
changes in placental weight but no effects on newborn growth. As
post-receptor defects in the insulin signalling cascade have been
proposed to link obesity, insulin resistance and inflammation [73, 106,
107], my hypothesis was that components of this signalling, i.e.
insulin-like growth factor-1 receptor (IGFR1), insulin receptor
substrate-1 (IRS1) and v-akt murine thymoma viral oncogene homolog
1 (Akt) within the placenta would be modified with high BMI and
gestational diabetes.
2. Placental and fetal growths are regulated by maternal concentrations
of leptin [101] and glucocorticoids (GC) [185], through an interaction
with insulin signalling cascade. The placenta also secretes leptin, thus
contributing to maternal hyperleptinaemia in pregnancy [242], and
protects the fetus from an excess of GC exposure by producing the
HQ]\PH EHWD K\GUR[\VWHURLG GHK\GURJHQDVH W\SH ǃ+6'
Therefore, I tested the hypothesis that obesity and diabetes in
pregnancy would increase leptin concentrations in the mother in
addition to altering the expression of this hormone and its receptor
(LEPR) in the placenta. Moreover, I hypothesised that placental
ǃ+6'DQG*&UHFHSWRU*5ĮZRXOGEHUHGXFHGDVDFRQVHTXHQFH
of high BMI and glucose tolerance in pregnancy.
3. Insulin, IGF1 and leptin are upstream regulators of the mammalian
target of rapamycin (mTOR) [302], which is a positive regulator of
trophoblast transporters and enzymes involved in energy intake and
metabolism [304]. Along with AMP-activated protein kinase (AMPK),
mTOR regulates mitochondrial energy metabolism via changes in
uncoupling protein-2 (UCP2) and nuclear factor kappa B (NFkB) action,
thus promoting cellular pro-inflammatory and pro-oxidative pathways
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[536]. The activity of mTOR is negatively regulated by sirtuin-1
(SIRT1) [333], an antioxidant protein contributing to cell survival
[335]. Excess fat mass and/or altered glucose metabolism can,
therefore, modify the expression of these key metabolic regulators and
potentially alter fetal homeostasis. Analysis of placental thiobarbituric
reactive oxygen species (TBARS) concentrations, as a marker of
oxidative stress [332], would help to elucidate the degree of oxidative
stress in placenta of women with high BMI and gestational diabetes.
4. Finally, the peroxisome-proliferator activated receptor-gamma (PPAR-
gamma) acts as an anti-inflammatory factor and regulates pathways
influencing cellular fatty acid uptake and transport [308, 313]. The
toll-like receptor-4 (TLR4) is also activated by free fatty acids (FFA)
and is the main placental receptor that stimulates the pro-
inflammatory response to bacterial infection [537]. Alterations of those
proteins may play a major role in the low grade inflammatory response
frequently observed with obesity [95, 538] and diabetes [94, 96, 97].
Additionally, markers of macrophage infiltration, such as CD14 and
CD68, may confirm higher degree of inflammation in these complicated
pregnancies [451].
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4.2. Materials and methods
A more detailed description of the study can be found in Materials and
Methods (Chapter 2). Pregnant women participating in the Preobe study (P06-
CTS-02341) were recruited in the 20th week of pregnancy and classified
according to their BMI. They were further classified at 28 weeks of gestation
on the basis of BMI and glucose tolerance, making six groups (Chapter 2,
Section 2.2, Figure 2.2).
Collection of maternal venous blood was performed at 24, 34 and 40 weeks of
gestation for women in the BMI group whereas blood samples from
participants with gestational diabetes were measured only at weeks 34 and 40
(Figure 4.1).
Figure 4.1: Programme of evaluations in the Preobe study.
Maternal examinations during gestation and after delivery. Collection of samples and
measurements are reported in white boxes whereas greyed out boxes represent time
before, during and after pregnancy. Aspects studied in this Chapter are highlighted in
white boxes marked with solid black line.
At delivery, umbilical venous blood samples were collected and placentas
were snap frozen and stored at -80oC for further analysis in Nottingham.
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After birth, umbilical venous blood samples were collected and placentas were
snapped frozen and stored at -80oC for further analysis in Nottingham.
Total RNA was extracted from 100 mg placental samples with TRI Reagent®
and chloroform and cDNA obtained using the High Capacity RNA-to-cDNA kit
(Applied Biosystems, CA 94404, USA). Key molecular proteins involved in
LQVXOLQVLJQDOOLQJ,*)5 ,65JOXFRFRUWLFRLGPHWDEROLVP*5Įǃ+6'
nutrient transport and energy sensing (mTOR, Akt, p70S6K, AMPK, leptin,
/(35 PLWRFKRQGULDO ELRDFWLYLW\ 6,57 8&3 DQG LQIODPPDWLRQ 33$5Ǆ
TLR4) were analysed within the placenta using RT-QPCR.
The thiobarbituric acid reactive substances (TBARS) method, based on the
reaction between malondialdehyde (MDA) and thiobarbituric acid (TBA), was
used as an index of lipid peroxidation to measure global oxidative stress, a
well-established mechanism of cellular injury often linked to obesity and
diabetes [441, 442]. As such, for quantitative measurement of TBARS
concentrations, the Oxiselect TBARS Assay kit (Cell Biolabs Inc, CA, USA)
was used [539] and the bicinchoninic acid total protein (BCA) method (Sigma-
Aldrich kit) was applied to estimate the MDA content of the samples.
An attempt to look at placental inflammation through macrophages infiltration
[451] by using antibodies for CD14 and CD68 was executed; however, a lack
of antibody specificity did not permit successful completion of this planned
analysis (see Chapter 2, Section 2.10.1, Figure 2.11 for details).
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4.3. Results
4.3.1. Maternal and cord blood physiological
outcomes
As discussed in Chapter 3, maternal plasma glucose concentrations at term
increased with both obesity and GDM independently, and with the combined
effect of the two. This was accompanied by enhanced maternal insulin at late
gestation as a consequence of maternal obesity alone and when it is
accompanied by GDM (Chapter 3, Figure 3.3-3.4). Leptin concentrations in
maternal plasma increased throughout, and after, pregnancy with maternal
obesity (Figure 4.2).
Figure 4.2: Effect of maternal BMI on maternal plasma leptin concentrations
at 24, 34, 40 gestational weeks (24, 34, 40 prenatal), 24 weeks after delivery
(24 postnatal), and on fetal plasma leptin concentrations in cord blood
(birth).
Orange markers represent control (maternal blood, n=59; cordblood, n=33), green
markers overweight (maternal blood, n=29; cordblood, n=15) and blue markers obese
(maternal blood, n=22; cordblood, n=12) pregnant women. Data represent means ±
S.E.M. Statistical differences between groups denoted at each time point by *, **, ***
corresponds to p<0.05, p<0.01 and p<0.001 respectively compared to control group
(1-way ANOVA; Bonferroni post-hoc test).
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Similarly, cord blood leptin concentrations were significantly higher in
neonates of obese mothers compared with their lean counterparts.
Interestingly, leptin concentrations in maternal plasma showed very weak
correlation with maternal BMI, and no correlation was found between
maternal leptin concentrations and placental or neonatal weight. Conversely,
leptin concentrations in cord blood were positively associated with placental
(R2=0.43, p=0.049, n=110) and newborn weight (R2=0.52, p=0.019,
n=110).
GDM alone did not affect plasma leptin in the mother but when GDM was
accompanied with high BMI, leptin concentrations at term and 24 postnatal
weeks were significantly raised (Figure 4.3).
Figure 4.3: Effect of maternal BMI on maternal plasma leptin concentrations
at 24, 34, 40 gestational weeks (24, 34, 40 prenatal), 24 weeks after delivery
(24 postnatal), and on fetal plasma leptin concentrations in cord blood
(birth).
Orange markers represent control (maternal blood, n=59; cordblood, n=33), red
markers lean gestational diabetic (maternal blood, n=14; cordblood, n=7), purple
markers overweight gestational diabetic (maternal blood, n=14; cordblood, n=12),
and blue markers obese gestational diabetic (maternal blood, n=11; cordblood, n=7)
pregnant women. Data represent means ± S.E.M. Statistical differences between
groups denoted by * at each time point corresponds to p<0.05 (1-way ANOVA;
Bonferroni post-hoc test).
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Furthermore, there was a trend (p=0.08) to raised leptin concentrations in
cord blood of lean women with GDM but not when GDM was associated with
high BMI.
Surprisingly, inflammatory markers in maternal plasma were not influenced
by high maternal BMI throughout pregnancy (Table 4.1).
Table 4.1: Maternal counts of white blood cells at 24, 34 and 40 gestational
weeks (gw) in control (C), overweight (OV) and obese (OB) pregnant women.
Maternal white
blood cells (106 µl)
C
(n=59)
OV
(n=29)
OB
(n=22)
Monocytes
24 gw 0.50±0.02 0.50±0.03 0.52±0.02
34 gw 0.53±0.02 0.56±0.03 0.58±0.03
40 gw 0.56±0.03 0.57±0.04 0.60±0.04
Neutrophils
24 gw 7.57±0.26 7.68±0.36 7.69±0.57
34 gw 7.53±0.27 7.92±0.39 7.89±0.50
40 gw 11.50±0.57 11.72±1.02 12.19±0.99
Lymphocytes
24 gw 1.84±0.07 1.80±0.09 1.74±0.10
34 gw 1.78±0.07 1.83±0.09 1.70±0.09
40 gw 1.41±0.09 1.53±0.11 1.27±0.17
Data are expressed as relative to control group and represents mean ± S.E.M.; n =
women/group.
However, monocyte levels in cord blood were higher in newborns from obese
mothers compared to their lean counterparts and cord neutrophils had a trend
(p=0.09) to increase with obesity (Table 4.2).
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Table 4.2: Cord blood counts of white blood cells in infants of control (C),
overweight (OV) and obese (OB) pregnant women.
Cord blood white
blood cells (106 µl)
C (n= 33) OV (n=15) OB (n=12)
Monocytes 0.97±0.07 1.07±0.11 1.53±0.18
**
Neutrophils 7.55±0.51 8.98±1.44 11.32±1.44
Lymphocytes 4.43±0.29 4.19±0.35 4.77±0.86
Data are expressed as relative to control group and represents mean ± S.E.M.; n =
women/group. Data represent means ± S.E.M. Statistical differences denoted by **
correspond to p<0.01 compared to infant of control women (1-way ANOVA; Bonferroni
post-hoc test).
Similarly, GDM did not influence the concentrations of inflammatory markers
in either maternal or cord blood as illustrated in Tables 4.3 and 4.4.
Table 4.3: Maternal counts of white blood cells at 24, 34 and 40 gestational
weeks (gw) in control (C), gestational diabetic lean (GDL), gestational
diabetic overweight (GDOV) and gestational diabetic obese (GDOB) pregnant
women.
Maternal white
blood cells (106 µl)
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
Monocytes
34 gw 0.53±0.02 0.50±0.05 0.48±0.03 0.46±0.04
40 gw 0.56±0.03 0.64±0.09 0.42±0.07 0.39±0.08
Neutrophils
34 gw 7.53±0.27 6.58±0.53 7.53±0.47 7.25±1.01
40 gw 11.50±0.57 11.33±1.19 9.69±2.01 9.16±1.12
Lymphocytes
34 gw 1.78±0.07 1.76±0.19 1.52±0.12 1.61±0.12
40 gw 1.41±0.09 1.47±0.24 0.88±0.19 1.34±0.27
Data are expressed as relative to control group and represents mean ± S.E.M.; n =
women/group.
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Table 4.4: Cord blood counts of white blood cells in infants of control (C),
gestational diabetic lean (GDL), gestational diabetic overweight (GDOV) and
gestational diabetic obese (GDOB) pregnant women.
Cord blood white
blood cells (106 µl)
C
(n=33)
GDL
(n=7)
GDOV
(n=12)
GDOB
(n=7)
Monocytes 0.97±0.07 1.26±0.25 1.16±0.20 1.24±0.15
Neutrophils 7.55±0.51 8.20±1.43 6.16±0.87 6.47±1.32
Lymphocytes 4.43±0.29 4.60±0.58 4.61±1.01 4.63±0.81
Data are expressed as relative to control group and represents mean ± S.E.M.; n =
women/group.
4.3.2. Placental glucose metabolism and gene
expression
Being either overweight or obese was not associated with changes in the
expression of genes regulating cellular growth within the placenta as
described in Table 4.5.
Table 4.5: Placental gene expression of target genes involved in cellular
growth relative to housekeeping gene (ribosomal 18S) in control (C),
overweight (OV) and obese (OB) pregnant women.
Placental gene
expression (a.u.)
C (n=59) OV (n=29) OB (n=22)
IGFR1 1.00±0.07 1.17±0.15 1.20±0.18
IRS1 1.00±0.09 1.11±0.14 1.45±0.24
GHRL 1.00±0.15 1.24±0.20 1.24±0.23
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
Gene expression of mTOR decreased with obesity (Figure 4.4) and was
positively correlated with fetal, but not placental, weight at 34 gestational
weeks (R2=0.52, p=0.019, n=110). However, no changes in either the
upstream (Akt) or downstream (p70S6K) signalling molecules were observed
(Table 4.6).
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Figure 4.4: Effect of maternal BMI on the mRNA expression of placental
mammalian target of rapamycin (mTOR) as determined by real-time PCR.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=59); OV:
overweight (n=29); OB: obese (n=22). Data are non parametric and represent mean
± S.E.M; a.u.: arbitrary units; n = women/group. Statistical differences denoted by *
corresponds to p<0.05 (Kruskal-Wallis; Mann Whitney post-hoc test).
Table 4.6: Placental gene expression of target genes involved in mTOR
signalling relative to housekeeping gene (ribosomal 18S) in control (C),
overweight (OV) and obese (OB) pregnant women.
Placental gene
expression (a.u.)
C (n=59) OV (n=29) OB (n=22)
Akt1 1.00±0.08 1.01±0.16 1.17±0.20
p70S6KB1 1.00±0.12 1.08±0.20 1.57±0.37
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
Despite a marked increase in plasma leptin at term and cord blood leptin in
infants of obese mothers, no changes in the mRNA abundance of either
placental leptin or LEPR with increased BMI were observed (Table 4.7).
185
Table 4.7: Placental gene expression of target genes involved in energy
sensing signalling relative to housekeeping gene (ribosomal 18S) in control
(C), overweight (OV) and obese (OB) pregnant women.
Placental gene
expression (a.u.)
C (n=59) OV (n=29) OB (n=22)
AMPK 1.00±0.07 0.94±0.10 0.97±0.19
LEP 1.00±0.21 1.51±0.49 0.90±0.38
LEPR 1.00±0.20 0.83±0.14 1.06±0.29
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
Neither AMPK expression (Table 4.7) nor the expression of genes implicated in
FRUWLFRVWHURLG PHWDEROLVP +6'% *5Į 7DEOH  ZHUH LQIOXHQFHG E\
either being overweight or obesity in pregnancy.
Table 4.8: Placental gene expression of target genes involved in
glucocorticoids metabolism relative to housekeeping gene (ribosomal 18S) in
control (C), overweight (OV) and obese (OB) pregnant women.
Placental gene
expression (a.u.)
C (n=59) OV (n=29) OB (n=22)
*5Į 1.00±0.07 1.17±0.09 0.99±0.10
HSD11B2 1.00±0.18 1.16±0.26 0.74±0.17
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
Similarly, neither GDM alone nor GDM combined with increased BMI affected
the expression of genes involved in cellular growth (Table 4.9).
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Table 4.9: Placental gene expression of target genes involved in cellular
growth relative to housekeeping gene (ribosomal 18S) in control (C), lean
with GDM (GDL), overweight with GDM (GDOV) and obese with GDM (GDOB)
pregnant women.
Placental gene
expression (a.u.)
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
IGFR1 1.00±0.07 0.98±0.12 0.91±0.06 0.83±0.10
IRS1 1.00±0.09 0.91±0.15 0.93±0.10 0.80±0.09
GHRL 1.00±0.15 1.17±0.23 0.98±0.19 1.05±0.21
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
The downstream insulin signalling in placentas from GDM women was
characterised by a trend in mTOR (p=0.08, Figure 4.5) to decrease when
GDM was combined with obesity.
Figure 4.5: Effect of GDM on the mRNA expression of placental mammalian
target of rapamycin (mTOR) as determined by real-time PCR.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give the fold change. C: control (n=59); GDL: lean
women with GDM (n=14); GDOV: overweight women with GDM (n=14); GDOB: obese
women with GDM (n=11). Data are non parametric and represent mean ± S.E.M; a.u.:
arbitrary units; n = women/group.
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This was not accompanied by any changes in the expression of its upstream
and downstream signalling molecules (Akt and p70S6K) (Table 4.10).
Table 4.10: Placental gene expression of target genes involved in mTOR
signalling relative to housekeeping gene (ribosomal 18S) in control (C), lean
with GDM (GDL), overweight with GDM (GDOV) and obese with GDM (GDOB)
pregnant women.
Placental gene
expression (a.u.)
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
Akt1 1.00 ± 0.08 0.82 ± 0.10 0.80 ± 0.07 0.88 ± 0.12
p70S6KB1 1.00 ± 0.12 0.73 ± 0.18 1.09 ± 0.24 1.38 ± 0.21
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
The expression of genes related to energy sensing regulation was influenced
by diabetes in pregnancy. Decreased AMPK expression was observed with
GDM alone and when GDM was combined with high BMI (Figure 4.6).
Figure 4.6: Effect of GDM and BMI on the mRNA abundance of placental AMP-
activated protein kinase (AMPK) as determined by real-time PCR.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give the fold change. C: control (n=59); GDL: lean
women with GDM (n=14); GDOV: overweight women with GDM (n=14); GDOB: obese
women with GDM (n=11). Data are non parametric and represent mean ± S.E.M; a.u.:
arbitrary units; n = women/group. Statistical differences denoted by *, ** correspond to
p<0.05 and p<0.01 (Kruskal-Wallis; Mann Whitney post-hoc test).
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The increased plasma leptin at term in lean mothers with GDM (Figure 4.3)
was not accompanied by any changes in LEPR expression between GDM
groups, although a trend (p=0.07) was observed between lean mothers with
GDM and lean controls (Table 4.11).
Table 4.11: Placental gene expression of target genes involved in energy
metabolism relative to housekeeping gene (ribosomal 18S) in control (C),
lean with GDM (GDL), overweight with GDM (GDOV) and obese with GDM
(GDOB) pregnant women.
Placental gene
expression (a.u.)
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
LEPR 1.00 ± 0.20 0.48 ± 0.05 0.49 ± 0.09 0.51 ± 0.09
ǃ+6' 1.00 ± 0.18 0.67 ± 0.20 0.97 ± 0.23 0.88 ± 0.35
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
However, placental LEP was upregulated in lean women with GDM (Figure
4.7), reflecting the trend of leptin concentrations to increase in cord blood of
these women (Figure 4.3).
Figure 4.7: Effect of GDM and BMI on the mRNA abundance of placental leptin
(LEP) as determined by real-time PCR.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give the fold change. C: control (n=59); GDL: lean
women with GDM (n=14); GDOV: overweight women with GDM (n=14); GDOB: obese
women with GDM (n=11). Data are non parametric and represent mean ± S.E.M; a.u.:
arbitrary units; n = women/group. Statistical differences denoted by * corresponds to
p<0.05 (Kruskal-Wallis; Mann Whitney post-hoc test).
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Genes related to local cortisol production showed a clear effect of GDM.
([SUHVVLRQ RI SODFHQWDO *5Į LQFUHDVHG LQ SUHJQDQFLHV FRPSOLFDWHG E\ *'0
compared to controls and the combined effect of GDM with high BMI led to
overexpression of this corticoid receptor (Figure 4.8).
Figure 4.8: Effect of gestational diabetes on the mRNA abundance of placental
JOXFRFRUWLFRLGUHFHSWRUDOSKD*5ĮDVGHWHUPLQHGE\UHDOWLPH3&5
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give the fold change. C: control (n=59); GDL: lean
women with GDM (n=14); GDOV: overweight women with GDM (n=14); GDOB: obese
women with GDM (n=11). Data are non parametric and represent mean ± S.E.M; a.u.:
arbitrary units; n = women/group. Statistical differences annotated by *, ** correspond
to p<0.05 and p<0.01 respectively (Kruskal-Wallis; Mann-Whitney post-hoc test).
,QWHUHVWLQJO\QRGLIIHUHQFHLQWKHP51$DEXQGDQFHRIWKHHQ]\PHǃ+6'
was observed (Table 4.11).
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4.3.3. Placental antioxidant and inflammatory
response
Although both maternal overweight and obesity during pregnancy were
associated with changes in placental anti-oxidative response, such differences
were not detected as a consequence of GDM.
The two fold downregulation of placental mTOR with obesity (Figure 4.4) was
accompanied by a 1.5 fold upregulation of SIRT1 (Figure 4.9) and UCP2
(Figure 4.10) within the placenta. Similarly, maternal overweight led to
increased placental SIRT1 and UCP2 expression compared to lean control
mothers.
Figure 4.9: Effect of maternal BMI on the mRNA expression of sirtuin 1
(SIRT1) as determined by real-time PCR.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=59); OV:
overweight (n=29); OB: obese (n=22). Data are non parametric and represent mean
± S.E.M; a.u.: arbitrary units; n = women/group. Statistical differences denoted by
*,** corresponds to p<0.05 and p<0.01 respectively (Kruskal-Wallis; Mann Whitney
post-hoc test).
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Figure 4.10: Effect of maternal BMI on the mRNA expression of placental
uncoupling protein 2 (UCP2) as determined by real-time PCR.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=59); OV:
overweight (n=29); OB: obese (n=22). Data are non parametric and represent mean
± S.E.M; a.u.: arbitrary units; n = women/group. Statistical differences denoted by
*,** corresponds to p<0.05 and p<0.01 respectively (Kruskal-Wallis; Mann Whitney
post-hoc test).
Figure 4.11: Effect of maternal BMI on placental thiobarbituric acid reactive
substances (TBARS) determined as the ratio of malondialdehyde (MDA) and
protein concentrations.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=59); OV:
overweight (n=29); OB: obese (n=22). Data are non parametric and represent mean
± S.E.M; a.u.: arbitrary units; n = women/group.
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Placental TBARS concentrations were not statistically different between any of
the groups (Figure 4.11) confirming placental gene expression analysis, which
indicated inhibition of placental pro-oxidative response (Figure 4.3, 4.9 and
4.10).
On the other hand, maternal GDM did not influence placental antioxidant
response as reflected by an absence of an effect on UCP2 expression and
TBARS concentration (Table 4.12). The mRNA abundance of SIRT1 within the
placenta of GDM women had a trend (p=0.08) to increase when the effect of
GDM was combined with high BMI.
Table 4.12: Placental gene expression of sirtuin-1 (SIRT1) and uncoupling
protein-2 (UCP2) relative to housekeeping gene (ribosomal 18S), and
placental thiobarbituric acid reactive substances (TBARS) in control (C), lean
with GDM (GDL), overweight with GDM (GDOV) and obese with GDM (GDOB)
pregnant women.
Placental gene
expression (a.u.)
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
SIRT1 1.00±0.11 0.79±0.21 1.57±0.31 1.52±0.35
UCP2 1.00±0.16 1.31±0.38 0.93±0.23 0.76±0.30
Placental TBARS
0'$ǋ0
3URWHLQǋJPO
1.00±0.04 0.95±0.09 0.73±0.13 1.02±0.10
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group;
MDA: malondialdehyde.
Placental expression of genes involved in the inflammatory response (TLR4,
PPARڸ) did not change with maternal BMI (Table 4.13) or gestational diabetes
(Table 4.14), reflecting the concentrations of inflammatory markers in
maternal plasma (Table 4.1 and Table 4.3 respectively).
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Table 4.13: Placental gene expression of toll-like receptor-4 (TLR4) and
peroxisome proliferator receptor gamma (PPARڸ) relative to housekeeping
gene (ribosomal 18S) in control (C), overweight (OV) and obese (OB)
pregnant women.
Placental gene
expression (a.u.)
C (n=59) OV (n=29) OB (n=22)
TLR4 1.00±0.10 0.90±0.08 0.93±0.11
33$5Ǆ 1.00±0.09 0.93±0.07 0.95±0.09
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
Table 4.14: Placental gene expression of toll-like receptor-4 (TLR4) and
peroxisome proliferator receptor gamma (PPARڸ) relative to housekeeping
gene (ribosomal 18S) in control (C), lean with GDM (GDL), overweight with
GDM (GDOV) and obese with GDM (GDOB) pregnant women.
Placental gene
expression (a.u.)
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
TLR4 1.00±0.10 0.80±0.13 0.84±0.09 0.81±0.16
33$5Ǆ 1.00±0.09 1.03±0.16 1.08±0.10 0.87±0.07
Data are non parametric and expressed as normalised ratio relative to the mean of
control group. Data represent mean ± S.E.M; a.u.: arbitrary units; n = women/group.
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4.4. Discussion
This study is the first to systematically compare the effects of both high
maternal BMI and GDM on the regulation of placental energy homeostasis
focusing on the main factors regulating placental nutrient transport capacity.
As such, critical cellular mechanisms, which can contribute to long term
adverse outcomes associated with both maternal obesity and gestational
diabetes, have been highlighted.
4.4.1. Influence of high maternal BMI and diabetes
in pregnancy on placental insulin signalling
As discussed in Chapter 3, one of the major interventions aimed at decreasing
the risk of becoming obese in pregnancy is to limit maternal weight gain by
reducing food intake [24, 523, 540]. The outcomes presented in this Chapter
indicate that such an intervention should be carefully considered as in the
obese groups, characterised by the smallest increase in gestational weight
gain, upregulation of hormonal regulators involved in insulin signalling within
the placenta did not occur.
The pathophysiology of insulin resistance involves abnormalities of insulin-
sensitive tissues and insulin signalling [73, 106, 107], which lead to an
inadequate insulin response [96]. My previous results showed that increased
maternal insulin and glucose concentrations at term in obese and diabetic
women occurred without altered fetal growth, newborn weight or changed
glucose concentrations in cord blood (Chapter 3). As such, I hypothesised that
components of insulin signalling within the placenta would be modified by
altered maternal BMI and glucose tolerance to compensate for enhanced
maternal substrate supply. Insulin and IGFs are growth factors implicated in
fetal growth, which act through the activation of their receptors (IR and
IGF1R) leading to phosphorylation of IRS1 and activation of insulin
downstream signalling [240, 541].
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In this study, no changes in the expression of placental IGFR1 and IRS1 were
observed in either women with high BMI or GDM. Previous studies on skeletal
muscle and adipose tissue [109, 131], showed decreased expression of IRS1
protein and upregulation of IRS2 associated with impaired insulin action in
lean and obese pregnant women with GDM (Figure 4.13). Similarly, Colomiere
et al. [195] found a significant reduction of IRS1 protein expression in human
term placenta of lean and obese mothers with insulin-dependent GDM, whilst
obesity or GDM diet-treated alone did not influence the expression of this
receptor. The same authors reported enhanced IRS2 with insulin- and diet-
treated GDM and with obesity alone, suggesting a compensatory relationship
between these two insulin substrate receptors [195].
The lack of difference in the expression of placental IRS1 and IGFR1 observed
in my study can be explained as a placental compensatory mechanism against
maternal hyperinsulinaemia and hyperglycaemia (see details in Chapter 3). In
fact, placental adaptive regulation involves a change in the expression or
activity of specific transporters, like insulin/IGFs receptors and glucose
transporters, in response to altered substrate concentrations [183, 270].
However, this placental response is not seen within the range of glucose
concentrations normally observed in maternal diabetes [542]. Therefore, the
severity of diabetes and/or the method of glycaemic control after GDM
diagnosis might account for the disparity between my study and those of
others. This would additionally accord with similar concentrations of cord
blood glucose reported here.
Table 4.15 summarises some of the findings reporting the effects of obesity
and GDM on the expression of insulin signalling components, leptin and leptin
receptor in different maternal tissues, placenta and fetus.
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Table 4.15: Effect of maternal obesity (A) and gestational diabetes (B) on the
concentrations and/or expression (mRNA or protein) of different hormones
and receptors in the mother, placenta and fetus.
A) Factor Mother Placenta Fetus
Insulin [83, 93, 216, 236, 253, 543] ļ1 Ĺ1 - ļ1 Ĺ1
IGF1 [236, 241] Ĺ1 n.m. Ĺ1
IGF2 [236, 544] Ĺ1 n.m. Ĺ1
IRS1 [2, 109, 195] Ļ2 Ĺ1 Ļ2 ļ2 n.m.
IRS2 [195] Ĺ Ĺ1 ļ2 n.m.
Leptin [83, 93, 216, 236, 253, 543] Ĺ1 ļ1 ļ1 Ĺ1
LEPR [253] n.m. Ļ1 n.m.
B) Factor Mother Placenta Fetus
Insulin [11, 130, 237, 295] Ĺ3,4 - Ĺ3,4
IGF1 [237, 295] Ĺ
4
ļ
3,4
Ļ
3 ļ3 Ļ4 Ĺ3,4
IGF2 [237, 295] Ĺ3,4 ļ3,4 Ĺ3,4 Ļ4 Ĺ3,4
IRS1 [109, 131, 195, 545] Ļ
3 Ļ3 ļ4 Ĺ3 n.m.
IRS2 [131, 195] Ĺ3 Ĺ3,4 n.m.
Leptin [214, 259, 545-548] Ĺ3 Ĺ3,4 ļ3,4 Ĺ3,4
LEPR [214, 259, 545] Ĺ3 ļ3 Ĺ
3,4
ļ
3 n.m.
Higher (Ĺ), lower (Ļ) or similar (ļ) levels in obese (1), obese gestational diabetes
insulin (2), T1D (3), GDM (4) compared to normal pregnancies; n.m.: not measured. In
the legend IGF1: insulin growth factor-1; IGF2: insulin growth factor-2; IRS1: insulin
substrate receptor-1; IRS2: insulin substrate receptor-2; LEPR: leptin receptor.
Similar to insulin, the adipokine leptin stimulates cell proliferation by inducing
the IRS1/MAPK pathway in a glucose-dependent manner [549]. Circulating
leptin dramatically increases during late pregnancy [550], suggesting a
contribution of placental leptin [550, 551] to maternal hyperleptinaemia.
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Leptin produced within the placenta has been reported to have a different role
from that in the hypothalamus, where it acts as a sensor for appetite
regulation [242, 246]. In agreement with previous studies [252, 253], my
results reported higher maternal leptin concentrations with obesity alone and
when obesity was accompanied by GDM. Increased adipocyte numbers, as the
main source of leptin [263], in pregnant obese women might account for their
higher leptin concentrations compared to lean mothers. Nonetheless, the
contribution of locally produced leptin by trophoblast cells is also expected to
underlie the hyperleptinaemia of pregnancy [244, 550]. Placental leptin mRNA
abundance was not different in pregnancies complicated by high BMI than
those in lean control women. This suggests that increased adiposity, rather
than placental leptin, accounts more for enhanced leptin at term in these
mothers. Similar conclusions can be drawn for obese mothers with GDM, who
had higher maternal leptin concentrations but no differences in placental
leptin expression.
Conversely, placentas of lean women with GDM had higher leptin expression
despite similar maternal blood concentrations at term. These results are in
agreement with the findings of other authors [214, 259], who have shown
increased placental leptin in GDM pregnancies, although these studies did not
look at maternal or fetal outcomes.
The mRNA abundance of the placental leptin receptor, mainly located on the
maternal side of the syncytiotrophoblast [550], was unaltered with either
obesity or GDM, substantiating the results of Meller et al. [259] but not
Radaelli et al. [214], who reported, instead, a 4.3 fold upregulation of this
receptor with GDM. In the study of Gavrilova et al., the soluble leptin receptor
(ObRe) was reported to increase with insulin-dependent diabetes [258]. My
findings reported total leptin receptor expression without differentiating all its
splice variants. As such, it might be that different receptors account for
maintaining similar leptin concentrations in both mother and fetus because of
placental hyperleptinaemia in lean women with GDM.
198
Obesity in pregnancy, which was associated with maternal hyperleptinaemia
at term, did not result in changes of leptin receptor gene expression within
the placenta. Leptin is co-localised to both syncytiotrophoblast and villous
endothelial cells, and it is likely to be released into both the maternal and
fetal blood circulation [244, 252]. The expression of its receptor on the MVM
of the syncytiotrophoblast suggests a possible autocrine role of leptin at the
maternal side [244, 252]. Although total leptin receptor expression was not
modified at a gene expression level, alteration in its activity or changes in the
expression of different isoforms might have occurred with obesity, thus
contributing to the higher placental weight observed. Furthermore, the peak
in maternal leptin found in their circulation can reflect leptin resistance at the
end of pregnancy suggesting an endocrine activity of leptin [258]. On the
other hand, unchanged placental leptin receptor expression was accompanied
by increased cord blood leptin concentrations in infants of obese mothers.
This might indicate that, on the fetal side, leptin release by vascular
endothelial cells may act directly on the fetus [244, 252]. Umbilical cord leptin
concentrations can be viewed as a marker of adiposity in the fetus and a
marker of obesity after birth and in adulthood [552]. This is further supported
by the ability of fetal adipose tissue to synthesise leptin in proportion to
neonatal ponderal index [546]. Alternatively, fetal hyperleptinemia can
contribute to induce leptin resistance by chronic activation of leptin receptors
in several fetal tissues [553]. Animal studies have indicated that adult
offspring of obese mothers show impairment of hypothalamic metabolic
regulation associated with leptin resistance [554, 555]. However, it is not
known whether the hypothalamic targets of leptin are already responsive to
its metabolic signals in the fetus. The main effect of placental leptin is thought
to be on placental and fetal growth through autocrine and paracrine regulation
[550, 551] and its influence on maternal physiology is less clear [120]. These
observations are consistent with the positive correlations described here
between cord blood leptin and both placental and birth weight, whereas no
correlation with maternal leptin was found.
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A potential role of leptin on placental and fetal growth, independent of
maternal leptin metabolism [254], is hereby highlighted. The pleiotropic role
of this adipokine could, therefore, explain the increased placental weight
observed in obese subjects, who are more likely to experience placental
hypertrophy [526]. As discussed in Chapter 3, an alternative role of insulin or
glucose, which was also positively related to placental weight in obese
subjects, could also explain enhanced placental weight with obesity.
Corticosteroids can also be involved in the regulation of insulin and leptin
signalling. Excess GC have been associated with reduced leptin transport
across the placenta [249] with a potential role in post-receptor inhibition of
insulin signalling [265, 266, 269]. Giorgino et al. found that total tyrosine
phosphorylation of insulin receptors was decreased in glucocorticoid-treated
skeletal muscle, and this was accompanied by decreased IRS1 content and
reduced serine and/or threonine phosphorylation of IRS1 [266]. Although the
expression of key metabolic markers involved in placental insulin signalling
and energy homeostasis was not influenced at a gene expression level in this
study, post-transcriptional alteration might have occurred, accounting for the
observed placental outcome. Interestingly, placental mRNA abundance of the
GC receptor increased with GDM alone and when GDM was associated with
high BMI, whilst overweight or obesity alone did not influence its expression.
As such, GDM, rather than high BMI, seems to be the driving force
upregulating this receptor. The activation of GC receptor initiates transcription
of genes involved in metabolic homeostasis [292] and, additionally, it is
associated with the transcription of inflammatory genes [293]. Thus,
increased placental GC receptor observed in GDM pregnancies might
contribute to a placental immunosuppressive response [292, 293] and this
ZLOOEHDGGUHVVHGLQWKHIROORZLQJVHFWLRQ7KHǃ+6'HQ]\PHH[SUHVVHGE\
the trophoblast represents a functional placental barrier to maternal GC by
FRQYHUWLQJFRUWLVROWRLQDFWLYHFRUWLVRQH>@(TXLYDOHQWSODFHQWDOǃ+6'
gene expression in both obese and diabetic participants may indicate good
placental protection of the fetus against high maternal cortisol [282, 288].
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This was confirmed by the delivery of normal weight neonates from these
pregnancies [284].
Insulin, IGF1 and leptin, as well as glucose and amino acids, are upstream
regulators of mTOR, which regulates protein translation, thereby controlling
cellular growth and metabolism [556-559]. In the placenta, mTOR has a
major role in the regulation of trophoblast cell proliferation by stimulating
amino acids placental transporters [300, 306]. I found that increased
maternal BMI and GDM, both resulting in higher insulin and glucose plasma
concentrations, were not associated with upregulation of mTOR signalling in
the placenta as judged by gene expression. In contrast with previous studies
[2, 300, 306], these results show inhibition of placental mTOR gene
expression with obesity. This was accompanied by unchanged mRNA
abundance of Akt, reflecting no differences in the expression of either IGFR1,
ISR1 or p70S6K, a downstream regulator of mTOR signalling [298, 299].
These findings do not support those from Jansson et al. [2], who found
activation of mTOR and insulin/IGF1 signalling in association with high BMI.
Although placental and birth weight were not statistically different between
groups, the authors found a positive association between these outcomes and
activation of mTOR signalling. This correlation was not observed in my study,
suggesting that mTOR signalling within the placenta did not significantly
contribute to changes in placental or fetal growth. The BMIs considered here
were pregestational whereas in Janssons work BMI was measured between 8
and 12 weeks of gestation. Therefore, my study cannot exclude the possibility
that a few subjects, classified as lean and overweight before pregnancy, might
have moved to the obese group by gaining excess gestational weight at the
beginning of pregnancy, potentially affecting the results. Furthermore, the
average BMI of obese participants in my study was significantly lower than
the mean BMI in Janssons population. More importantly, the gestational
weight gain of their participants was 2-3 fold higher than the weight gained
by obese mothers in my study, and this was reflected by higher placental
weight.
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Although the authors did not measure food intake or maternal physiological
outcomes, it is likely that their participants considerably increased their
nutrient intake during pregnancy, and this was not observed in my study
(Chapter 3). Raised nutrient intake in the obese mothers participating in
Jansson study might be explanatory of their enhanced placental weight [512]
and raised mTOR expression [300, 558, 559]. The type of diet and reduction
in food intake observed here may account for downregulation of placental
mTOR expression [299, 482]. It is established that individual nutrients, such
as glucose, regulate mTOR signalling by AMPk leading to inhibition of mTOR
gene expression [305, 560], although how changes in diet through pregnancy
can reset this mechanism is currently unknown.
Obese women showed a reduction in their food intake and lower rate of
weight gain, but their plasma glucose concentrations at term were higher.
Additionally, no alterations in AMPK expression with obesity were observed,
indicating that some other mechanisms are responsible for mTOR
downregulation. As another function of mTOR is to act as a homeostatic ATP
sensor with autophosphorylation activity [307], it is possible that high BMI
acts as a signal to silence this protein.
Despite the adaptations described above, these pleiotropic genes in the
placenta can be also involved in cellular metabolism and pro-inflammatory
pathways as discussed in the following section. An overview of the effect of
both obesity and gestational diabetes on maternal, placental and fetal
metabolic outcomes is illustrated in Figure 4.12 and 4.13.
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Figure 4.12: Effect of obesity on maternal, placental and fetal metabolism.
MVM: microvillous plasma membrane; BM: basal plasma membrane; FFAs: free fatty
acids; UCP2: uncoupling protein-2; ROS: reactive oxygen species; IL6: interleukin-6;
71)Į WXPRXU QHFURVLV IDFWRUĮ 1)N% QXFOHDU IDFWRU NDSSD % 7/5 WROO OLNH
receptor-4; IR: insulin receptor; IGFR1: insulin-like growth factor-1 receptor; IRS1/2:
insulin substrate receptor-1/2; Akt: v-akt murine thymoma viral oncogene homolog;
mTOR: mammalian target of rapamycin; p70S6K: ribosomal protein S6 kinase 70kDa
SROLSHSWLGH/(3OHSWLQ/(35OHSWLQUHFHSWRU*&JOXFRFRUWLFRLGVǃ+6'EHWD
K\GUR[\VWHURLG GHK\GURJHQDVH *5Į JOXFRFRUWLFRLG UHFHSWRUDOSKD 0$3.(5.
mitogen-activated protein kinase/extracellular regulated kinase; JAK2: janus kinase-2;
$03. $03DFWLYDWHG SURWHLQ NLQDVH 33$5Ǆ SHUR[LVRPH SUROLIHUDWRUDFWLYDWHG
receptor gamma; SIRT1: sirtuin-1. Arrows and bars represent activation and inhibition
respectively. Blue arrows represent the effect driven by obesity: Ĺ upregulation, ļ
unchanged, Ļ downregulation.
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Figure 4.13: Effect of gestational diabetes on maternal, placental and fetal
metabolism.
MVM: microvillous plasma membrane; BM: basal plasma membrane; FFAs: free fatty
acids; UCP2: uncoupling protein-2; ROS: reactive oxygen species; IL6: interleukin-6;
71)Į WXPRXU QHFURVLV IDFWRUĮ 1)N% QXFOHDU IDFWRU NDSSD % 7/5 WROO OLNH
receptor-4; IR: insulin receptor; IGFR1: insulin-like growth factor-1 receptor; IRS1/2:
insulin substrate receptor-1/2; Akt: v-akt murine thymoma viral oncogene homolog;
mTOR: mammalian target of rapamycin; p70S6K: ribosomal protein S6 kinase 70kDa
SROLSHSWLGH/(3OHSWLQ/(35OHSWLQUHFHSWRU*&JOXFRFRUWLFRLGVǃ+6'EHWD
K\GUR[\VWHURLG GHK\GURJHQDVH *5Į JOXFRFRUWLFRLG UHFHSWRUDOSKD 0$3.(5.
mitogen-activated protein kinase/extracellular regulated kinase; JAK2: janus kinase-2;
$03. $03DFWLYDWHG SURWHLQ NLQDVH 33$5Ǆ SHUR[LVRPH SUROLIHUDWRUDFWLYDWHG
receptor gamma; SIRT1: sirtuin-1. Arrows and bars represent activation and inhibition
respectively. Red arrows represent the effect driven by gestational diabetes: Ĺ
upregulation, ļ unchanged, Ļ downregulation.
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4.4.2. Placental anti-oxidant and anti-inflammatory
response
It is well established that obesity induces chronic low-grade inflammation and
increases circulating concentrations of inflammatory molecules, which can
further induce insulin resistance [83, 561]. Diabetes in pregnancy also elicits
major changes in the expression profile of placental genes with a prominent
increase in markers and mediators of inflammation such as interleukins,
OHSWLQ DQG 71)Į OLQNLQJ LQIODPPDWRU\ SDWKZD\V DQG JHVWDWLRQDO GLDEHWHV
associated insulin resistance [214]. The resulting inflammatory environment
can cause an antioxidant response by increasing antioxidant gene expression
[562] and represents a protective or adaptive mechanism to prevent damage
from further oxidative insults in utero.
Both maternal body fatness and the prevailing maternal glucose environment
influence the magnitude of hormonal adaptations to pregnancy which, in
turn, modulate adjustments in maternal and fetal energy metabolism [315].
This study appears to demonstrate that a diverse, but protective, response of
the placenta is generated within the altered intra-uterine environments
caused by obesity and gestational diabetes.
The impaired insulin resistance seen in these pregnancies [88] increased the
circulatory availability of glucose, which could have developed an oxidative
reaction within the placenta [82]. As placental metabolism is dependent on
the availability of oxygen and glucose [7], any reduction in utero-placental
oxygen uptake results in the increased production of placental ROS seen in
both obesity and diabetes during pregnancy [14, 175, 519]. Changes in ROS
production might act on pro- or anti-apoptotic pathways that interact with
DNA stability, with potential re-programming of fetal energy homeostasis
[536]. My findings showed that reduced placental mTOR observed with
obesity was associated with overexpression of SIRT1 and UCP2, suggesting an
enhanced placental antioxidant capacity [332].
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Conversely, placentas of gestational diabetic women, with lean or increased
BMI, were characterised by similar levels of antioxidant markers, possibly
because of the small sample size or the mild severity of diabetes in these
participants.
In normal physiologic situations, mitochondria directly regulate cellular ATP
and AMP concentrations [563] through the activity of AMPK, Akt, and mTOR
with the former sensing energy depletion [321], whereas the latter are
stimulated by raised energy [300]. Mitochondria also regulate ROS production
and oxidative stress by uncoupling energy supply. Both AMPK and mTOR
regulate oxidative stress through changes in UCP2 [538] and NFkB action
[326-328], thereby promoting pro-inflammatory and pro-oxidative pathways
within the trophoblast cells. On the other hand, mitochondrial replication is
dependent on SIRT1 activity, which has been implicated in cell survival and
senescence through inhibition of mTOR activity [333, 334]. Consequently,
because SIRT1 and mTOR have been linked to age-associated diseases with
SIRT1 activation and mTOR inhibition having beneficial effects [333, 335,
564], these findings might indicate an increased placental protective response
against oxidative stress [333, 334]. In addition, higher placental weight in
obese women was associated with similar placental TBARS concentration,
which is considered a marker of oxidative stress [332]. Unchanged TBARS
concentrations may indicate that placenta of mothers with high BMI
participating in this study is not altered by exagerred ROS production. This
would therefore support the gene expression outcome reflecting the
generation of a compensatory response to protect the fetus from excess
maternal or placental ROS.
Excess availability of oxidised lipids has potential implications for placental
development, lipid transport and metabolism by inhibiting trophoblast
invasion leading to effects on fetal development [84]. Maternal concentrations
of TG, which are the primary source of FFA, were similar between BMI groups
and this was reflected by similar expression of placental genes involved in
inflammatory response [216, 330].
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33$5ǄKDVEHHQSURSRVHGDVDQDQWLLQIODPPDWRU\IDFWRULQERWKKXPDQDQG
animal studies [308, 313] with a potential role in the initiation of labour
[310]. High concentrations of circulating FFA and oxidised lipids have been
DVVRFLDWHG ZLWK GHFUHDVHG 33$5Ǆ H[SUHVVLRQ DQG VXEVHTXHQW F\WRNLQH
activation [309, 329]. This nuclear transcriptor is primarily involved in lipid
metabolism [337], and is directly regulated by FFA [343, 344].
Similarly, the receptor TLR4, which plays an important role in inducing
inflammation by activating NFkB pathway, is also activated by FFA [345]. The
lack of changes in the expression of these two pro-inflammatory genes with
increased BMI are in keeping with the similar TG content in placenta and cord
blood (Chapter 3), thus suggesting that no major signs of inflammation were
present in these participants [329]. As measurement of placental markers of
macrophage infiltration (CD14, CD68) [91-93] was not possible due to the
poor specificity of available antibodies, these findings could not be further
substantiated.
Despite apparently good metabolic homeostasis within the placenta and
normal fetal and neonatal growth, some inflammatory markers in the cord
blood of the infants of the obese participants were altered with potential
adverse outcomes for the offspring [87, 88]. Enhanced circulating leptin in
obese women was associated with higher leptin and monocyte concentrations
in the cord blood of their infants. In addition to its potential role in newborn
adiposity [546, 552], growing evidence has linked leptin with the maturation
of fetal and neonatal immune system [244, 565]. In normal physiological
situations, this adipokine can have a protective role in setting an acute
systemic immune response and protect the infant from allergic conditions
[259, 260]. However, in newborns with abnormally raised leptin
concentrations impaired immune response is observed and this may result in
the perpetuation of adaptive immunity through local modulation of pro-
LQIODPPDWRU\F\WRNLQHV>@VXFKDV71)ĮDQG,/>@
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$OWHUQDWLYHO\LQFUHDVHGSURLQIODPPDWRU\F\WRNLQHVH[SUHVVLRQLQFOXGLQJ71)Į
and IL6, and/or enhanced circulating monocyte chemoattractant protein 1
(MCP1) concentrations in the maternal circulation of obese women may
account for the monocytes rise observed in cord blood of their infants [566].
MCP1 is well established to regulate macrophage recruitment to sites of
inflammation [567]. Hence, higher plasma levels of this protein may be
involved in the monocyte recruitment into adipose tissue of newborns from
obese individuals [566]. Here, they differentiate into macrophages and
produce proinflammatory cytokines, contributing to a state of insulin
resistance and low grade inflammation.
The effect of gestational diabetes on the placental inflammatory milieu
UHVXOWHG LQXSUHJXODWLRQRISODFHQWDO OHSWLQDQG*5ĮDVVRFLDWHGZLWK UHGXFHG
AMPK expression. Leptin can regulate its own expression within the placenta
through a mechanism involving the mitogen-activated protein kinase (MAPK)
pathway and, alternatively, the suppression of AMPK [551]. A direct
transcriptional action of GC on placental leptin expression has also been
highlighted [568], suggesting that a local inflammatory response within the
placenta of lean and obese diabetic women may have been generated [250,
261, 262, 293]. Nonetheless, cord blood inflammatory markers were similar
in these participants, indicating that placental inflammation, if any, was not
transferred to the fetus.
In conclusion, these findings suggest that changes in cellular energy status
within the placenta can be very different between women that are obese
compared to those that exhibit gestational diabetes. Overexpression of
pleiotropic genes involved in key metabolic pathways within the placenta of
diabetic mothers could regulate nutrient uptake, thereby contributing to a
localised chronic pro-inflammatory state, which, eventually, does not seem to
negatively affect the fetus. Conversely, high BMI in pregnancy might
contribute to the development of an impaired immune response in the fetus
despite a good antioxidant response within the placenta.
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Chapter 5 - Effects of
maternal BMI and diabetes on
folate metabolism and placental
methylation
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5.1. Introduction and hypotheses
Folate is essential for DNA synthesis and cell proliferation and, together with
vitamin B12 and methylenetetrahydrofolate reductase (MTHFR), is involved in
the homocysteine-methionine cycle through complex biochemical pathways
(Figure 1.17, Chapter 1). This micronutrient serves as single carbon donor in
the vitamin B12-dependent remethylation of homocysteine into methionine
[43] whilst normal MTHFR activity maintains the pool of circulating folate by
preventing a rise of cellular homocysteine [569, 570].
Folate deficiency in pregnancy increases the risks of premature delivery, with
NTDs and lower birthweight, all of which can be reduced by adequate
maternal folate intake [350, 518, 571]. The incidence of these complications
in diabetic pregnancies is lowered by good glycaemic control and folate
administration [508]. However, despite being recommended in the
management of obesity in pregnancy, folate supplementation in pregnant
women with high BMI [38, 45] does not reduce the risk of delivering a child
with NTD [352]. In addition, large epidemiological studies have reported a
strong association between obesity and lower folate concentrations in women
of childbearing age [572, 573]. The present study investigated the association
between maternal dietary intake of folate and maternal and cord blood folate
in pregnancies complicated by high BMI and gestational diabetes. Its novel
focus was to examine the contribution of different BMI categories as well as
the distinct effects of gestational diabetes amongst lean, overweight and
obese subjects on folate metabolism. Folate and its metabolites are strongly
involved in DNA methylation. S-adenosyl methionine (SAM) is used by DNA
methyltransferases (DNMTs) to methylate DNA [371, 379], an essential
process for the developing embryo. Previous studies have shown that altered
levels of DNA methyl transferases -1 and -3 (DNMT1, DNMT3) in liver, serum
and the uterus during embryo implantation are associated with dietary folate
deficiency [574].
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Defective folate metabolism, or limited folate availability, can contribute to
modifications in feto-placental function by influencing DNA methylation status
in peripheral blood cells [369] or altering expression of inflammatory markers
in the placenta [500]. The resulting individual is, therefore, at an increased
risk of metabolic dysfunction and CVD in later life [366, 575]. As the
relationship between maternal folate and DNMTs has not been fully
investigated, this Chapter also contributes to current knowledge about the
influence of maternal diet on gene expression during fetal development.
Oyama, Wentzel and colleagues have recently demonstrated in rodents that
diabetes leads to decreased gene expression of folic acid binding protein
(Folbp) in the mother resulting in intracellular folate deficiency in the embryo
[518, 576]. Although the placenta is crucial for ensuring fetal development,
few studies have focused on folate transport within the placenta and the
resulting outcomes for the fetus. In the Introduction (Chapter 1) to this
thesis, I have described how cellular uptake of folate is mediated by specific
transport mechanisms in the placenta, which include the folate receptor alpha
)5Į SURWRQ FRXSOHG IRODWH WUDQVSRUWHU 3&)7 DQG UHGXFHG IRODWH FDUULHU
(RFC) [329, 330, 331]. %ULHIO\ IRODWH LV ERXQG WR WKH )5Į RQ WKH PDWHUQDO
side and transported within the placenta by endocytosis/exocytosis at a
neutral to mildly acidic pH. Subsequently, PCFT mediates the co-transport of
folate and protons at low pH and, finally, RFC mediates the cellular uptake of
folate in exchange for specific anions such as organic phosphates. RFC has
been proposed as the major route of folate delivery to the fetal circulation at
a physiological pH [577]. Carter et al. suggested that placental folate
transport in overweight and obese pregnancies is impaired and results in
lower fetal folate concentrations [354]. Nevertheless, few studies have
investigated placental transport of folate nor have focused on its effect on
pregnancies complicated by epidemic diseases such as obesity or diabetes.
'LHWDU\FRPSRQHQWVVXFKDVIRODWHKDYHEHHQVKRZQWRLQÀXHQFHPHWK\ODWLRQ
patterns during development [578] with potential effects on the offsprings
health [579, 580].
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Changes in epigenetic profile in response to perturbations within the in utero
environment could contribute to modifications in feto-placental function that
ultimately place the resulting individual at increased risk of metabolic disease
in later life [575, 579-581]. This is because differences in the methylation
pattern of genes expressed in the placenta are associated with changes in
gene expression, which could impair placental function [575] resulting in
gestational and early life diseases [370]. The use of genome-wide methylation
arrays enables a more detailed examination of human epigenomics although
this can lead to controversial interpretations [402].
Therefore, in this Chapter the hypotheses are:
1. Pregnant women with high BMI and gestational diabetes are
characterised by inadequate dietary intake of folate and this will result
in changes in serum folate. Due to the consumption of a poor quality
diet [38, 41, 45], overweight and obese mothers will have lower folate
concentrations whereas these will be increased in gestational diabetic
women, who are advised to follow healthier food choices [508, 509].
2. Alterations in maternal folate concentrations will influence folate status
in the newborn via changing placental folate transport and metabolism.
The fetus can survive on maternal folate stores even in conditions of
profound dietary deficiency [348] resulting in newborn folate
concentrations within the normal range [582]. This raises the
possibility that the placenta buffers maternal folate deficiency to
protect the fetus. I hypothesise that placental folate transport in
overweight and obese women will be upregulated in order to
compensate for lower maternal folate. On the other hand, placental
folate transport in diabetic women, associated with higher plasma
folate concentrations, will be reduced contributing to a newborn with
normal folate levels.
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3. Due to the crucial role of folate in providing methyl donors [583] and
its proposed influence on DNMT1 and DNMT3 [574], I hypothesise that
changes in placental folate transport resulting from maternal high BMI
and/or gestational diabetes, will reflect alterations in expression of
these DNMTs and possible modifications in DNA methylation within the
placenta [583]. Epigenetic alterations can be of critical importance in
highlighting both novel pathways and regulatory molecules associated
with an adverse nutritional environment [581].
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5.2. Methods
The design of the study and all materials and methods used are detailed
described in Chapter 2 (Materials and Methods). In summary, pregnant
women participating in the Preobe study (P06-CTS-02341) were recruited in
the 20th week of pregnancy and classified according to their BMI. At 28th
weeks of gestation, they were further classified on the basis of BMI and
glucose tolerance, making six groups (Chapter 2, Section 2.2, Figure 2.2).
Maternal and fetal anthropometries were evaluated at 24 and 34 weeks of
pregnancy as illustrated in Figure 5.1. As maternal weight at 40 weeks of
gestation was self-reported, and may not have equal accuracy in all BMI
groups, this was not used in calculations of gestational weight gain and
postnatal weight loss [62, 482]. After birth, infant anthropometry was
evaluated by a paediatrician at 3, 6, 9 and 12 months of age respectively and
maternal anthropometry was performed at 6 months.
Information relating to folate and vitamin B12 intake before delivery was
collected using 7 day estimated food intake records at 34 weeks of gestation.
Nutritional data were then analysed for nutrient intake by using a nutritional
software program (CESNID 1.0, Barcelona University, Spain) based on
validated [412] Spanish food tables (Tablas de composición de alimentos del
CESNID). Maternal venous blood was collected at 34 and 40 weeks of
gestation as well as at 6 months post-delivery. At birth, umbilical venous
blood samples were collected and placentas were snapped frozen and stored
at -80oC for further analysis in Nottingham.
Total RNA was extracted from 100 mg of placental samples with TRI Reagent®
and chloroform and cDNA obtained using the High Capacity RNA-to-cDNA kit
(Applied Biosystems, CA 94404, USA) as described in Chapter 2. Gene
expression of target genes implicated in placental folate transport and
PHWDEROLVP )5Į 3&)7 6/&$ 5)& 6/&$ DQG07+)5 DQGP51$
abundance of DNMT1 and DNMT3 were assessed by real-time PCR.
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Gene expression of PCFT and RFC was examined in the later part of the study
on a representative random selection of samples (C=20; OV=20; OB=20;
GDL=10; GDOB=10).
Figure 5.1: Programme of evaluations in the Preobe study.
Maternal examinations during gestation and after delivery. Collection of samples and
measurements are reported in white boxes whereas greyed out boxes represent time
before, during and after pregnancy. Aspects studied in this Chapter are highlighted in
white boxes marked with solid black line.
Total protein was extracted from frozen tissues using CelLytic MT and
protease inhibitor cocktail (Chapter 2, Section 2.11.1), whilst a further
extraction using RIPA buffer was performed from a few samples stored in RNA
ODWHU &KDSWHU  6HFWLRQ  3URWHLQ DEXQGDQFH RI )5Į DQG 5)& ZDV
determined by Western Blotting; however, none of the two antibodies were
found to be specific for the target products. All primer sequences and
antibodies used in these analyses are listed in Tables 2.4 and 2.7 (Chapter 2,
page 82 and page 110, respectively).
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Lastly, a set of 24 placental samples were selected from 5 of the groups (C,
n=5; OV, n=4; OB, n=5; GDL, n=5; GDOB, n=5) to guarantee homogeneity
of the population, by maternal age (between 25 and 35 years ), BMI (no
borderline BMIs), smoking during pregnancy (only no smokers), nulliparity
(only first pregnancy) and newborn weight (only AGA). Genomic DNA isolation
was achieved by thorough disruption and digestion of the tissues, which were
then purified using QIAamp DNA Mini Kit (50) (QIAGEN) (see Chapter 2,
Section 2.12.1, page 119).
The HumanMethylation450 15017482 v.1.1 manifest from Illumina [400] was
used to measure genomic DNA methylation patterns and the Matlab package
NIMBL (Numerical identification of Methylation Biomarker Lists) [402] for the
analysis of annotation data (including, for example, gene and gene region
information). According to this, Infinium methylation profiles for all samples
were provided as a text file and analysed by Emes et al. using NIMBL [470].
Several output plots were generated to visualise the sample quality including
a plot of the beta value distribution of each sample, which represents the
estimates of methylation levels at a given locus [400]. Additionally, gene
centric plots providing genomic DNA sequence and coordinate of gene coding
regions, were generated for the novel genes, which were most differentially
methylated, and their expression determined by QPCR.
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5.3. Results
5.3.1. Folate intake and physiological outcomes
Characteristics of the participants are given in Table 5.1 and Table 5.2. Of all
the participants, 130 women out of 149 reported daily intake of folate and
iodine supplements at 24th week of pregnancy. Only 86 out of 149 participants
completed and returned the 7 day dietary questionnaires and these showed
no influence of maternal BMI in maternal folate and vitamin B12 intake in late
gestation. Whilst the reduction in folate intake as assessed by dietary
questionnaire did not reach statistical significance in this subset of women,
when data from more women within the Preobe study was available,
overweight and obese women had a significantly lower folate intake compared
to lean controls [520]. On the other hand, maternal folate intake increased
with gestational diabetes as shown in Table 5.3, but this was statistically
significant only in the overweight group (GDOV).
Folate concentrations in all subjects were within the normal range (5-16
ng/ml) with no evidence of folate deficiency (<5 ng/ml) [584]. However, a
marked decrease in folate concentrations from mid to late pregnancy was
observed in both overweight and obese subjects (p<0.001) compared to lean
women.
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Table 5.1: Maternal nutrient intake and plasma folate during late pregnancy
and after delivery in lean control (C), overweight (OV) and obese (OB)
pregnant women.
0DWHUQDOQXWULHQWLQWDNHǋJGD\ C (n=37) OV (n=16) OB (n=8)
7 day folate intake 298.3±12.0 258.6±18.6 260.4±46.2
7 day vitamin B12 intake 5.76±2.91 4.7±2.2 5.0±2.7
Maternal folate (ng/ml) C (n=59) OV (n=29) OB (n=22)
Plasma folate at 34 gw 12.9±0.6 10.6±0.9* 11.1±0.9
Plasma folate at 40 gw 12.9±0.6 9.5±0.9** 8.4±0.9*
Plasma folate 6 m post-delivery 10.3±0.7 10.8±0.9 8.09±1.19
Data represents means ± S.E.M.; n = women/group; gw: gestational weeks; m:
months. Statistical differences denoted by *,** correspond to p<0.05 and p<0.01
respectively (1-way ANOVA, Bonferroni post-hoc test).
Cord blood folate concentrations in newborns from overweight and obese
mothers were significantly lower compared to controls (Table 5.2). In
addition, the difference between umbilical cord folate and maternal folate at
40 gestational weeks (Delta folate) increased with maternal BMI.
Table 5.2: Cord blood folate in lean control (C), overweight (OV) and obese
(OB) subjects.
Cord blood folate (ng/ml) C (n=33) OV (n=15) OB (n=12)
Cord blood folate 18.7±0.4 17.1±0.8* 17.4±0.7*
Delta folate 5.80±0.81 7.66±0.82* 9.01±0.90*
Data represents means ± S.E.M.; n = women/group; gw: gestational weeks; m:
months.
Delta folate: difference between maternal folate at 40 gestational weeks and umbilical
cord folate. Statistical difference denoted by * corresponds to p<0.05 (1-way ANOVA,
Bonferroni post-hoc test).
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As reported in Table 5.3, lean mothers who developed diabetes during
gestation showed the highest serum folate concentrations at both 34
gestational weeks and 6 months after delivery compared to lean women
without GDM. Interestingly, this difference was not observed with the
additional effect of BMI, which was associated with similar folate
concentrations to that of lean controls without GDM.
Table 5.3: Maternal nutrient intake and plasma folate during late pregnancy
and after delivery in lean control (C), lean gestational diabetic (GDL),
overweight gestational diabetic (GDOV), and obese gestational diabetic
(GDOB) pregnant women.
Maternal nutrient
LQWDNHǋJGD\
C
(n=37)
GDL
(n=11)
GDOV
(n=8)
GDOB
(n=6)
7 day folate intake 298.3±12.0 342.9±33.9 387.8±43.6* 299.5±53.5
7 day vitamin B12 intake 5.76±2.91 10.08±4.13 4.49±0.96 5.29±1.21
Maternal folate
(ng/ml)
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
Plasma folate 34 gw 12.9±0.6 17.0±1.0** 13.9±1.5 15.2±1.0
Plasma folate 40 gw 12.9±0.6 15.4±1.2 10.7±1.7 13.9±1.2
Plasma folate 6 m
post-delivery
10.3±0.7 15.3±1.4** 12.1±2.1 11.5±1.9
Data represents means ± S.E.M.; n = women/group; gw: gestational weeks; m:
months. Statistical difference denoted by *,** corresponds to p<0.05 and p<0.01
respectively (1-way ANOVA, Bonferroni post-hoc test).
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Cord blood folate concentrations and Delta folate were similar between
gestational diabetic groups with or without the influence of BMI (Table 5.4).
Table 5.4: Cord blood folate in lean control (C), lean gestational diabetic
(GDL), overweight gestational diabetic (GDOV), and obese gestational
diabetic (GDOB) pregnant women.
Cord blood folate
(ng/ml)
C
(n=33)
GDL
(n=7)
GDOV
(n=12)
GDOB
(n=7)
Cord blood folate 18.7±0.4 19.3±0.7 18.6±0.8 20.0±0.1
Delta folate 5.93±0.81 4.45±1.43 7.56±1.72 6.78±1.62
Data represents means ± S.E.M.; n = women/group; gw: gestational weeks; m:
months.
Delta folate: difference between maternal folate at 40 gestational weeks and umbilical
cord folate.
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5.3.2. Placental gene expression of folate
transporters and metabolism
The relative expression of placental genes implicated in folate transport and
metabolism and in DNA methyl transfer is reported below.
Despite obese subjects showing the highest difference in folate levels between
PRWKHU DQG IHWXV WKHLU SODFHQWDO H[SUHVVLRQ RI )5Į ZDV VLJQLILFDQWO\ ORZHU
compared to control group (Figure 5.2).
)LJXUH3ODFHQWDOIRODWHUHFHSWRUDOSKD)5ĮP51$H[SUHVVLRQUHODWLYHWR
18S of lean control (C), overweight (OV), and obese (OB) pregnant women.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=59); OV:
overweight (n=29); OB: obese (n=22). Data are non parametric and represent mean
± S.E.M; a.u.: arbitrary units; n = women/group. Statistical difference detected by **
corresponds to p<0.01 (Kruskal-Wallis; Mann Whitney post-hoc test).
$ PXOWLUHJUHVVLRQ DQDO\VLV LQYHVWLJDWLQJ SUHGLFWRUV IRU SODFHQWDO )5Į
highlighted pre-gestational BMI and placental weight as the factors with
greatest influence on the expression of this transporter (Table 5.5). After
adjusting for other cofounders, such as gestational age and maternal folate at
40 gestational weeks, no additional factors were found to be associated with
pre-gestational BMI, indicating an independent contribution of these factors
on placental gene expression.
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Table 5.5: Association between placental gene expression of folate receptor
DOSKD )5Į DQG GLIIHUHQW SUHGLFWRUV LQ FRQWURO RYHUZHLJKW DQG REHVH
pregnant women.
Linear regression model
(n=110)
Changes in placental
)5ĮJHQHH[SUHVVLRQ
p value
Model 1Ǔ 1.66 (0.85 to 2.47) 0.047
Model 2ǓǓ 2.13 (1.20 to 3.05) 0.017
Model 3ǓǓǓ 5.47 (0.13 to 10.82) 0.118
Ǔ Adjusted for the a priori confounders BMI; ǓǓ adjusted for the a priori confounders
BMI and placental weight; ǓǓǓ adjusted for the a priori confounders BMI, placental
weight, gestational week and maternal folate at 40 gestational weeks. Numbers in
brackets are 95% confidence intervals.
7KH)5ĮLVUHVSRQVLEOHIRUIRODWHXSWDNHIURPWKHPDWHUQDOFLUFXODWLRQLQWRWKH
placenta and, together with PCFT and RFC, ensures its transport to the fetus
[328, 329]. The mRNA abundance of placental folate transporters PCFT and
RFC was measured in a randomly selected subgroup of samples but no
differences were detected (Table 5.6). Furthermore, gene expression of
placental MTHFR did not change significantly between groups although a trend
(p=0.09) to decrease was observed with obesity (Table 5.6).
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Table 5.6: Placental mRNA expression relative to housekeeping gene
(ribosomal 18S) of lean control (C), overweight (OV), and obese (OB)
pregnant women.
Placental gene
expression (a.u.)
C
(n=59)
OV
(n=29)
OB
(n=22)
PCFT
Ǔ 1.00±0.15 0.96±0.11 1.11±0.14
RFC
Ǔ 1.00±0.19 0.93±0.12 1.04±0.17
MTHFR 1.00±0.16 1.04±0.19 0.76±0.13
DNMT3 1.00±0.20 1.08±0.23 0.66±0.10
Data are non parametric and expressed as relative to housekeeping gene (ribosomal
18S). Data are normalised to the lean control group to give fold change and represent
means ± S.E.M; a.u.: arbitrary units; n = women/group. The abundance of genes
denoted by Ǔ has been measured in a representative selection of samples (n=20).
$OWKRXJKWKHUHZHUHQRVLJQLILFDQWFKDQJHVLQ'107ĮH[SUHVVLRQ7DEOH
mRNA expression of DNMT1 was upregulated 2 fold with overweight
(p=0.001), and 1.5 fold with obesity (p=0.023) (Figure 5.3).
Figure 5.3: Placental DNA methyl transferase 1 (DNMT1) mRNA expression of
lean control (C), overweight (OV), and obese (OB) pregnant women
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=59); OV:
overweight (n=29); OB: obese (n=22). Data are non parametric and represent mean
± S.E.M; a.u.: arbitrary units; n = women/group. Statistical difference detected by *, **
correspond to p<0.05 and p<0.01 respectively (Kruskal-Wallis; Mann Whitney post-hoc
test).
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Similarly, high BMI combined with gestational diabetes was associated with a
GHFUHDVH LQ WKHP51$DEXQGDQFHRI)5Į7DEOHDQHIIHFW WKDWEHFDPH
statistically significant with maternal obesity in a similar manner to that seen
in the non-diabetic groups (Figure 5.2). In addition, no differences in other
folate transporters were observed in mothers with GDM, possibly due to the
smaller number of samples.
Table 5.7: Placental mRNA expression relative to housekeeping gene
(ribosomal 18S) of lean control (C), lean gestational diabetic (GDL),
overweight gestational diabetic (GDOV), and obese gestational diabetic
(GDOB) pregnant women.
Placental gene
expression
C
(n=59)
GDL
(n=14)
GDOV
(n=14)
GDOB
(n=11)
)5Į 1.00±0.12 0.61±0.09 0.76±0.13 0.48±0.08*
PCFT
Ǔ 1.00±0.15 0.85±0.15 n.m. 0.84±0.11
RFC
Ǔ 1.00±0.19 0.73±0.14 n.m. 0.71±0.18
'107Į 1.00±0.20 0.86±0.33 1.30±0.49 0.64±0.08
Data is expressed as relative to housekeeping gene (ribosomal 18S) and normalised to
the lean control group to give fold change. Data are non parametric and represent
mean ± S.E.M; a.u.: arbitrary units; n = women/group; n.m.: not measured.
Statistical difference annotated by * corresponds to p<0.05 (Kruskal-Wallis). The
abundance of genes denoted by Ǔ has been measured in a representative selection of
samples (n=20).
As a consequence of gestational diabetes combined with high BMI, gene
expression of placental MTHFR, the enzyme that catalyses the synthesis of 5-
methyl THF, was upregulated (Figure 5.4). Interestingly, enhanced expression
of placental MTHFR was observed with gestational diabetes alone in
overweight (GDOV vs OV) and obese (GDOB vs OB), but not lean (GDL vs C)
GDM groups (Figure 5.5).
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Figure 5.4: Effect of GDM and BMI on the mRNA abundance of placental
methylenetetrahydrofolate reductase (MTHFR) as determined by real-time
PCR.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give the fold change. C: control (n=59); GDL: lean
women with GDM (n=14); GDOV: overweight women with GDM (n=14); GDOB: obese
women with GDM (n=11). Data are non parametric and represent mean ± S.E.M; a.u.:
arbitrary units; n = women/group. Statistical differences denoted by *, ** correspond to
p<0.05 and p<0.01respectively (Kruskal-Wallis; Mann Whitney post-hoc test).
Figure 5.5: Effect of GDM on the mRNA abundance of placental
methylenetetrahydrofolate reductase (MTHFR) as determined by real-time
PCR.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give the fold change. C: control (n=59); GDL: lean
women with GDM (n=14); GDOV: overweight women with GDM (n=14); GDOB: obese
women with GDM (n=11). Data are non parametric and represent mean ± S.E.M; a.u.:
arbitrary units; n = women/group. Statistical differences denoted by * and ʋʋ
correspond to p<0.05 and p<0.01 respectively (Kruskal-Wallis; Mann Whitney post-
hoc test).
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The abundance result of folate transporters was further investigated by
PHDVXULQJWKHSURWHLQH[SUHVVLRQ,QWRWDOWKUHHGLIIHUHQWDQWLERGLHVIRU)5Į
and one for RFC were used with the aim of detecting their specific targets.
Protein concentrations in previously frozen placental tissues were unusually
low and the antibody did not bind the protein of interest (see Chapter 2,
Section 2.11.7). This suggests that these tissues might have been degraded
during collection or storage and were not suitable for any further analysis.
Consecuently, attempt to extract proteins from placental tissues stored in
RNA later solution, was performed. Although protein was better preserved
from degradation, as demonstrated by running the samples in agarose gel
(Figure 2.5, Section 2.6.2, Chapter 2), none of the polyclonal or monoclonal
antibodies used detected specific bands for their target antigens. Any binding
was non-specific to proteins of similar molecular weight as shown by
incubation of the membrane with non-immune rabbit serum (NRS) (Figure
5.6). This negative control is known not to express the target protein and is
used to check for non-specific binding and false positive results.
)LJXUH  ([DPSOH RI LPPXQRGHWHFWLRQ IRU )5Į LQ 51$ ODWHU SODFHQWDO
samples.
7KHDQWLERG\ELQGVDVSHFLILFSURWHLQRIDSSUR[LPDWHO\N'DLQWKHVDPSOHV)5ĮDQG
this can be due to protein aggregation (i.e. albumin). A protein of the correct
molecular weight (37-42 kDa) is instead recognised by the antibody in the positive
FRQWURO +H/D FHOOV )5Į IRODWH UHFHSWRU DOSKD 156 QRQLPPXQH UDEELW VHUXP
HeLa: cervical cancer cells.
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A positive control (HeLa cells lysate) known to express the target protein, was
also run alongside the placental samples to test the specificity of the antibody.
7KHN'DEDQGRILQWHUHVWIRU)5ĮZDVGHWHFWHGVKRZLQJWKDWWKHDQWLERG\
was specific for the target protein.
As a specific band of 68-72 kDa was recognised by the monoclonal antibody
WR)5ĮLWLVOLNHO\WKDWWKHSURWHLQRILQWHUHVWLQWHUDFWHGZLWKDQRWKHUSUHVHQW
LQWKHVDPSOHLPSHGLQJ)5ĮSURWHLQIUHHPLJUDWLRQWKURXJKWKHSRO\DFU\ODPLGH
gel. As discussed in Chapter 2 (section 2.11.8), in the case that protein
aggregation occurred, the interaction can be broken by adding a reducing
agent, such as anti-ubiquitin or urea 4-8M. Therefore, a further procedure
using urea 4M to separate the aggregate was performed giving a better
resolution of the protein bands. Once more, the immunodetection did not
show a specific binding of the antibody to the target protein as highlighted in
positive controls (HeLa) and by incubation of the membrane with NRS (Figure
5.7).
)LJXUH  ,PPXQRGHWHFWLRQ IRU )5Į DIWHU WUHDWPHQW RI VDPSOHV ZLWK 
Urea.
The 37-42 KDa band of interest was detected only in the positive control (HeLa).
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5.3.3. Methylation analysis
5.3.3.1. Identification of differentially methylated sites using
NIMBL
A plot of beta value distribution [400], representing the relative methylation
level of each sample is illustrated in Figure 5.8. Array sites with one or more
of the 24 samples having a p value of less than 0.05, and sites with missing
beta values measurements, were excluded from further analysis. The figure
represents twenty three of the 24 samples being of good quality with one
showing measurements with low confidence of methylation accuracy (e.g.
detection p-value > 0.05).
Figure 5.8: Summary output plots of the distribution of beta-values of all
samples.
Estimation of the proportion of methylation at a given locus (beta value) of 24 samples
(5 controls, 4 overweight, 5 obese, 5 gestational diabetic lean, 5 gestational diabetic
obese). A ratio of 0 equals to non-methylation of the locus whereas a value of 1 equals
to total methylation; a ratio value of 0.5 means that one copy is methylated and the
other is not, in the diploid human genome. One of the samples in purple shows an
aberrant distribution and was excluded from further analysis.
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Each beta-value indicates the proportion of methylation at a given CpG site
with values ranging from 0 (CpG site always found unmethylated in sample
DNA) to 1 (CpG site always found methylated in sample DNA) [468].
The differential methylation settings used are based on a constant level of
beta value inter-group distance of 0.2 corresponding to 20% minimum
difference between groups. Therefore, differentially methylated sites were
identified as sites with the largest difference in methylation levels between
two groups with a minimum beta value distance between non-overlapping
groups (Chapter 2, Figure 2.15). If this minimum beta value distance was not
reached, samples were masked and sites with previously overlapping groups
or low discrimination were additionally identified and flagged.
The greatest difference in methylation was found between placentas sampled
from normal and overweight mothers. These showed more than 200
differentially methylated CpG sites, which was almost 10 fold greater when
compared with the obese group. Examples of gene centric plots of the sites of
methylation changes were then generated for the genes with most differential
methylation (i.e. FAM3B and WNT2) as follows.
Methylation of the promoter regions for both FAM3B and Wnt2 was raised in
placenta of overweight women as shown in their methylation profile in Figure
5.9 and 5.10 respectively.
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Figure 5.9: Methylation profile of gene FAM3B.
NIMBL-gene output showing a zoomed region of the genomic location of the gene
FAM3B displaying 14 out of 20 CpG sites associated with this gene on the array. The
stems below the x-axis correspond to all CpG sites located in this region. CpG sites
identified as differentially methylated by NIMBL (d=0.2, m=1) are highlighted with
asterisks. TSS-1500, TSS-200: position 1500bp and 200bp respectively upstream of
transcriptional start site (TxStart).
Figure 5.10: Methylation profile of gene Wnt2.
NIMBL-gene output showing a zoomed region of the genomic location of the gene
Wnt2 displaying 14 out of 20 CpG sites associated with this gene on the array. The
stems below the x-axis correspond to all CpG sites located in this region. CpG sites
identified as differentially methylated by NIMBL (d=0.2, m=1) are highlighted with
asterisks. TSS-1500, TSS-200: position 1500bp and 200bp respectively upstream of
transcriptional start site (TxStart).
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5.3.3.2. Gene expression of differentially methylated genes
Gene expression analysis of FAM3B and Wnt2 was further performed in all five
groups to determine if the results from the methylation analysis were
accompanied by alterations in gene expression. Interestingly, greater
methylation in the promoter region of FAM3B and Wnt2 was not accompanied
by comparable changes in gene expression.
Figure 5.11 shows downregulation of placental FAM3B in obese compared to
overweight subjects, but not between overweight and lean control groups, as
was expected from the methylation analysis.
Figure 5.11: Placental FAM3B mRNA expression in lean control (C),
overweight (OV) and obese (OB) pregnant women.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=20); OV:
overweight (n=20); OB: obese (n=20). Data are non parametric and represent mean
± S.E.M; a.u.: arbitrary units. Statistical differences detected by * corresponds to
p<0.05 (Kruskal-Wallis; Mann Whitney post-hoc test).
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Similarly, mRNA abundance of placental FAM3B was reduced with the
combined effect of GDM and obesity (Figure 5.12), although the promoter
region of this gene had not been previously found to have greater
methylation.
Figure 5.12: Placental FAM3B mRNA expression in control (C), gestational
diabetic lean (GDL) and gestational diabetic obese (GDOB) pregnant women.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=20); GDL:
gestational diabetic lean (n=10); GDOB: gestational diabetic obese (n=10). Data are
non parametric and represent mean ± S.E.M; a.u.: arbitrary units. Statistical
differences detected by ** corresponds to p<0.01 (Kruskal-Wallis; Mann Whitney post-
hoc test).
As predicted by methylation analysis, gene expression of placental Wnt2 was
downregulated with overweight (Figure 5.13). However, hypomethylation of
the Wnt2 promoter region detected on Illumina analysis, as a consequence of
obesity and gestational diabetes, was not accompanied by higher or similar
expression of this gene. On the contrary, Wnt2 expression was reduced with
obesity (Figure 5.13) and gestational diabetes alone and when the two were
both present (Figure 5.14).
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Figure 5.13: Placental Wnt2 mRNA expression in control (C), overweight (OV)
and obese (OB) pregnant women.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=20); OV:
overweight (n=20); OB: obese (n=20). Data are non parametric and represent mean
± S.E.M; a.u.: arbitrary units. Statistical differences annotated by **, *** correspond to
p<0.01 and p<0.001 respectively (Kruskal-Wallis; Mann Whitney post-hoc test).
Figure 5.14: Placental Wnt2 mRNA expression in control (C), gestational
diabetic lean (GDL) and gestational diabetic obese (GDOB) pregnant women.
Data were expressed relative to housekeeping gene (ribosomal 18S RNA) and
normalised to the control group to give fold change. C: control (n=20); GDL:
gestational diabetic lean (n=10); GDOB: gestational diabetic obese (n=10). Data are
non parametric and represent mean ± S.E.M; a.u.: arbitrary units. Statistical
differences detected by **, *** correspond to p<0.01 and p<0.001 respectively (Kruskal-
Wallis; Mann Whitney post-hoc test).
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5.4. Discussion
Obesity and diabetes in pregnancy are associated with a variety of
complications including increased risk of premature delivery and NTD, which
have been related to maternal folate deficiency [44, 353, 585]. In this study,
the effects of both high maternal BMI and gestational diabetes on folate
concentrations and folate metabolism from mother to fetus have been
investigated.
5.4.1. Effect of high BMI
Epidemiological studies have demonstrated that clinical complications
associated with folate deficiency are reduced by adequate dietary intake [350,
518]. As folate supplements in obese women do not improve, or reduce, the
risk of fetal malformations [352], I hypothesised that placental transport is
impaired with raised BMI. As such, I investigated whether low maternal folate
intake and reduced folate concentrations in maternal serum resulted in
decreased levels of folate in the fetus.
My results suggest that folate metabolism differs according to the body weight
of pregnant women as previously indicated by others [349, 572]. It is likely
that women entering pregnancy with a high BMI consumed a poor diet lacking
in essential micronutrients, including folate [38, 41, 45]. In this regard,
overweight and obese mothers in this study reported reduced dietary folate
intake, and a lower percentage (OV: 44.1%; OB: 33.3%) reported taking
folate and iodine supplements at 24 weeks of pregnancy. Although folate
deficiency (<5ng/ml) was not observed amongst these women, serum folate
concentrations at both 34 and 40 gestational weeks were reduced in
overweight and obese participants, reflecting their lower folate intake.
Maternal BMI was inversely related to serum folate and this can be explained
by changes in plasma volume and folate distribution amongst maternal
tissues [586].
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In addition, hormonal changes in pregnancy and endocrine modifications
associated with high BMI might be responsible for reduced serum folate
concentrations [349]. Interestingly, cord blood folate concentrations in
overweight and obese women were within the normal range but lower than in
lean controls. The fact that those offspring showed appropriate cord blood
folate concentrations despite reduced maternal folate reflects the dependence
of the fetus on maternal stores even in conditions of lower folate
concentrations. This illustrates the crucial function of the placenta in buffering
the low maternal folate, therefore, ensuring adequate fetal supply. One
previous study on the effect of high BMI on folate transport in the placenta
was conducted by Carter et al. They hypothesised that obesity in pregnancy
was associated with lower fetal folate concentrations and impaired placental
folate transport [354]. However, their findings indicated that maternal obesity
did not alter maternal or fetal serum folate concentrations. In addition, the
effect of obesity on protein expression and activity of folate transporters in
placental homogenates and placental microvillus membrane (MVM) was
markedly different [354]. The authors suggested that post-translational
modifications are responsible of this discrepancy. Gene expression data in my
VWXG\ VKRZHG WKDW P51$ DEXQGDQFH RI )5Į ZKLFK LV WKH PDLQ IRODWH
transporter on the maternal side [351], was significantly reduced with
obesity. Conversely, no differences in the expression of the other two
transporters, PCFT and RFC were observed. The smaller number of samples
used for analysing the expression of these two transporters might have
resulted in a lack of statistical power to show any difference. A retrospective
sample size calculation to estimate the number of samples needed to show a
statistical difference at a power of 80%, using the mean and SD obtained in
my study, revealed that the necessary sample size would be very large
(n=1127). The lack of difference PCFT and RFC mRNA expression between
body weight groups was unexpected as the ratio between maternal folate at
40 gestational weeks and umbilical cord folate was higher in obese mothers
(Table 5.2) suggesteing increased folate transfer in these pregnancies.
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A multilinear regression model confirmed an independent effect of pre-
JHVWDWLRQDO %0, DQG PDWHUQDO IRODWH DW WHUP RQ SODFHQWDO )5Į $ SRVVLEOH
explanation for the increased transfer of folate to the fetus to compensate for
maternal deficiency is that the mRNA transcripts of those folate transporters
undergo post-transcriptional or post-translational modifications. According to
this, upregulation at a protein expression level or higher activity of placental
folate transporters might have occurred resulting in normal fetal folate status.
,Q P\ VWXG\ SURWHLQ H[SUHVVLRQ RI )5Į DQG 5)& KDV EHHQ DQDO\VHG XVLQJ
different antibodies, two of which were also used by Carter et al. [354].
However, due to the non-specific nature of available antibodies, it was not
possible to quantify those proteins, leaving the question of how the placenta
can compensate low maternal supply unanswered [577]. In agreement with
Carter et al., my data does not indicate increased fetal malformations in
obese pregnancies as a consequence of fetal folate deficiency and placental
impairment [365]. As obese women participating in this study were not folate
deficient, it is unsurprising that they gave birth to infants who did not have
NTDs. However, the lack of an observed increase in the incidence of NTD may
result from the sample size reported here. Furthermore, as folate
concentrations at term were analysed, normal values of folate in the fetus at
term do not exclude that folate availability was limited during early
pregnancy. Folic acid, vitamin B12 and MTHFR are involved in the
homocysteine-methionine cycle. Normal MTHFR activity maintains the pool of
circulating folate thus preventing an increase in intracellular homocysteine
levels [587]. The latter, together with low folate concentrations, is associated
with an increased risk of adverse pregnancy outcomes [365, 369]. In the
present study, the lower folate intake in women with high BMI was not
accompanied by changes in dietary vitamin B12 intake. Wilson et al. studied
the methionine cycle in the pregnant rat and advocated that the placenta is
not contributing to homocysteine in the maternal circulation. [367]. These
authors found that, even in conditions of severe methyl-deficient diets, little
or no methionine cycle activity was present in the placenta.
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Conversely, methionine synthesis from homocysteine in fetal tissues was
maintained or increased, indicating protection to some extent of these rats
within fetal tissues. In my study, neither homocysteine nor choline were
measured in either maternal or cord blood, therefore it is difficult to draw
conclusions regarding these metabolites and their contribution to folate
metabolism. Folate deficiency has been associated with reduced hepatic SAM
and increased placental SAM/SAH ratios, which are commonly used as
indicators of cellular methylation potential [361, 500]. It is, therefore,
possible that the lower levels of folate observed in obese mothers contribute
to reduce the availability of placental SAM, which is used by DNMTs to
methylate DNA, as a key epigenetic contribution associated with gene
silencing [371, 379].
The hypothesis currently tested was that limited maternal folate supply would
influence methyl group transfer to the fetus via alteration in DNMT expression
[43]. DNMT1, an enzyme required for both the maintenance of the DNA
methylation patterns and essential for cellular development, was upregulated
in both high BMI groups compared to controls, reaching the highest values in
the placenta of overweight women. DNMT1 exists in a complex with a
sequence specific DNA-binding factor and has implications for targeting
methylation, transcriptional control, DNA replication and tumourgenesis
[588]. The increased mRNA abundance of DNMT1 might be a placental
compensatory response to reduced maternal folate concentration in order to
maintain adequate methylation pattern in the fetus [589]. This upregulation
of DNMT1 with increased BMI was not accompanied by changes in DNMT3 and
this may reflect the fact that the latter enzyme is only highly expressed and
active during early gestation when the embryo is developing and not at term
[574].
A summary of the above findings is illustrated in Figure 5.15.
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Figure 5.15: Effects of maternal obesity on folate intake and placental
transport and metabolism.
A lower dietary intake of folate in obese women leads to decreased folate
concentrations in maternal serum. As a consequence, gene expression of placental
IRODWHUHFHSWRUDOSKD)5ĮGHFUHDVHVOHDGLQJWRUHGXFHGWHWUDK\GURIRODWH7+)DQG6
adenosylmethionine (SAM). To buffer low maternal folate concentrations and provide
the fetus with adequate folate, the placenta can increase the expression of other folate
transporters on the microvillous plasma membrane (1), within the syncytiotrophoblast
(2) or on the basal plasma membrane (3). By increasing DNA methyltransferase-1
(DNMT1) gene expression (4) to compensate a decrease in the methyl donor (SAM),
the placenta ensures the maintenance of the methylation pattern in the fetus.
PCFT: proton coupled folate transporter; RFC: reduced folate carrier; 5-MTHF: 5-
methylenetetrahydrofolate; MTHFR: methylenetetrahydrofolate reductase; HCys:
homocysteine; Met:methionine.
Red arrows show the effects of obesity as found in the study (solid line) and its
hypothesised effects (dotted line) in folate metabolism within the syncytiotrophoblast;
blue arrows represent the resultant placental response (solid line) and the
hypothesised compensatory mechanisms (dotted line); yellow stars show folate
concentrations as found in the mother, placenta and cord blood, whereas blue stars
indicate the hypothesised placental response at a transporter level. Ĺ represents
upregulation and Ļ downregulation.
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5.4.2. Effect of gestational diabetes
Diabetic pregnancies have also been associated with congenital malformations
122and NTD even though the incidence of these can be reduced by good
glycaemic control and folate supplementation [508, 518]. Upon diagnosis of
gestational diabetes mellitus (GDM), diabetic participants in my study were
referred to a dietician for nutritional counselling in order to develop
appropriate meal plans. Their higher folate intake compared to lean controls
could reflect that they were more conscious of a healthier diet [508, 509].
Diabetic women with lean BMI showed significantly higher serum folate at 34
gestational weeks and 6 months post-delivery compared to lean controls.
Interestingly, gestational diabetes and higher BMI combined did not change
serum folate concentrations compared to lean women without diabetes.
Nonetheless, cord blood folate in all four groups was similar, and within the
normal range, highlighting a regulatory role of the placenta in controlling the
passage of folate to the fetus. The effect of diabetes on placental transport of
macronutrients including glucose and amino acids is being currently
investigated by other authors [145, 179, 183] and has been discussed in
Chapter 4.
However, the passage of micronutrients during pregnancies complicated by
GDM is less well established. Folic acid deficiency is associated with
compromised fetal growth resulting in reduced birth weight with high risk of
developing metabolic syndrome and CVD later in life [500]. The risk of
diabetes-induced congenital defects in hyperglycaemic mice has been shown
to be reduced by folic acid treatment [518, 576]. As already discussed in
Chapter 3, weight at birth and weight gain in infants of gestational diabetic
mothers with lean as well as high BMI, did not differ from those born from
healthy pregnancies. Thus, good glycaemic control with a healthy diet and/or
folic acid supplements during gestation, was sufficient to ensure this positive
outcome. Nonetheless, the small number of participants in the diabetic groups
might have reduced the power of the study, thus skewing the results.
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To my knowledge, there are currently no published studies in vivo
investigating the effect of diabetes on folate transport within the placenta.
Keating et al. examined, in vitro, the modulation of folic acid uptake by
human syncytiotrophoblast under detrimental conditions, including
hyperglycaemia and hyperinsulinaemia [590]. Despite insulin not affecting
placental folate uptake in vitro, hyperglycaemia chronically inhibited placental
XSWDNH RI WKLV PLFURQXWULHQW >@ VXJJHVWLQJ GRZQUHJXODWLRQ RI )5Į DV
principal cause. An association between diabetes and reduced mRNA
expression of folic acid binding protein in the embryo of hyperglycaemic mice
was also found, resulting in decreased embryonic concentrations of folate
[518, 576]. In contrast, my findings did not suggest placental modifications in
folate transport, since no difference was found in gene expression of any
folate transporters as a consequence of gestational diabetes. The unchanged
placental transport of folate might reflect the lack of difference in cord blood
folate found in these pregnancies, despite enhanced maternal serum folate at
late gestation and at 6 months post-delivery. This may represent a placental
way of compensating any excess maternal folate to avoid a surplus in the
fetus, which can also be detrimental [591]. Interestingly, upregulation of the
placental MTHFR gene was observed when gestational diabetes was
associated with high BMI reflecting higher folate intake. The lack of difference
in folate intake between gestational diabetic obese and lean controls may also
be due to the small number of women (43 out of 70) who completed the
questionnaire. By enhancing folate metabolism and, therefore, the
concentrations of its metabolites, the placenta avoids accumulation of
homocysteine within the trophoblast, which could result in fetal complications
[364, 365]. Therefore, the increased MTHFR expression may be due to higher
IRODWHZLWKLQWKHSODFHQWDDOWKRXJKQRGLIIHUHQFHVLQ)5ĮZHUHREVHUYHGDWD
gene expression level. Other post-translational mechanisms might be
responsible to increase placental folate metabolism, which results in the
observed MTHFR upregulation.
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Methylenetetrahydrofolate (MTHF) uptake in the MVM can be measured on
published techniques for amino acid uptake in syncytiotrophoblast plasma
membrane vesicles as reported by other authors [351, 354, 358].
The enzymes DNMT1 and DNMT3, involved in DNA methylation, did not
significantly change because of diabetes probably reflecting good maternal
folate concentrations. The overall effect of gestational diabetes on folate
metabolism and transport is summarised in Figure 5.16.
Figure 5.16: Effects of gestational diabetes on folate intake and placental
transport and metabolism.
A higher dietary intake of folate in diabetic women leads to an increase in
tetrahydrofolate (THF) within the placenta. As a consequence, placental
methyltetrahydrofolate reductase (MTHFR) gene expression increases thus ensuring
transformation of homocysteine (HCys) into methionine (Met).
)5Į IRODWH UHFHSWRU DOSKD 3&)7 SURWRQ FRXSOHG IRODWH WUDQVSRUWHU 5)& UHGXFHG
folate carrier; 5-MTHF: 5-methylenetetrahydrofolate; S-adenosylmethionine (SAM);
DNA methyltransferase-1 (DNMT1). Red arrows show the hypothesised effects (dotted
line) of gestational diabetes in folate metabolism within the syncytiotrophoblast; blue
arrows represent the resultant placental response (solid line) in folate metabolism;
yellow stars show folate concentrations as found in the mother, placenta and cord
blood;Ĺ represents upregulation.
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Finally, a potential mechanism by which folate could influence body mass and
obesity later in life is via epigenetic control of gene expression [349, 371,
592, 593]. Folate depletion in humans has been observed to reduce genomic
DNA methylation [368, 594]. Additionally, previous studies have linked
modifications in the methylation pattern of placental genes with changes in
gene expression contributing to impaired placental function [575] and
development of early life disease [370]. Variations in DNA methylation could
be linked to adult obesity since, in humans, key genes, which are closely
correlated with fetal growth [595] and body fat distribution [596] exhibited
changes in expression. Therefore, it was reasonable to hypothesise that
obesity, which was associated with lower folate concentrations, would result in
the greatest modification of DNA methylation, and this would be reflected in
gene expression, with potential long term implications. In this study, the
placenta of overweight women showed a much greater adaptation in their
global methylation profile, with about 200 genes differentially methylated,
compared with obese women, for whom only 50 genes were differentially
methylated. The DAVID database [597] was used to analyse the function of
these genes and elucidate potential molecular pathways in which they were
involved. The outcome of the analysis indicated that most of these markers
were related to neurodevelopment and brain function and in the immune
response signalling. This substantiates the hypothesis stated in Chapter 4,
according to which obesity might contribute to the development of an
impaired immune response in the fetus.
However, the apparently reduced methylation response with the highest
maternal BMI was unexpected as the majority of changes in placental gene
expression observed here were with obesity rather than overweight. In
addition, a highly methylated promoter was not always directly related with
changes in gene expression, which might reflect inaccuracy of array probes in
capturing the levels of the target [403, 404].
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The discrepancy between the degree of methylation of the promoter region
and the resulting gene expression might be also explained by the distribution
of large partially methylated domains (PMDs). In the human placenta, these
domains are associated with distinct methylation compared with that of the
global genome [598]. Genes located in PMDs are usually repressed and have
tissue-specific functions unrelated to the tissue of origin. It could be
hypothesised that the placenta of obese mothers, although less globally
methylated than that of overweight women, is more rich in PMD loci on the
promoter region. This would explain the higher variation in gene expression
with obesity despite their lower global methylation. Nevertheless, the extent
to which these PMDs may be related to regulation of gene expression is still
under investigation.
Taken together, my results show that pregnancies complicated by high BMI
and gestational diabetes are differentially associated with altered maternal
serum folate at mid and late gestation. The placenta responds to both low and
high maternal folate intake and serum folate by modulating its transport and
metabolism, highlighting its protective role for the fetus as demonstrated by
the delivery of healthy offspring. My outcomes, therefore, support the need to
provide sufficient folate intake in pregnancy for adequate fetal nourishment in
particular in obese pregnant women, who are encouraged to take a daily
folate supplement [534]. Nonetheless, even in situations of relative folate
deficiency, such as in pregnancies complicated by obesity, the placenta seems
to be able to compensate and supply the newborn with appropriate amount of
nutrients. Despite potential epigenetic biomarkers highlighted from analysis of
methylation at specific genes, interpretation of methylation differences still
require further investigation (for example, through consideration of both
global and local methylation context).
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Chapter 6 - Conclusions
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6.1. General aims
The aims of this thesis were to investigate the independent and combined
effects of a high maternal BMI and gestational diabetes on the placenta in a
population of Spanish pregnant women and their potential contributions to
neonatal growth and health.
These objectives were first achieved by assessing the metabolic status of the
mother through analysis of her dietary intake, weight gain, and physiological
characteristics during pregnancy.
Secondly, the contributions of these maternal conditions to placental size,
fetal weight and postnatal growth were assessed by analysing anthropometric
outcomes of the placenta, fetus and infant until 12 months of postnatal age,
and the fetus physiological characteristics at the time of delivery as reflected
in cord blood.
Placental metabolism was assessed by analysis of gene expression within the
placenta focusing on specific molecular pathways, including placental insulin
signalling, oxidative stress and inflammation.
Finally, folate concentrations in the mother and cord blood were examined
alongside placental folate metabolism and placental DNA methylation. This
allowed elucidating the contribution of folate on epigenetic modifications
within the placenta and highlighting potential critical pathways.
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6.2. Summary of findings
6.2.1. Maternal diet and weight gain in women with
high BMI and GDM
According to self-reported food records, the independent and the combined
effects of obesity and diabetes in pregnancy were associated with reduced
carbohydrate intake in late gestation. This was accompanied by a lower
gestational weight gain (GWG) in women in all observational groups (high
BMI, GDM, both high BMI and GDM) compared to lean controls mothers
without GDM.
In addition, the majority of overweight and obese women with GDM gained
less weight than recommended by IOM for their BMI categories [3]. Among
lean women with GDM and among mothers with both high BMI and GDM, a
significantly greater proportion gained less than adequate gestational weight
compared to their lean healthy counterparts. Interestingly, overweight and
obese mothers without GDM, although gaining less weight than their lean
counterparts, did exceed the recommended weight gain for their BMI by IOM
[3]. The latter finding suggests a lack of reliability in reporting food intake
[406] and/or a lack of awareness or less adherence to the recommended
weight gain [3, 66] by women with a higher BMI, especially overweight
mothers without GDM.
Nevertheless, reduced food consumption, lower GWG and the significantly
lower proportion of women with GDM exceeding the IOM weight gain limits
may also reflect a better control and awareness of their condition. The first
line of treatment of GDM in this study was through nutritional [508, 518] and
lifestyle advice [483] delivered to pregnant women in maternity welfare
clinics. Therefore, the dietary advice received by women with GDM may have
been effective in eliciting these outcomes. As such, it might be possible to
ameliorate the adverse outcomes of obesity in pregnancy through good
regular clinical management.
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According to this, patients would be educated towards healthy lifestyle choices
with the introduction of physical activity programmes and nutritional
interventions [486, 515]. The aim of the latter is to avoid excess weight gain
throughout pregnancy, thus reducing the high risk of delivery of a LGA infant
often observed in those women.
6.2.2. Influence of obesity and GDM on placental
and newborn anthropometry and metabolism
Despite similar fetal weight, obese women without GDM had heavier placentas
[14, 47, 93] but newborn of similar weights, the latter in contrast with the
findings commonly reported in the literature [14, 24, 169, 520]. Similarly,
GDM in the participants of the present study did not contribute to greater
infant birth weight, even though maternal hyperglycaemia has been strongly
associated with the development of macrosomia and heavier offspring [75,
478]. Enhanced maternal glucose concentrations and/or increased leptin
plasma concentrations in obese mothers might be associated to their higher
placental weight. On the other hand, good glycaemic control through the diet
could have contributed to similar placental weight in women with GDM.
My findings support a higher prevalence of LGA neonates (>90th population
percentile) with increasing pre-pregnancy BMI among women with or without
GDM. Once more, the effect of GDM on increasing the risk of having a LGA
infant was less significant than that of obesity independently. This indicates
that, in the present study, high BMI is a stronger risk factor for the increased
risk of having a LGA infant, rather than GDM [474, 485, 521, 522]. One
reason contributing to the delivery of LGA infants despite lower GWG in obese
women without GDM could be the metabolic adjustments [87] or placental
hypertrophy [526] in these mothers.
The findings, in this study, that newborn weight and infant weight gain during
the first year of age were not influenced by either maternal obesity, GDM or
the combined effect of the two could reflect good metabolic control by the
placenta.
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In the present study, insulin and mTOR signalling, within the placenta of
women with high BMI and GDM, did not significantly contribute to changes in
placental or fetal growth. Glucose and insulin plasma concentrations increased
in both obese and GDM mothers whilst similar glucose concentrations were
observed in cord blood of their infants. As gene expression of components in
the insulin and mTOR signalling pathways was unaltered, it is likely that other
factors contribute to compensate for maternal hyperglycaemia. Obesity in
pregnancy was associated with increased placental gene expression of
antioxidant factors, including UCP2 and SIRT1, and decreased pro-
inflammatory markers, such as mTOR. However, monocyte concentrations in
cord blood were higher in infants of obese mothers. These findings suggest
that maternal obesity might contribute to the development of an impaired
immune response in the fetus despite a good antioxidant response within the
placenta. Gestational diabetes was associated with different outcomes,
probably reflecting improved glycaemic control through the diet. Upregulation
of pleiotropic genes involved in key metabolic pathways within the placenta,
LQFOXGHGOHSWLQDQG*5ĮZDVREVHUYHG LQ OHDQZRPHQZLWK*'07KHGLUHFW
transcriptional action of glucocorticoids on placental leptin expression [568]
might indicate the generation of a localised pro-inflammatory state within the
placenta of lean diabetic women [250, 261, 262, 293]. Nonetheless, cord
blood inflammatory markers were similar in infants of these participants,
indicating that placental inflammation, if this occurred, did not adversely
affect the fetus. A summary of the effects of obesity and gestational diabetes
on placental metabolism is illustrated in Figure 4.12 and 4.13 respectively.
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6.2.3. Folate availability and DNA methylation
Pregnancies complicated by high BMI were associated with reduced plasma
folate in the mother at both 34 and 40 gestational weeks compared to lean
controls. This most likely reflects the lower dietary folate intake and folate
supplements reported by these women during pregnancy. Infants of
overweight and obese women had similar cord blood folate concentrations,
although these were lower than those of lean controls. This resulted in a
greater difference between maternal folate at 40 gestational weeks and
umbilical cord folate in those pregnancies complicated by high BMI,
suggesting a crucial function of the placenta in compensating the low
maternal folate by ensuring adequate fetal supply.
Therefore, it is expected that folate transport across the placenta increased
ZLWK RYHUZHLJKW DQG REHVLW\ +RZHYHU SODFHQWDO JHQH H[SUHVVLRQ RI )5Į
[351] was significantly reduced with obesity, whilst no differences in the
expression of the other two transporters, PCFT and RFC were observed. It is
hence likely that other factors, such as modifications at a post-translational
level or higher protein activity, might be responsible of enhanced folate
transport, ensuring adequate folate concentrations in the fetus.
Furthermore, increased mRNA abundance of DNMT1 was observed with
overweight and obesity. As folate supply can influence the availability of
methyl donors to the fetus via alteration in DNMT expression [43], this finding
suggests that the placenta can compensate for reduced maternal folate
concentrations by maintaining adequate methylation pattern in the fetus
[589]. On the other hand, gestational diabetes was associated with increased
maternal folate intake compared to lean controls, probably reflecting a
healthier diet [508, 509]. In lean women with GDM, serum folate at mid and
late gestation was enhanced and might be a result of their higher folate
intake. The effect of overweight and obesity in mothers with GDM was, once
more, associated with lower serum folate concentrations compared to their
lean counterparts.
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This indicates that metabolic differences associated with high BMI, such as
those related to adipose tissue function [263, 314, 546], could influence the
availability of this micronutrient. In addition, infants of lean GDM women
showed similar cord blood folate concentrations alongside unchanged
placental expression of folate transporters. This finding suggests that, despite
enhanced maternal serum folate in late gestation and at 6 months post-
delivery, the placenta is able to buffer any excess maternal folate to avoid a
surplus in the fetus, which can also be detrimental [591]. Gene expression for
the enzymes DNMT1 and DNMT3, involved in DNA methylation, did not
significantly change as a result of diabetes, probably reflecting good maternal
folate concentrations. An overview of the effects of obesity and gestational
diabetes on folate metabolism and transport are summarised in Figure 5.15
and 5.16 respectively.
These outcomes, therefore, support the need to provide sufficient folate
intake in pregnancy for adequate fetal nourishment in particular in obese
pregnant women, who are encouraged to take a daily folate supplement
[534]. Nonetheless, it seems that the placenta is able to compensate and
supply the newborn with appropriate amounts of folate, even when this is
provided by the mother in lower quantities, such as was observed with
obesity.
Methylation analysis performed in this study indicated a greater influence of
being overweight on DNA methylation at specific promoter regions compared
to obesity or gestational diabetes. This was unexpected as the major gene
expression differences were detected as a consequence of obesity rather than
overweight or GDM. In addition, analysis of the expression of some of the
genes, which had been found to be differentially methylated, did not always
confirm the methylation analysis. Several reasons, which could explain this
discrepancy, include, for example, consideration of both global and local
methylation. However, to achieve comprehensive interpretation of
methylation differences further investigation is required.
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6.3. Limitations of the study
6.3.1. Sampling and data collection
As in many investigations involving human populations, the main limitation of
this study lay in the collection of an adequate number of samples to reach
substantial clinical evidence. Recruitment of volunteers is not usually straight
forward, and the principles of informed participant consent mean that subjects
need time and think about what has been proposed to them. This is even
more difficult with pregnant women, especially those who already have to
routinely undertake visits for other conditions, such as diabetes. For instance,
most of the women with gestational diabetes initially recruited, preferred not
to take part or continue to participate to the study because of additional visits
and difficulty of organising their time. Owing to the incidence of GDM in this
population, a limited number of subjects from this group were available for
recruitment and contributed to reduce the power of the analysis. As such,
increasing the sample population in the future would be beneficial.
In addition to the above difficulties in recruitment, unexpected circumstances
have sometimes occurred during sample collection. For instance, when
delivery took place overnight, out of usual working hours, collection of
placenta and cord blood could have been subject to delay out of our control.
As described in the Materials and Methods (Chapter 2), degradation of
placental samples, due to delay in collection, was responsible for the
unsuccessful histological analysis, performed at a first attempt in frozen
placentas. Although placental tissues stored in RNA later did not suffer such
degradation, a limited number of samples stored in this way was available at
the time of analysis and, therefore, this did not allow meaningful further
H[DPLQDWLRQ $WWHPSWV WR H[DPLQH SURWHLQ H[SUHVVLRQ RI )5Į DQG 5)& ZHUH
undertaken, as reported in Chapter 5. However, due to the non-specific
nature of available antibodies, these proteins could not be quantified.
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6.3.2. Measurements and self-reported data
There is general concern about self-reported data, especially related to BMI
estimations in obese women [406-408]. Unfortunately, at the time of
recruitment, it was not possible to measure maternal anthropometry.
Therefore, pregestational maternal weight was self-reported. This could have
contributed to erroneously classifying some subjects as lean or overweight
before pregnancy. In fact, those women might have moved into the obese
group by gaining excess gestational weight at the beginning of pregnancy,
before the first study measurements of height and weight could be made at
24 weeks of gestation.
Furthermore, the nature of the study in a multidisciplinary clinic setting did
not enable visits of the participants to be undertaken in the morning, where
subjects were in a fasting state. Indeed, all the visits in the hospital took
place in the afternoon, between 3-7 pm. This resulted in postprandial
maternal blood collection, the analysis of which could have contributed to
skew some results (i.e. maternal glucose, TG and cholesterol), which are
classically performed after an overnight fast.
Finally, although detailed information regarding the completion of food
records was given to all participants, it is likely that some of them did not
complete them correctly, underestimating or overestimating their portions. As
discussed in Chapter 2 (Section 2.3), some nutritional data was missing due
to the mother not returning or completing the questionnaires.
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6.4. Future work
In order to further explore the above findings, further investigations would be
required as suggested in the following sub-sections.
6.4.1. Future directions for the study of offspring
obesity
As previously discussed, a limitation of this study was the small number of
samples, especially from mothers with gestational diabetes. During the Preobe
Follow-on study, more participants have been recruited and more samples are
now available. Analysis of samples from the follow-on studies, which have a
similar design, would allow inclusion of a larger and, thus, more powerful
sample size to more specifically investigate the effects of gestational diabetes
and high BMI on the placenta and on the offspring metabolic health. A larger
number of samples would also allow further investigation of the effects of
overweight and obesity in women with gestational diabetes, thus elucidating
the separate effects of the two conditions on infant weight gain.
Since one of the most alarming issues of todays western societies is obesity
and the consequent development of offspring diabetes, these further studies
should examine, in addition to weight and ponderal index, fat and lean mass
in the infants at different stages of the first year of life. This would allow to
further determine whether fetal hyperleptinaemia observed in the umbilical
cord blood of infants of obese mothers is associated with increased adiposity
in those infants. It would also contribute to investigate whether these infants
have a higher incidence of obesity and metabolic diseases in adulthood.
Analysis of neonatal and infant nutrition, through maternal recording at the
first 1, 3, 6, 12 months of age under paediatric supervision, would be useful
to corroborate infant anthropometric data.
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6.4.2. Future directions for the study of offspring
neurodevelopment
The role of epigenetic modifications in the placenta was assessed through
analysis of DNA methylation, providing a list of several genes differentially
methylated, some of which were common to overweight, obesity and/or
diabetes. A first analytical procedure to analyse the function of these genes
was performed using the DAVID database [597], which indicated that most
of them were related to neurodevelopment and brain function as well as to
immune response signalling. It would be of interest, therefore, to further
investigate novel pathways in which these genes are implicated in order to
focus clinical fields of potential future research. As discussed in Chapter 5,
gene expression of these potential novel markers can be a useful tool in
hypothesis-setting research, although interpretation of these results requires
caution. With regards to the potential long term implications in the
neurodevelopment of these infants, further observational studies could use
functional measures of infant neurodevelopment, such as Bayley III
neurodevelopmental scores at three years of age, and developmental
assessments at school entry by formal validated testing.
6.5. Final remarks
This PhD study has illustrated relationships between key factors in pregnancy,
the placenta and fetal development to term, and later neonatal growth, and
how these are affected by maternal overweight, obesity and diabetes in
pregnancy. Importantly, the placenta could compensate for maternal
hyperglycaemia and folate deficiency of obese mothers by increasing its own
use of glucose and/or placental folate transport respectively, resulting in
normal glucose and normal folate concentrations in the newborns. However,
increased concentrations in cord blood monocyte of infants of obese mothers
and hypermethylation of genes involved in placental immune response
pathways requires further investigation.
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European Society for Paediatric Gastroenterology,
Hepatology, and Nutrition (ESPGHAN), London, UK,
May 2013 (poster presentation by Cristina Campoy)
DNA methylation in the human placenta and its
association with high maternal body mass index.
J. Martino, R. D. Emes, L. García-Valdés, M. T. Segura, I. Rusanova, M. D. C.
Padilla, H. McArdle, H. Budge, M. Symonds, C. Campoy.
Objectives and Study: Changes in epigenetic profile in response to
perturbations within the in utero environment could contribute to
modifications in feto-placental function that ultimately place the resulting
individual at increased risk of metabolic disease in later life. This is because
differences in methylation pattern of genes expressed in the placenta are
associated with changes in gene expression that could impair placental
function. Furthermore, the use of genome-wide methylation arrays enables a
more detailed examination of human epigenomics although this can lead to
controversial interpretations. The present study, therefore, aimed to examine
the influence of maternal body weight on the epigenomic profile in the human
placenta followed by the determination of gene expression of genes identified
to be differentially methylated.
Methods: Term placental samples as part of the PREOBE study* were
collected from 3 groups of pregnant women with normal glucose tolerance,
according to pre-pregnancy BMI classified as normal weight (BMI<25 kg/m2;
Q  RYHUZHLJKW %0, NJP Q  DQG REHVH %0, NJP
n=5). Illumina Infinium HumanMethylation450 BeadChip array was used to
examine genome-wide DNA methylation patterns and annotation data were
analysed using NIMBL software. Gene centric plots were generated for novel
genes which were most differential methylated and their expression was
determined by QPCR.
Results: The greatest difference in methylation was found in placenta sampled
from overweight mothers in which there were more than 200 differentially
methylated CpG sites, an adaptation that was largely absent in placenta
sampled from obese women. Methylation of the promoter regions for both
FAM3B and Wnt2 was raised in placenta of overweight women, but this
adaptation was only accompanied with comparable changes in FAM3B gene
expression.
Conclusion: Placenta ,of overweight women show greater adaptation in their
global methylation profile than those of women who are obese although this is
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not consistently directly related to changes in gene expression. The
globalmethylation response, therefore, with increasing maternal BMI suggests
that enhanced maternal overweight may result in adverse fetal outcomes.
World Congress on Developmental Origins of Health
and Disease (DOHaD), Portland, OR, USA, September
2011 (poster presentation by Jole Martino)
Effect of high maternal BMI on folate concentrations and
placental DNA methyltransferase 1 (DNMT-1) gene
expression in humans: the PREOBE Follow up study.
Martino J, Sebert S, Segura MT, Rusanova I, Martínez-Zaldívar MC, García-
Valdés L, Padilla MC, McArdle HJ, Budge H, Symonds ME and Campoy C.
Background: The importance of maternal methyl donors, including folate, in
DNA methylation and embryogenesis has been demonstrated in animal
studies. Maternal obesity has been associated with adverse neonatal
outcomes which could be linked to folate deficiency. Therefore, we
investigated whether maternal BMI can alter folate status and whether that,
in turn, modifies the activity of placental DNMT-1 and offspring folate
concentrations.
Methods: Women were recommended to take folate supplements (0.4mg)
during the first 3 months of gestation. Pregnant women were recruited at 20
weeks of gestation and classified according to their pre-pregnancy BMI into
control (BMI<25kg/m2; n=56), overweight (25 kg/m2<BMI<30kg/m2; n=26)
and obese (BMI>30kg/m2; n=21) groups. Plasma folate concentrations were
analysed in maternal samples taken at 34 weeks of pregnancy and at delivery
(38.7 ± 1 weeks of gestation), and in cord blood. Placental DNMT-1 gene
expression was determined using real-time PCR. Data were analysed
according to their parametric distribution with Kruskal-Wallis and 1-way
ANOVA.
Results: Although there was no difference in maternal folate intake in early
pregnancy as determined by lifestyle questionnaire, overweight mothers had
lower folate concentrations at both 34 weeks of pregnancy (C=12.9±0.6;
OV=10.3±0.9, (p=0.02)) and at delivery (C=12.8±0.7; OV=9.5±0.9,
(p=0.005)) whilst in obese women, plasma folate was only reduced at
delivery (OB=8.9±1.2ng/mL (p=0.007)). There were no differences in cord
blood folate. Placental mRNA abundance of DNMT-1 was upregulated 2 fold
with overweight (C=0.0115±0.0019; OV=0.021±0.002; (p=0.0004)), and
1.5 fold with obesity (OB=0.0168±0.0029; (p=0.04)) but was not directly
associated with folate concentrations.
Conclusions: Although plasma folate concentrations were lower in women of
increased BMI, there was no reduction in their newborns, suggesting
enhanced placental folate transport. The extent to which upregulation of
placental DNMT-1 may act with altered DNA methylation in the placenta to
increase folate supply to the fetus is currently being investigated.
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The physiological Society main summer meeting,
Oxford, UK, July 2011 (Oral presentation by Jole
Martino)
Placental sirtuin 1 (SIRT-1) and mammalian target of
rapamicyn (mTOR) in the Preobe Study*: a protective
response for the fetus against the adverse outcomes of
maternal obesity?
Martino J, Sebert S, Segura MT, Rusanova I, Martínez-Zaldívar MC, García-
Valdés L, Padilla MC, McArdle HJ, Budge H, Symonds ME and Campoy C.
Background: The maternal metabolic environment influences both fetal
development and long-term health in the offspring [24]. These responses can
be modulated by the placenta due, in part, to its capacity to protect the fetus
from adverse conditions.
Aim: We, therefore, investigated whether maternal body mass index (BMI)
influences placental oxidative status as a result of changes in gene expression
for SIRT-1 and mTOR.
Methods: Pregnant women were recruited at 20 weeks of gestation and
classified according to their pre-pregnancy BMI as control (BMI<25kg/m2;
n=56), overweight (BMI=25-30kg/m2; n=26) or obese (BMI>30kg/m2;
n=21). At delivery, placentae were sampled and SIRT-1 and mTOR gene
expression determined using real-time PCR. OxiSelectTM TBARS assay was
used as a measure of lipid peroxidation. Data were analysed according to
their parametric distribution by Kruskal-Wallis or 1-way ANOVA.
Results: Obesity had no effect on gestational length, birth weight, or postnatal
morbidity but obese mothers did produce the largest placentae
(C=468.4±15.8g; OB=520±29.1g; (p=0.022)). Placental SIRT-1 gene
expression showed a 1.5 fold upregulation with obesity (C=88±10;
OB=134±19 x10-5 a.u. (p=0.024)) whereas mTOR expression was halved
(C=177±18; OB=87±11 x10-4 a.u. (p=0.022)). TBARS concentrations were
similar between groups.
Discussion and conclusion: Overexpression of the anti-oxidant gene SIRT-1,
combined with reduced mTOR in obese mothers, may indicate an enhanced
placental anti-oxidative capacity. Surprisingly, higher placental weight was
not associated with increased oxidative stress as measured by TBARS
concentrations suggesting a placental compensatory response to raised
maternal BMI. A follow up study of the offspring is currently being undertaken
up to 18 months of age to establish whether obesity in pregnancy is
accompanied with longer term responses.
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European Society for Paediatric Gastroenterology,
Hepatology, and Nutrition (ESPGHAN), Istanbul,
Turkey, June 2010 (oral presentation by Cristina
Campoy)
Influence of maternal BMI and gestational diabetes on
mTOR and PPARG gene expression in the term placenta
Martino J, Sebert S, Budge H, García-Valdés L, Segura MT, Anjos T, López-
Tarragona R, Marti-Romero MA, Florido J, Symonds M.E. and CampoyC.
Background: It is now well established that changes in the maternal diet at
defined stages of pregnancy can affect offsprings risk of later metabolic
disease [473]. Such alterations of fetal growth can be due to substantial
modifications of materno-fetal energy partitioning regulated in part by the
mammalian target of rapamycin (mTOR) (2) and the peroxisome-proliferator
activated receptor (PPAR-gamma) (3,4). However, the influence of maternal
body mass index (BMI) and/or insulin sensitivity on the regulation of placental
energy metabolism has yet to be established. This is clearly important as it
will improve our understanding of the potential adverse effect of maternal
obesity and gestational diabetes on pregnancy outcomes.
Methods: Placental samples were collected from healthy pregnant women
participating in the PREOBE Project*(P06-CTS-02341) directed by the
University of Granada (Spain). The subjects were recruited at 20 weeks of
gestation and divided into four groups according to their BMI and glucose
tolerance. Mothers were either classified as lean (pre-pregnancy
BMI<25kg/m2; normal glucose tolerance; n = 56), overweight (pre-pregnancy
25 kg/m2<BMI<30kg/m2; normal glucose tolerance; n = 23), obese (pre-
pregnancy BMI>30kg/m2; normal glucose tolerance; n = 12) or gestational
diabetic (pre-pregnancy BMI<25 kg/m2; glucose intolerant; n = 17). At
delivery, placenta from each individual was sampled in order to analyse mTOR
and PPAR-gamma gene expression by real-time RT-PCR.
Results: The mRNA abundance for mTOR in placenta of lean mothers was
respectively two and three times lower than in the placenta of overweight (but
not obese) (p<0.05) and gestational diabetic mothers (p<0.001).
Interestingly, diabetic mothers overexpressed mTOR when compared to
overweight (p<0.05) and obese (p<0.005). In addition, the placenta of
overweight, obese and gestational diabetic mother overexpressed the gene
encoding for PPAR-gamma compared to lean women (P<0.05).
Conclusions: We have shown that both being overweight and glucose
intolerance during pregnancy alters placental energy metabolism pathways.
Overexpression of mTOR and PPAR-gamma within the placenta could promote
nutrient uptake thereby altering fetal growth and body composition. This may
also contribute to local chronic pro-inflammatory states within the placenta or
fetus and further suggests that mTOR and PPARG are key gene targets for
fetal programming.
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International Conference on The Early Nutrition
Programming Project (EARNEST), Munich, Germany
May 2010 (Oral presentation by Jole Martino)
Gene expression in the term placenta: effect of maternal
BMI and glucose tolerance on uncoupling protein 2 (UCP-
2), toll-like receptor 4 (TLR-4) and DNA
methyltransferase-1 (DNMT-1)
Martino J., Sebert S., García-Valdés L., Segura MT., Anjos T., Marti-Romero
MA., Florido J., Budge H., Symonds M.E. and Campoy C.
Background: Maternal obesity and diabetes are critical public health issues
that can compromise maternal and offspring health. The regulation of genes
involved in placental energy metabolism, pro-inflammation and DNA
remodelling (UCP-2, TLR-4, DNMT-1) can determine the partitioning of energy
between the mother and fetus1. In addition, they may be altered by weight
gain and diabetes during pregnancy and subsequently result in long-term
adverse outcomes.
Methods: As part of The PREOBE project* pregnant women were recruited at
20 weeks of gestation and classified as lean (BMI<25kg/m2; n = 58),
overweight (BMI = 25-30kg/m2; n = 25), obese (BMI>30kg/m2; n = 12) or
gestational diabetic (BMI<25 kg/m2; glucose intolerant; n = 13). At delivery,
placentas were sampled and UCP-2, TLR-4 and DNMT-1 gene expression
determined using real-time PCR.
Results: In overweight and obese mothers the genes encoding for UCP-2 and
TLR-4 were increased two-fold compared to lean mothers (P<0.05). Diabetes
resulted in further overexpression (p<0.001) of these genes. Additionally, the
mRNA abundance of DNMT-1 was enhanced two-three times in all groups
compared to lean controls (P<0.001).
Conclusions: Upregulation of UCP-2 and TLR-4 in the placenta with increased
maternal body weight or diabetes indicates a resetting of fatty acid oxidation
and chronic pro-inflammatory status, whilst raised DNMT-1 is indicative of
epigenetic adaptations. These findings suggest that UCP-2, TLR-4 and DNMT-
1 are key gene targets for fetal programming and highlight critical cellular
mechanisms that contribute to long term adverse health outcomes associated
with maternal obesity and diabetes.
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Appendix B: Suppliers
Abcam®, Cambridge, UK
Abgene Ltd, Epsom, UK
Alpha Laboratories Ltd, Eastleigh, UK
Anglia Scientific Ltd, Cambridge, UK
Applied Biosystems, Carlsbad, California (CA), USA
Biotek UK, Potton, UK
Bio-Rad Laboratories Ltd, Hemel Hempstead, UK
Bioron, Ludwigshafen, Germany
Cell Biolabs Inc., San Diego, California (CA), USA
Diagnostic Products Corporation, Caernarfon, UK
Ecolabs®, Saint Paul, Minnesota (MN), USA
Fisher Scientific UK Ltd, Loughborough, UK
Hoefer® Inc., Holliston, Massachusetts (MA), USA
IBM UK Ltd, Portsmouth, UK
Invitrogen Ltd, Paisley, UK
Leica Microsystems (UK) Ltd, Buckinghamshire, UK
Linton Instrumentation, Norfolk, UK
Manor Farm Feeds Ltd, Rutland, UK
Mercodia, Uppsala, Sweden
Menzel-Gläser Inc., Braunschweig, Germany
Microsoft Corporation, Redmond, Washington (WA), USA
Millipore, Billerica, Massachusetts (MA), USA
Minitab Ltd, Coventry, UK
PerkinElmer, Cambridge, UK
Premier Biosoft International, Palo Alto, California (CA), USA
Primer Design Ltd, Southampton, UK
Qiagen UK Ltd, Crawley, UK
Randox Laboratories Ltd, Crumlin, UK
Roche Diagnostics Ltd, West Sussex, UK
Scientific Laboratory Supplies (SLS) Ltd, East Riding of Yorkshire, UK
Severn Biotech Ltd, Worcestershire, UK
Sigma-Aldrich Company Ltd, Dorset, UK
VWR International, Lutterworth, UK
